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Abbreviations 
The  abbreviations  used  in  this  thesis  are  those  suggested  in  the 
Instructions  to  Authors  of  the  Biochemical  Journal  (1983)  with  the 
following  additions: 
A  Absorption 
Ab  Antibody 
Ag  Antigen 
BSA  Bovine  Serum  Albumin 
C'  Complement 
C'F  Complement  Fixation 
DMSO  Dimethyl  sulfoxide 
DTT  Dithiothreitol 
EDTA  Ethylenediamine  tetra-acetic  acid 
ELISA  Enzyme  Linked  Immunosorbent  Assay 
FCS  Foetal  Calf  Serum 
FITC  Fluorescein  Isothiocyanate 
GMEM  Glasgow  Modification  of  Minimal  Essential  Medium 
GS  Goat  Serum 
HAT  Hypoxanthine,  aminopterin,  thymidine 
HT  Hypoxanthine,  thymidine 
Ig  Immunoglobulin 
K  Kilo  (  1000) 
MCA  Monoclonal  Antibody 
NEAA  Non-Essential  Amino  Acids 
NHCP  Non-Histone  Chromosomal  Protein 
PAGE  Polyacrylamide  Gel  Electrophoresis 
PBS  Phosphate  Buffered  Saline 
PEG  Polyethylene  Glycol 
ppo  2,5-diphenyloxazole -  iv  - 
SDS  Sodium  dodecyl  sulfate 
SLE  Systemic  Lupus  Erythromatosus 
SRBCs  Sheep  Red  Blood  Cells 
TN  Tris-Saline 
Tris  Tris(hydroxymethyl)  methylamine 
Triton-X100  Iso-octyl  phenoxy  polyethoxy  ethanol 
Tween  20  Polyoxyethylene  (20)  sorbiton  monolaurate -v- 
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Summary 
Chromosomal  proteins  are  exceptionally  difficult  to  analyse  by 
biochemical  techniques  because  of  their  complexity,  heterogeneity  and 
insolubility.  An  immunological  approach  is  therefore  of  considerable 
value  since  it  may  be  employed  to  identify  antigens  within  the  cell  by 
immunocytochemistry,  to  test  for  the  distribution  of  antigens  among 
different  cell  phenotypes  by  ELISA  and  complement  fixation  and  to 
characterise  protein  antigens  by  immunoblotting. 
Immunological  analysis  of  the  sera  from  two  rabbits  and  a  single 
monoclonal  antibody  has  been  undertaken  in  detail.  One  serum,  from 
rabbit  3.1,  was  obtained  from  a  rabbit  which  was  immunised  with  HeLa 
chromatin  extracted  with  2M  NaCl  and  5M  urea.  The  antibodies  showed  a 
moderately  strong  preference  for  HeLa  chromatin.  The  major  antigens  in 
this  antiserum  required  DNA  for  immunological  activity  in  compelment 
fixation  and  ELISA.  The  molecular  weights  of  the  major  antigens  on 
immunoblotting  in  the  absence  of  DNA  were  in  the  range  43,000-45,000. 
In  the  presence  of  DNA,  faint  additional  bands  at  molecular  weight 
68,000-70,000  could  be  detected.  The  discrepancy  between  the  three 
techniques  suggests  that  the  major  antigens  detected  on  these  assays  may 
differ.  In  particular,  the  immunoblotting  technique  may  not  detect 
complex  interactions  involving  more  than  one  protein  antigen  in 
combination  with  DNA.  Immunocytochemical  analysis  suggested  that  the 
antigen  localised  in  the  nuclei  and  in  particular,  in  the  peripheral  area 
generally  associated  with  envelope,  matrix  or  lamina  proteins. 
Preparations  of  lamina  proteins  showed  considerable  reaction  with  the 
antiserum  so  that  at  least  some  of  the  major  antigens  are  in  this 
fraction.  This  does  not  preclude  the  presence  of  these  or  other  major 
antigens  in  the  nuclear  matrix  or  envelope. -  xix  - 
In  rabbit  2.1,  antiserum  to  chromatin  extracted  with  only  2M 
NaCl  was  produced.  This  gave  a  totally  different  spectrum  of  antigens 
with  many  of  the  major  antigens  having  cytoplasmic  localisation. 
Antigens  detected  by  immunoblotting  included  proteins  present  in  2M  NaCl 
extracted  chromatin  and  also  present  in  keratin  preparations.  the 
reaction  with  HeLa  chromatin  was  preferential  but  not  specific  and 
immunoblotting  indicated  that  the  major  antigens  detected  by  this 
technique  were  present  in  a  large  number  of  cell  lines. 
The  difference  in  response  between  the  two  rabbits  could  be 
correlated  with  the  fact  that  they  were  not  syngeneic.  However,  it  is 
more  likely  that  the  major  antigens  in  rabbit  2.1  are  extracted  by  the 
additional  5M  urea  used  to  prepare  the  immunising  antigen  in  rabbit  3.1. 
Many  of  the  difficulties  associated  with  the  analysis  of 
0 
polyclonal  serum  samples  raised  to  a  heterogeneous  antigen  are  removed  by 
hybridoma  technology.  A  murine  monoclonal  antibody,  HNo-G7,  detected  a 
single  specific  antigen  which  was  not  apparent  in  the  analysis  of  the 
serum  of  either  rabbit.  The  mouse  was  immunised  with  2M  NaCl  5M  urea 
extracted  chromatin  of  the  type  used  to  immunise  rabbit  3.1.  This 
monoclonal  antibody,  localises  strongly  on  the  nucleoli  of  HeLa  cells, 
has  a  preference  for  epithelial  cells  and  HeLa  cells  in  particular,  and 
reacts  with  chromatin  which  has  been  treated  with  RNase  A  and  DNase  I. 
It  also  does  not  react  with  HeLa  DNA  alone.  Sensitive  immunoblotting 
showed  a  molecular  weight  of  45,000. 
The  data  emphasise  the  difference  between  conventional 
serological  analysis  and  monoclonal  antibody  technology.  Among  the  most 
important  of  these  is  the  fact  that  HNo-G7  is  a  fully  stabilised 
monoclonal  antibody  which  can  be  synthesised  in  culture  indefinitely  and 
produced  from  frozen  hybridoma  cells.  It  can,  therefore,  be  produced  in 
whatever  quantities  are  required  and  be  utilised  in  the  future  to  further 
investigate  the  role  of  its  antigen  in  processes  involved  in  nucleolar 
function. Introduction -1- 
1.  INTRODUCTION 
1.1  Chromatin  and  Chromosome  Structure 
1.1.1  Nucleosome  Structure 
It  is  now  widely  accepted  that  the  nucleosome  is  the  elementary 
repeat  subunit  of  chromatin  structure  in  eukaryotes.  The  nucleosome 
consists  of  an  internal  core  of  histones  surrounded  by  DNA  (for  review 
see  Felsenfeld,  1978;  McGhee  &  Felsenfeld,  1980;  Laskey,  1981; 
Igo-Kemenes  et  al,  1982).  The  globular  core  particle  is  sealed  off  by 
another  species  of  histone,  Hl,  which  is  usually  attached  to  the 
complex  at  the  entry  and  exit  of  DNA  (Thoma  et  al,  1979). 
1.1.1.1  Nucleosome  Core  Particle 
The  first  level  of  chromatin  structure  organisation  is  the  core 
particle.  It  has  flat  cylindrical  shape  with  a  diameter  of  1l.  Onm  and  a 
height  of  5.5  nm  (Finch  et  al,  1977).  The  core  consists  of  an  octamer 
of  the  basic  histone  proteins,  two  molecules  of  each  H2A,  H2B,  H3 
and  H4.  This  octameric  particle  is  surrounded  by  146  base  pair  (bp) 
of  DNA  (Lutter,  1979)  forming  1.75  turns.  This  is  further  extended  by 
another  10  bp  at  each  end  to  form  a  supercoil  of  a  full  two-turns 
comprising  166.0  bp  surrounding  the  particle  (Thoma  et  al,  1979).  The 
166  bp  particle  has  been  termed  "Chromatosome"  (Simpson,  1978).  The 
nucleosome  structure  and  its  involvement  in  gene  transcription  and 
initiation  has  been  the  subject  of  intense  research  interest  over  the 
last  few  years  (Lohr,  1981,1983;  Weisbrod,  1982;  Paul,  1982;  Oda, 
1983). 
1.1.1.2  Histone  H1-Containing  Nucleosome 
The  next  level  in  the  organisation  of  chromatin  structure  is  the 
"Mononucleosome".  The  mononucleosome  consists  of  the  core  particle,  the 
linker  DNA  and  one  molecule  of  the  lysine-rich  histone  protein  (H1). 
The  involvement  of  H1  in  the  organisation  of  the  nucleosome  has  been 
the  focus  of  many  research  groups  (reviewed  by  McGhee  &  Felsenfeld,  1980). -2- 
From  nuclease  digestion  experiments,  it  has  become  clear  that 
the  globular  core  particle  is  well  protected.  H1  histone  is  located 
at  the  entry  and  exit  of  the  166.0  bp  superhelical  DNA  (Simpson,  1978; 
Moyne  et  al,  1981;  Thoma  et  al,  1979).  It  has  been  shown  that  H1 
histone  species  consists  of  three  distinct  domains.  The  central  one  is 
a  globular  protein  subunit  (Isenberg,  1979)  which  is  in  close  contact 
with  the  histone  octamer  and  is  able  to  close  two  full  turns  of  DNA 
around  the  core  (Allan  et  al,  1980). 
1.1.1.3  The  Linker  DNA  and  Periodicity 
The  chromatosomes  are  linked  with  each  other  by  "Linker"  or 
"Spacer"  DNA.  The  linker  length  varies  from  zero  bp  in  lower  eukaryotes 
(Noll,  1976;  Morris,  1976;  Thomas  &  Furber,  1976)  to  around  80  bp  in 
sea  urchin  sperm  (Spadafora  et  al,  1976,1978).  A  considerable  amount 
of  attention  has  been  paid  to  the  organisation  of  internucleosomal  DNA 
(Lawrence  &  Goeltz,  1981;  Strauss  &  Prunell,  1982,1983;  Karpov  et  al, 
1982).  Data  from  nuclease  digestion  experiments  have  suggested  that 
there  may  be  classes  of  different  spacer  lengths  in  different  organisms 
and  tissues  from  the  same  organism  (Kornberg,  1977;  Chambon,  1978). 
This  has  been  substantiated  using  different  kinds  of  nucleases  as  well  as 
a  combination  of  nucleases.  Using  micrococcal  nuclease,  Karpov  et  al 
(1982)  have  reported  the  presence  of  20,30  and  40  bp  spacers  in 
Drosophila.  They  have  also  concluded  that  lOn  bp  (n=2,3  and  4)  long 
intercore  DNA  is  organised  by  H3  histone  in  particular  and  together 
with  the  core  DNA  forms  a  continuous  superhelix.  In  rat  liver 
chromatin,  the  highly  variable  lengths  of  linker  DNA  within  the  same 
cell,  have  been  studied  extensively  by  Prunell  and  Kornberg.  They  have 
developed  a  direct  method,  using  a  combination  of  nucleases,  by  which 
nucleosome  dimers  are  trimmed  to  166  bp  of  the  core  position  retaining 
H1  histone.  In  rat  liver  chromatin,  the  mean  value  of  the 
centre-to-centre  distance  between  nucleosomes  has  been  found  to  be -3- 
190  bp  by  using  exonuclease  III  (Prunell  &  Kornberg,  1982;  Strauss  & 
Prunell,  1982).  A  considerable  difference  of  the  helical  periodicity  of 
DNA  on  the  nucleosome  is  found  in  the  literature,  due  to  variable 
interpretations  of  the  nuclease  digestion  data.  By  electrophoresis  of 
nuclease  digests  in  denaturing  gels,  DNA  fragments  give  rise  to  a 
characteristic  ladder  pattern  with  fragments  spaced  about  10.0 
nucleotides  apart  (Noll,  1974).  However,  Lutter  (1979)  and  Bryan  et  al 
(1979)  have  noted  a  10.4  nucleotide  spacing  in  DNase-I  digestion. 
Simpson  and  Stafford  (1983)  have  shown  recently,  by  using  cloned  segments 
of  DNA  in  vitro,  that  a  cutting  site  spacing  of  near  10.0  nucleotides 
occurs  for  a  large  part  of  a  reconstituted  nucleosome.  This  reflects  a 
DNA  helical  repeat  of  10.0  bp  in  the  core  particle.  Klug  and  Lutter 
(1981)  have  concluded  that  the  variation  of  angle  of  attack  of  nucleases 
deduced  on  the  basis  of  a  10.5  fold  screw  in  the  DNA  double  helix  leads 
to  steric  inaccessibilities,  whereas  all  data  are  compatible  with 
periodicity  of  10.0  bp  per  turn  of  the  helix.  An  earlier  conclusion  by 
Finch  et  al  (1977)  in  what  they  described  as  the  "Linking-number  paradox" 
has  suggested  that  in  solution,  the  helical  twist  of  free  DNA  corresponds 
to  a  full  turn  per  10.5  bp.  When  coiled  around  the  histone  core,  the 
helical  twist  of  the  DNA  corresponds  to  a  full  turn  per  10.0  bp. 
1.1.2  Supranucleosomal  Structure 
It  is  now  well  accepted  that  the  first  level  of  DNA  condensation 
is  provided  by  nucleosome  structure  which  in  low  salt  concentration  gives 
rise  to  a  (nucleosomal)  beaded  chain  (Oudet  et  al,  1975;  McGhee  et  al, 
1980;  Thoma  &  Koller,  1977;  Thoma  et  al,  1979).  At  the  second  level 
of  chromatin  organisation,  the  beaded  chain  (nucleofilament)  condenses  in 
solution,  containing  magnesium  or  a  high  concentration  of  monovalent 
cations,  to  form  a  thick  supercoil  or  "Solenoidal  Structure"  of  a  pitch 
around  llnm  (Finch  &  Klug,  1976).  The  thick  fibre  diameter  in  high  salt 
concentration  has  been  reported  to  be  around  25-30nm  in  nuclease -4- 
digestion  experiments  (Finch  &  Klug,  1976),  by  electron  microscopy  (Thoma 
et  al,  1979)  and  by  electric  dichroism  (McGhee  et  al,  1980). 
Moreover,  a  radial  arrangement  for  the  faces  of  chromatosomes 
around  the  fibre  axis  of  30nm  solenoid  has  been  suggested  (Finch  &  Klug, 
1976;  McGhee  et  al,  1980).  In  this  model,  six  chromatosomes,  each  of 
llnm  in  diameter  and  5.5nm  thick,  are  arranged  per  turn  of  left  handed 
solenoid.  Evidence  for  the  6-7  nucleosomes  per  turn  in  the  solenoid 
fibre  has  been  substantiated  by  different  techniques  such  as  electron 
microscopy,  neutron  diffraction  and  x-ray  scattering  (for  review  see 
Igo-Kemenes  et  al,  1982). 
An  alternative  model  to  the  solenoid  is  the  "Superbead".  Renz 
et  al  (1977),  using  electron  microscopy,  have  reported  the  presence,  at 
high  ionic  strength,  of  a  fibre  of  20  nm  in  diameter,  composed  of 
discrete  globular  structures  that  are  held  by  H1  histone.  This 
superbead  structure  has  been  supported  by  further  work  on  hen  erythrocyte 
chromatin.  Chromatin  fibre  fragments  with  a  length  of  500  nm  and  an 
average  diameter  of  32  nm  have  been  observed  by  electron  microscopy. 
Each  fibre  has  been  found  to  consist  of  13  globular  subunits  comprising 
a  "Superbead".  The  globular  subunits  contain  a  different  number  of 
nucleosomes  at  an  average  of  17  (Meyer  &  Renz,  1979).  Chromatin 
fibres  of  33  nm  long  and  30  nm  in  diameter  have  been  also  reported  in  a 
variety  of  different  systems  (Subirana  et  al,  1981).  Biochemical 
studies  supporting  the  superbead  model  suffer  from  the  lack  of  repeated 
periodicity  of  DNA  pattern  by  nuclease  digestion  (Igo-Kemenes  et  al, 
1982). 
1.1.3  Chromosome  Structure 
1.1.3.1  Metaphase  Chromosome 
There  is  accumulating  evidence  that  the  25  nm  chromatin  fibre 
appears  to  be  folded  further  both  in  interphase  nuclei  (Benyajati  & 
Worcel,  1976;  Igo-Kemenes  &  Zachau,  1978;  Adolph,  1980a;  Lebkowski  & 
Laemmli,  1982),  and  in  metaphase  chromosomes  (Adolph  et  al,  1977a;  Lewis -5- 
&  Laemmli,  1982;  Earnshaw  &  Laemmli,  1983).  The  fibres  in  interphase 
and  metaphase  chromosomes  have  been  found  to  be  arranged  in  the  form  of 
loops  or  domains  of  50  -100  Kb  of  DNA  which  are  constrained  by  protein 
framework  (Paulson  &  Laemmli,  1977;  Igo-Kemenes  &  Zachau,  1978). 
Stubblefield  and  Wray  (1971)  have  proposed  that  mitotic  chromosomes 
consist  of  distinct  axial  and  peripheral  chromatin  components. 
Recently,  Paulson  and  Laemmli  (1977)  have  shown  that,  in  dehistonised 
chromosome  preparations,  loops  of  DNA  are  seen  surrounding  a  residual 
axial  structure. 
A  general  radial  loop  model  has  been  suggested  in  which 
chromatin  loops  emanate  from  a  central  axis  formed  by  a  network  of 
nonhistone  proteins  designated  as  the  "scaffolding"  that  links  the  bases 
of  the  loops  (Laemmli  et  al,  1978).  Support  for  such  a  model  comes  from 
thin-section  electron  microscopy  of  swollen  metaphase  chromosomes 
(Adolph,  1980b;  Hozier  et  al,  1981)  and  swollen  cells  (Adolph,  1981). 
The  scaffold  structure  is  composed  primarily  of  two  high 
molecular  weight  proteins  (Scl  and  Sc2)  whose  interactions  are  believed 
to  be  stabilised  by  metallo-protein  interactions  (Lewis  &  Laemmli, 
1982).  Further  support  for  the  involvement  of  scaffold  proteins,  comes 
from  nuclease  digestion  studies  of  chromosomes  after  low  salt  protein 
extraction  which  reveal  a  nonhistone  protein  residual  scaffold,  visible 
by  electron  microscopy  (Earnshaw  &  Laemmli,  1983).  These  residual 
proteins  have  been  found  to  be  fibrous  in  nature,  retaining  the 
differentiated  regions  of  the  chromosomes  derived  from  the  "kinetochores" 
and  chromatid  axis  (Earnshaw  &  Laemmli,  1983).  It  has  also  been  noted 
that  in  the  presence  of  magnesium  or  at  high  NaCl  concentrations,  the 
fibrous  network  undergoes  a  lateral  aggregation  which  is  reversible. -6- 
1.1.3.2  Nucleoids 
Structures  resembling  the  nucleus  and  retaining  its 
morphological  features  but  depleted  of  protein  have  been  known  for  many 
years  (Cook  &  Brazell,  1975,1980).  These  structures  which  have  been 
called  "Nucleoids"  are  released  by  gently  lysing  cells  in  solutions 
containing  non-ionic  detergent  and  high  concentration  of  monovalent 
cations.  The  nucleoids  consisted  predominantly  of  superhelical,  intact 
DNA,  looped  during  lysis  (Cook  &  Brazell,  1976;  Lavin  &  Davidson, 
1981).  The  linear  nuclear  and  unbroken  DNA  has  been  found  to  be 
packaged  within  a  cage  of  RNA  and  protein  in  these  nucleoids.  However, 
they  lack  any  organised  membrane  structure  (McCready  et  al,  1980). 
A  model  based  on  the  premise  that  replication  takes  place  at  the 
nuclear  cage  has  also  been  suggested  (McCready  et  al,  1980)  and  supported 
by  the  sequencing  of  loops  of  the  nuclear  DNA  coding  for  the  alpha-  and 
beta-globin  genes  (Cook  &  Brazell,  1980).  Recently,  it  has  been 
proposed  that  regions  of  the  chromosomes  involved  in  replication  may  be 
preferentially  bound  to  the  nuclear  matrix  (Valenzuela  et  al,  1983). 
This  idea  has  been  supported  by  electron  microscopy  of  DNA  fragments 
showing  an  enrichment  of  replicating  forks. 
1.1.4  Nuclear  Pores 
Electron  microscopy  of  non-membranous  ghosts  from  HeLa  cell 
nuclei,  has  shown  the  presence  of  an  array  of  "Rod-like"  (250nm  long  and 
60nm  diameter)  and  "Annular"  structures  interconnected  by  thin  strands 
(Keller  &  Riley,  1976).  These  strands  are  composed  of  double  stranded 
DNA.  The  array  is  believed  to  be  responsible  for  the  spherical  shape  of 
the  interphase  nuclei.  Candidates  for  the  structural  components  that 
determine  the  nuclear  shape  have  been  isolated  (Keller  &  Riley,  1976)  and 
variously  called  the  "Pore  Complex-Lamina"  (Aarson  &  Blobel,  1975)  or 
"Nuclear  Protein  Matrix"  (Berezney  &  Coffey,  1974).  The  major 
components  of  the  ghost  include  annuli  with  inner  and  outer  diameters -7- 
43nm  and  90nm  respectively  which  are  consistent  in  dimensions  with 
nuclear  pore  structures  (Riley  &  Keller,  1978).  It  has  also  been 
proposed  that  the  non-membranous  layer  could  correspond  to  a  structural 
nuclear  framework  or  "Skeleton"  which  confines  and  possibly  organises 
interphase  nuclear  chromatin  and  confers  a  degree  of  mechanical  rigidity 
on  isolated  nuclei.  These  nucleoskeletons  have  been  isolated  from  cells 
in  all  stages  of  the  cell  cycle  except  mitosis  (Riley  &  Keller,  1978). 
Recently,  it  has  been  found  that  digestion  of  the  thin  connecting  strands 
by  DNases  results  in  the  destruction  of  the  gross  morphology  of  the 
nucleoskeleton  and  the  release  of  thick  rod-  and  pore-like  structures 
(Detke  &  Keller,  1982).  This  has  led  to  the  conclusion  that  DNA  is 
required  to  maintain  the  structural  integrity  of  the  nucleoskeleton.  In 
addition,  it  has  been  shown  that  the  major  nucleoskeletal  proteins  are 
also  present  as  major  components  of  the  chromosome  scaffold.  At  least 
two  of  the  nucleoskeletal  proteins  appear  to  be  modified  during  the 
transition  into  mitosis  suggesting  that  nuclear  dissolution  associated 
with  open  mitosis  is  accompanied  by  gross  rearrangement  of  the 
nucleoskeletal  elements  to  form  components  of  metaphase  chromosomes 
(Detke  &  Keller,  1982). -8- 
1.2  Control  of  Gene  Expression 
The  control  of  gene  expression  has  been  a  major  focus  of 
research  over  the  past  decade.  The  experimental  results  have  provided 
the  solution  to  a  number  of  structural  questions,  but  little  has  been 
achieved  with  respect  to  the  actual  mechanism.  Many  candidates  have 
been  suggested  to  play  a  part  in  this  process  including  RNA,  nonhistone 
chromosomal  proteins  and  ribonucleoproteins.  Research  on  the  control  of 
gene  expression  at  the  level  of  RNA  processing  and  DNA  modification  has 
been  particularly  intensive  and  has  shown  considerable  progress. 
1.2.1  Control  of  Initiation  of  RNA  Synthesis 
Eukaryotic  mRNAs  are  synthesised  in  the  nucleus  of  a  cell  as  a 
part  of  a  long  transcriptional  precursor  unit  referred  to  as 
heterogeneous  nuclear  RNA  (hnRNA). 
The  development  of  new  techniques  in  DNA  and  RNA  sequencing  has 
led  to  the  identification  of  sequences  in  and  near  many  structural  genes 
which  have  common  features  (reviewed  by  Paul,  1982).  The  isolation  of 
RNA  polymerases  has  helped  in  understanding  part  of  the  mechanism  of 
transcription.  In  addition,  other  mechanisms  involved  in  processing  and 
maturation  of  the  genetic  message  in  nuclei,  and  its  transportation  to 
the  cytoplasm  has  become  clearer.  It  is  now  widely  accepted  that  many 
eukaryotic  gene  sequences  on  the  DNA  are  discontinuous.  The  primary  RNA 
transcripts  (hnRNAs)  which  are  derived  from  these  DNA  segments  contain 
coding  sequences  (exons)  and  non-coding  sequences  (introns  or  intervening 
sequences)  (Abelson,  1979). 
The  formation  of  mature  eukaryotic  mRNA  in  nuclei  involves  a 
complex  series  of  reactions,  including  capping,  methylation, 
polyadenylation  and  splicing,  before  being  exported  to  the  cytoplasm.  A 
possible  control  mechanism  of  expression  has  been  suggested  at  each  level 
(Shatkin,  1976;  Banerjee,  1980;  Breathnach  &  Chambon,  1981;  Busch  et 
al,  1982;  Knowler,  1982). -9- 
A  simple  schematic  diagram  which  represents  some  important 
events  in  mRNA  maturation  is  shown  in  figure  1. 
1.2.1.1  Modulator  and  Enhancer 
The  fact  that  some  sequences  located  upstream  of  the  appropriate 
genes  are  associated  with  a  certain  level  of  control  of  gene  expression 
has  attracted  much  interest.  Sequences  comparable  to  the  promoter  in 
prokaryotes  have  been  reported  in  the  sea  urchin  H2A  histone  gene 
(Grosschedl  &  Birnstiel,  1980a)  and  in  cloned  mutants  of  SV40  (Benoist  & 
Chambon,  1980,1981). 
Recent  interest  has  been  focu  sed  on  other  sequences  situated 
upstream  of  the  initiation  site  of  transcription.  Grosschedl  & 
Birnstiel  (1980b)  working  on  sea  urchin  H2A  histone  gene,  have  shown 
the  presence  of  three  functional  DNA  segments  located  upstream  of  the 
gene,  given  the  names,  "Modulator  Selector  &  Initiator"  elements.  The 
modulator  has  been  shown  to  control  the  rate  at  which  the  specificity 
elements  operate.  Dierks  et  al  (1981)  have  reported  a  10  bp  sequence 
located  before  the  cap  site  and  also  found  preceding  rabbit  beta-globin 
genes  and  many  other  genes  at  a  similar  location.  This  sequence  may  be 
involved  in  modulating  the  efficiency  of  transcription. 
Sequences  called  "Enhancers"  with  analogous  characteristics  to 
the  modulator  described  earlier,  have  also  been  reported  in  the 
eukaryotic  viral  gene  of  SV40.  Banerji  et  al  (1981)  have  found  a  72 
base  sequence  which  greatly  enhances  transcription  of  genes  located 
upstream  of  the  initiation  site  of  the  gene. 
1.2.1.2  Initiators  and  Selectors 
Transcriptional  initiation  is  one  level  of  the  control  of 
eukaryotic  gene  expression.  The  specificity  for  the  location  and  the 
frequency  of  transcription  initiation  resides  in  the  upstream 
5'-sequences  for  genes  transcribed  by  RNA  polymerase  II  (Breathnach  & 
Chambon,  1981)  and  probably  by  RNA  polymerase  I  (Grummt,  1981). -  10  - 
Figure  1  Diagramatic  representation  of  the  processing  of  the  transcript 
of  a  gene  containing  a  single  intron 
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Sequences  situated  upstream  from  the  initiation  site  of  specific  genes 
have  been  reported  to  be  responsible  for  transcription  initiation.  A 
possible  consensus  sequence  for  such  initiation  is  called  the  "Chambon 
box"  (Benoist  et  al,  1980;  Struhl,  1981).  This  sequence  resides 
approximately  80  bp  upstream. 
Another  consensus  sequence  commonly  centred  about  25-30  bp 
upstream  from  the  cap  site  has  also  been  reported  in  most  of  the  genes 
sequenced  so  far.  This  (AT)  rich  sequence  which  is  known  as  "TATA"  box 
was  first  noted  by  Goldberg  and  Hogness  (see  e.  g.  Breathnach  &  Chambon, 
1981).  It  is  believed  that  this  sequence  is  necessary  for  accurate 
initiation,  since  in  its  absence  multiple  initiation  points  have  been 
reported  (Benoist  &  Chambon,  1981;  Grosveld  et  al,  1982).  It  is  also 
reported  that  upon  deleting  this  sequence,  a  lower  rate  of  initiation  has 
been  noted  in  other  genes  (Paul,  1982).  Other  workers,  using  mutants 
lacking  the  sequence  upstream  from  position-29,  have  shown  that  specific 
transcription  is  not  promoted  in  the  absence  of  such  consensus  sequence 
(Corden  et  al,  1980).  Recently,  Davison  et  al  (1983)  have  found  that 
the  TATA  box  region  is  involved  in  the  stable  binding  of  transcription 
factor(s). 
In  any  case,  since  the  TATA  box  is  absent  from  some  genes 
(Breathnach  &  Chambon,  1981),  Grosschedl  and  Birnstiel  (1980a,  1980b) 
have  proposed  that  the  TATA  box  acts  as  a  "selector". 
1.2.2  Control  at  the  Level  of  RNA  post-transcriptional  Modifications 
1.2.2.1  Polyadenylation 
Two  important  modifications  commonly  occur  to  hnRNA  before  it  is 
processed  further  to  yield  mRNA.  These  modifications  are 
polyadenylation  at  the  3'-end  and  capping  at  the  5'-end. 
Evidence  for  the  occurrence  of  poly(A)  sequences  in  cytoplasmic 
mRNA  was  first  reported  by  Edmonds  and  Caramela  (1969).  It  has  been 
shown  that  poly(A)  is  absent  in  nucleolar  RNA  (rRNA)  but  is  present  in 
the  RNAs  of  both  cytoplasm  and  nucleoplasm  (Edmonds  et  al,  1971). -  12  - 
An  important  hexanucleotide  sequence  (AAUAAA)  has  been  found  to 
signal  the  post-transcriptional  addition  of  polyadenylic  acid.  This 
hexaucleotide  is  located  at  about  25-30  nucleotides  from  the  3'-end  of 
mRNA  (Proudfoot  &  Brownlee,  1976),  and  it  has  been  observed  in  all 
eukaryotic  mRNAs  studied  so  far.  This  sequence  has  also  been  found  in 
the  late  gene  of  eukaryotic  virus  SV40  (Fitzgerald  &  Shenk,  1981). 
However,  other  components  or  structural  features  may  also  be  involved. 
It  is  worth  noting  that  in  a  number  of  genes,  the  hexanucleotide  sequence 
is  found  in  internal  positions  and  does  not  induce  polyadenylation. 
Moreover,  several  cases  are  known  where  transcription  units  contain  more 
than  one  polyadenylation  site  (for  review  see  Knowler,  1982). 
The  nature  of  the  mRNA  product  from  a  transcript  could  be 
post-transcriptionally  controlled  by  differential  selection  of 
polyadenylation  sites  (Nevins  &  Darnell,  1978).  However,  some  evidence 
supports  a  role  for  the  3'-end  poly(A)  tail  in  extending  the  stability  of 
mRNA  and  in  the  selection  of  the  3'-end  mRNA  chains  during  their 
biogenesis  (Browerman,  1981).  It  has  also  been  suggested  that  the 
polyadenylate  may  modulate  mRNA  transport  across  the  nuclear  membrane. 
However,  histone  mRNA  which  lacks  a  poly  (A)  tail,  has  been  found  to 
leave  the  nucleus  much  faster  than  the  polyadenylated  sequence  (Andesnik 
&  Darnell,  1972;  Greenberg  &  Perry,  1972).  Another  possible  role  for 
the  poly(A)  sequence  is  its  involvement  in  the  splicing  mechanism  (Bina 
et  al,  1981).  This  has  been  contradicted  by  Zeevi  et  al  (1981)  who  have 
shown  that  splicing  can  occur  in  the  absence  of  polyadenylation. 
1.2.2.2  Capping 
5'-Terminal  capping  is  one  of  the  important  post-transcriptional 
processes  to  which  an  hnRNA  is  subjected  before  maturation  to  yield 
mRNA.  The  unique  5'-cap  was  first  shown  by  Reddy  et  al  (1974).  The 
5'-end  of  the  gene  transcript  is  capped  by  the  addition  of  a  7-methyl 
guanosine  (Cap-O)  through  a  pyrophosphate  bond  (Zimmern,  1975;  Dubin  & -  13  - 
Stollar,  1975).  The  cap  may  then  be  modified  further  by  the 
2'-0-methylation  of  the  ribose  moieties  of  the  first  or  the  first  two 
nucleotides  of  the  transcripts  (Cap-1  and  Cap-2  respectively)  (Moyer  & 
Banerjee,  1976;  Rose,  1975;  Sommer  et  al,  1976).  The  cap  protects  the 
mRNA  against  attack  by  phosphatases  and  other  nucleases  at  its 
terminus.  In  addition,  it  promotes  the  mRNA's  functional  role  at  the 
level  of  initiation  of  translation  (Rottman  et  al,  1974). 
The  5'-termini  of  both  mature  mRNA  and  its  precursors  are 
identical  and  map  at  the  same  point  on  the  gene  sequence  (Weaver  & 
Weismann,  1979).  This  suggests  that  transcription  is  likely  to  be 
initiated  at  or  very  close  to  the  5'-end  of  the  mRNA  and  little,  if  any, 
5'-trimming  occurs. 
A  number  of  eukaryotic  genes  have  a  tetranucleotide  (CTCA) 
sequence  immediately  preceding  the  encoding  sequence  of  mRNA  which  may 
represent  a  capping  signal  (Vankatesan  et  al,  1980). 
Yamaguchi  et  al  (1982)  have  observed  another  sequence  which  is 
complementary  to  the  3'-terminal  of  18S  rRNA,  but  situated  in  the 
5'-noncoding  region  of  eukaryotic  mRNA.  This  sequence  together  with  the 
5'-cap  structure  enhance  the  rate  of  initiation  of  the  complex  formation 
in  protein  synthesis. 
1.2.3  Control  by  Differential  Gene  Splicing 
One  of  the  major  alterations  which  occur  to  the  primary  RNA 
transcript  (hnRNA)  is  cutting  various  sequences  (introns)  and  joining  the 
remaining  sequences  (exons)  in  a  process  called  "Splicing".  This 
process  produces  a  mature  mRNA  ready  to  cross  the  nuclear  membrane  to  the 
cytoplasm.  Splicing  has  attracted  a  considerable  amount  of  attention  in 
recent  times  as  potential  control  mechanism  (reviewed  recently  by  Mount, 
1982).  The  sites  of  splicing  points  at  the  exon-intron  junctions  has 
been  the  focus  of  interest.  Mount  (1982)  has  collected  a  catalogue 
containing  the  sequences  of  splicing  sites  from  a  large  number  of  nuclear -  14  - 
as  well  as  viral  gene  encoding  proteins.  These  are  called  the  consensus 
sequences.  The  catalogue  has  also  confirmed  the  presence  of  GT/AG  rule 
originally  described  by  Breathnach  et  al  (1978).  The  GT  is  present  at 
the  beginning  of  the  intron  and  AG  is  at  the  end.  This  rule  has  been 
obeyed  in  the  majority  of  the  collected  intron/exon  sequences  except  for 
few  cases  like  the 
-X  immunoglobulin  gene  of  MOPC-315  plasmacytoma 
(Bothwell  et  al,  1981)  and  in  alpha-crystallin  eye  lens  gene  (King  & 
Piatigorsky,  1983).  However,  splicing  is  not  a  simple  mechanism  and 
many  nuclear  proteins  and  poly-ribonucleotide  (such  as  the  small  nuclear 
RNAs-snRNA)  components  are  thought  to  be  involved  (Rogers  &  Wall,  1980; 
Lerner  &  Steitz,  1979;  Lerner  et  al,  1980). 
It  is  now  well  known  that  eukaryotic  genes  are  subjected  to 
various  degrees  of  regulation  at  the  transcriptional  and 
post-transcriptional  levels.  Two  categories  of  transcriptional  units 
can  be  identified.  A  "simple"  transcription  unit  which  encodes  single 
protein  genes  such  as  the  histone  genes  (Hentschel  &  Birnstiel,  1981)  and 
alpha-  and  beta-globin  transcription  units  (Nishioka  &  Leder,  1979).  On 
the  other  hand,  the  "complex"  transcription  units  are  those  whose  primary 
transcript  can  produce  more  than  one  mRNA  encoding  more  than  one 
protein.  These  transcripts  contain  two  or  more  poly(A)  sites,  and  two 
or  more  variations  of  post-transcriptional  gene  expression  (Darnell, 
1982).  Two  important  systems  of  this  type  are  the  viral  and 
immunoglobulin  systems. 
1.2.3.1  The  Viral  System 
Viral  systems  have  been  widely  employed  in  the  study  of  some  of 
the  mechanisms  involved  in  gene  structure  and  gene  expression.  Studies 
on  the  control  of  gene  expression  by  differential  transcript  processing 
or  splicing  in  viruses,  have  produced  much  information  relating  to  the 
complex  mechanism  of  mRNA  maturation. 
analysed  in  SV40  (Fiers  et  al,  1978; 
This  process  has  been  extensively 
Shermann  &  Weisman,  1980),  Polyoma -  15  - 
(Soeda  et  al,  1980),  adenovirus  and  other  viruses  (Darnell,  1982;  Logan 
&  Shenk,  1982)  and  more  recently  in  influenza  virus  (Lamb  &  Lai,  1982). 
In  practical  terms,  RNA  splicing  is  believed  to  be  a  control 
mechanism  and/or  a  regulatory  event.  The  adenovirus  system  provides  a 
good  model  for  this-theory.  The  study  of  the  formation  of  adenovirus 
mRNA  has  provided  many  of  the  details  of  eukaryotic  mRNA  biogenesis. 
Multiple  steps  are  required  to  produce  a  functional  mRNA  including  steps 
where  alternative  pathways  are  possible.  In  adenovirus,  at  early  stages 
after  infection,  at  least  six  transcription  units  are  expressed.  All  of 
these  units  encode  families  of  messenger  ribonucleic  acids  whose  members 
are  differentially  processed  by  splicing  and  as  a  result  encode  different 
polypeptides.  At  late  (L)  time  after  infection,  new  families  of  mRNAs 
are  made  and  most  of  these  are  produced  from  a  single  transcription  unit. 
At  early  (E)  time  after  infection,  E1A  gene  region  encodes  two 
mRNAs  which  are  produced  by  differential  splicing.  The  E1A  specific 
gene  product  facilitates  expression  of  other  mRNAs,  E1B,  E2,  E3,  E4  and 
L1  (Jones  &  Shenk,  1979).  It  is  also  likely  that  a  variety  of 
non-adenovirus  genes  are  regulated  by  similar  mechanisms.  In  addition, 
E1A  not  only  acts  at  the  level  of  initiation  of  transcription  but  may 
modulate  certain  cellular  genes  (Logan  &  Shenk,  1982). 
Recently,  analysis  of  the  product  of  adenovirus  L1  mRNA  during 
early  and  late  infection  has  provided  evidence  for  the  control  of  gene 
expression  through  an  alternative  splicing  pathway  (Chow  et  al,  1979). 
Evidence  for  the  expression  of  a  particular  region  of  a  genome  which  can 
be  controlled  through  alternative  splicing  of  the  primary  RNA  transcripts 
has  been  found  not  only  in  viruses  but  also  in  cellular  genes  (Amara  et 
al,  1982;  King  &  Piatigorsky,  1983). 
More  recently,  Mariman  et  al  (1983),  using  mapping  data  from  Sl 
nuclease  digestion  have  shown  that  there  are  alternative  splicing 
pathways  for  the  excision  of  the  first  and  second  introns  from  RNAs  that -  16  - 
are  derived  from  the  major  late  transcription  unit  in  adenovirus.  It  is 
interesting  to  note  that  the  first  cleavages  are  introduced  in  the 
nascent  RNA  before  the  RNA  polymerase  has  progressed  more  than  2000 
nucleotides  beyond  the  cleavage  sites.  It  is  also  shown  that  intron  (1) 
is  preferentially  removed  before  intron  (2),  however.  alternative  pathways 
have  also  been  found.  Similarly,  Sherman  and  Weissman  (1980)  have 
indicated  that  in  SV40  virus,  splicing  is  not  strictly  sequential. 
Moreover,  the  expression  of  a  transcription  unit  such  as 
adenovirus  unit,  could  also  be  controlled  through  differential  poly(A) 
site  selection  at  the  post-transcriptional  stem  (Darnell,  1982).  the 
same  is  true  of  the  immunoglobulin  heavy  chain  gene  (see  section 
1.2.3.2).  However,  nuclear  RNA  splicing  in  adenovirus-2  mRNA  formation 
has  also  been  noted  in  the  absence  of  poly(A)  sites  (Zeevi  et  al,  1981). 
1.2.3.2  The  Immunoglobulin  System 
{t.  J6 
Antibodies  are  composed  of  two  identical  heavy-  and, 
4 
light-chain 
polypeptides.  Each  heavy  (H)  and  light  (L)  chain  contains  an  amino 
terminal,  variable  (V)  region  and  a  carboxyl  end,  constant  (C)  region. 
The  variable  regions  are  encoded  by  several  hundred  germ-line  genes, 
while  a  very  limited  number  of  genes  encode  the  (C)  region.  The  various 
classes  of  immunoglobulins  with  different  functions  (IgM,  IgD,  IgG,  IgE 
and  IgA)  are  distinguished  by  different  heavy  chains  defined  by  their 
constant  regions.  The  mouse  CH  gene  locus  consists  of  eight  genes 
(p,  6,  Y3  .  12a,  12b, 
Y1.,  e  ,d)  (Marcu,  1982)  . 
Vertebrate  immune  systems  are  able  to  respond  specifically  to  an 
almost  unlimited  number  of  different  foreign  molecules  (antigens).  The 
production  of  immunoglobulins  that  bind  specifically  to  the  antigen 
comprises  the  major  component  of  this  response.  The  genes  encoding 
immunoglobulins  display  several  complex  features  associated  with  the  need 
to  generate  such  a  large  repertoire  of  specificities. -  17  - 
There  are  three  unlinked  immunoglobulin  gene  families:  the 
light  chain  (k)  and  ())  gene  families  and  a  single  gene  family  encodes 
heavy  chains  (Tonegawa,  1983).  Variable  regions  show  the  most 
diversity;  this  is  due  to  the  role  of  the  variable  region  to  recognise 
vast  varieties  of  immunogens  (antigens).  To  create  variable  region 
diversity,  at  least  one  specific  genetic  mechanism  exists;  the  process 
of  DNA  joining.  Light  chain  variable  regions  are  encoded  by  two  gene 
segments,  variable  (V)  and  joining  (J),  which  are  separated  in  germ  line 
DNA.  The  heavy  chain  variable  regions  are  encoded  by  three  such  gene 
segments,  (V),  diversity  (D)  and  (J)  (Early  et  al,  1982,  Marcu,  1982; 
Höchtl  &  Zachau,  1983;  Alt  &  Baltimore,  1982). 
It  has  been  found  that  during  B-lymphocyte  development  and 
immunoglobulin  synthesis,  the  (p)  heavy  chain  is  first  inserted  as  an 
integral  protein  in  the  plasma  membrane.  However,  a  similar  (p)  chain 
has  been  detected  as  part  of  secreted  immunoglobulins  (Alt  et  al, 
1980).  It  has  also  been  observed  that  the  mRNA  isolated  from 
B-lymphocyte  tumour  cell  lines  directs  the  synthesis  of  two  forms  of 
heavy  chains,  67,000  and  64,000  in  molecular  weight.  Rogers  et  al 
(1980)  using  cDNA  clones  of  mouse  B-lymphocyte  tumours  have  noted  the 
presence  of  two  mRNAs  which  differ  in  their  3'-termini.  One  3'-terminus 
has  been  found  to  dictate  amino  acid  sequences  appropriate  for 
membrane-binding  and  the  other  is  involved  in  secretion.  This  work  has 
been  substantiated  by  further  analysis  of  the  data  obtained  from  the 
cloning  experiments.  Early  et  al  (1980)  in  their  analysis  of  the 
genomic  cloned  DNA  data  have  revealed  the  presence  of  two  poly(A)  sites 
in  the  same  transcription  unit  and  the  primary  transcript.  It  has  also 
been  shown  that  depending  on  the  choice  of  poly(A)  site,  two  heavy  chain 
mRNAs  can  be  formed.  These  two  xRNAs  produce  two  different  products; 
the  pmembrane  (m)  chain  and  the  p  secreted  (S)  one.  Both  Nm  and  Ps 
mRNAs  are  produced  from  transcripts  of  a  single  gene.  The  mapping -  18  - 
analysis  data  have  also  suggested  that  developmental  control  of  the  site, 
at  which  poly(A)  is  added  to  the  transcripts  of  the  Ngene,  determines  the 
relative  levels  of  pm  or  ps  chain  synthesis.  Meanwhile,  Singer  et  al 
(1980)  working  on  human  lymphoma  cells  have  arrived  at  a  similar  finding 
regarding  the  presence  of  two  kinds  of  mRNA  coding  for  receptor  and 
secretory  forms  of  IgM  N-chains.  They  have  proposed  that  the 
synthetic  pathways  for  these  immunoglobulins  diverge  at  the  post 
transcriptional  level,  possibly  by  differential  RNA  splicing. 
Moreover,  murine  cell  lines  producing  IgG  have  also  been  found 
to  produce  two  mRNA  species  for  immunoglobulin  "(-chains  (Rogers  et  al, 
1981).  Membrane-bound  or  secreted  antibody  is  thought  to  be  expressed 
first  by  regulation  of  the  site  of  transcriptional  termination  or  poly(A) 
addition  and  then  by  site  specific  RNA  splicing  (Rogers  et  al,  1981). 
Recently,  Knapp  et  al  (1982)  have  noted  a  simultaneous 
expression  of  immunoglobulin  N-  and  5-chains  from  a  cloned  B-cell 
lymphoma,  where  a  single  copy  of  VH  gene  is  shared  by  two  adjacent  Cp 
and  CS  genes.  They  argue  that  dual  expression  of  P-  and  S-heavy 
chains  using  a  single  VH  gene  is  accomplished  by  alternate  RNA  splicing 
mechanism.  Similar  suggestion  by  Moore  et  al  (1981)  have  also  been 
reported  earlier,  using  clones  from  mouse  sperm  DNA.  They  have  also 
compared  their  results  with  that  of  rat  myeloma  DNA  whose  Cp  gene  has 
been  deleted.  They  have  concluded  that  two  alternative  mechanisms  may 
be  used  in  the  expression  of  IgD  molecules;  RNA  splicing  in  B-cells  and 
DNA  rearrangement  in  plasma  cells.  Other  workers  have  also  reported  RNA 
splicing  as  a  control  mechaiism  (Maki  et  al,  1981)  in  immunoglobulin 
synthesis.  They  have  also  suggested  that  the  same  five  exonic  regions 
common  to  both  N  chains  also  appear  in  9  chains. 
The  molecular  basis  of  the  presumed  differential  choices  of 
poly(A)  and  splice  sites  is  not  fully  known  and  it  remains  possible  that 
other  components  or  template  changes  may  dictate  a  post-transcriptional -  19  - 
outcome.  It  is  still  possible  that  a  selective  protein  that  binds  to 
the  DNA  at  one  or  the  other  poly(A)  site  might  instead  trigger  the  choice 
of  poly(A)  site  during  transcription  (Darnell,  1982). 
1.2.4  Translational  control 
The  initiation  of  polypeptide  chain  synthesis  in  eukaryotes 
involves  a  complex  series  of  events,  including  a  number  of  nonribosomal 
initiation  factors  (eIF)  (for  review  see  Thomas  et  al,  1981) 
The  primary  event  in  the  initiation  of  protein  synthesis  is  the 
A 
formation  of  a  ternary  complex  (80S.  Met-tRNA.  mRNA)  and  the  first 
important  step  in  the  formation  of  this  complex  is  the  association  of 
eukaryotic  initiation  factor  (2)  (eIF-2),  which  consists  of  three 
subunits  (0c,  A  ,  &1(),  with  met-tRNA  and  GTP  molecules  (Gupta  et  al, 
1973).  Factor  eIF-2  as  well  as  having  a  crucial  role  in  this 
association  is  subjected  to  regulation  by  phosphorylation  (Clemens  et  al, 
1982;  Pain  &  Clemens,  1983).  A  summary  of  the  initiation  of  protein 
synthesis  is  shown  in  Figure  (2). 
Figure  2  Initiation  of  protein  synthesis  (adapted  from  Thomas  et 
al,  1981) 
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Gene  expression  in  eukaryotes  often  involves  the  selective 
translation  of  certain  mRNA  templates  over  the  others.  This  type  of 
regulation  is  used  frequently  in  virus-infected  cells  and  in  cell 
differentiation.  Most  animal  viruses  are  able  to  adopt  the  protein 
synthesising  machinery  and  make  it  translate  the  viral  mRNA  and  shut-off 
the  translation  of  the  host  mRNA.  This  mRNA  discrimination  is  thought 
to  occur  mainly  at  the  initiation  step  which  involves  the  recognition  of 
mRNA  and  binding  of  the  ribosome. 
It  has  been  observed  that  Mengovirus  RNA  competes  thirty  five 
times  more  effectively  than  globin  mRNA,  in  the  reticulocyte  lysate 
system,  for  a  critical  component  in  translation  (Rosen  et  al,  1982). 
The  competition  is  relieved  by  the  addition  of  eIF-2.  This  suggests 
that  the  virus  RNA  competes  directly  or  indirectly  with  the  globin  mRNA 
for  eIF-2.  In  another  experiment  Walden  et  al  *(1981),  using  reovirus 
infected  SC-1  cells,  have  found  that  viral  and  host  mRNAs  must  compete 
for  a_message-discriminatory  component  prior  to  their  binding  to  the  40S 
ribosomal  complex.  However,  they  also  found  that  the  host  mRNAs  in 
general  have  greater  affinities  than  reovirus  mRNA. 
Among  the  other  possible  control  mechanisms  for  gene  expression 
at  the  translational  level  in  eukaryotes,  is  the  sequestering  of  mRNA 
into  inactive  particles  (mRNPs)  unassociated  with  ribosomes  (Heywood  & 
Kennedy,  1976;  Havaranis  &  Heywood,  1981).  In  addition,  Bester  et  al 
(1975)  have  suggested  that  a  small  RNA  named  translational-control  RNA 
(tcRNA)  is  involved  in  maintaining  the  mRNA  in  an  inactive  state.  It 
has  been  reported  recently  that  small  RNAs  are  associated  with  stored 
mRNPs  in  a  variety  of  cell  systems  (Vincent  et  al,  1980;  O'Loughlin  & 
Gross,  1981).  Indeed  a  myosin  heavy  chain  (MHC)  mRNA  has  been  purified 
and  shown  to  contain  a  number  of  low  molecular  weight  RNAs  (Havaranis  & 
Heywood,  1981).  Recently,  three  low  molecular  weight  RNAs  molecules 
including  tcRNA  have  been  found  in  chick  embryonic  skeletal  muscle.  The -  21  - 
tcRNA  (102  nucleotides)  has  been  shown  to  inhibit  the  translation  of 
mRNAs  with  which  it  is  associated  (McCarthy  et  al,  1983).  Interactions 
of  mRNA-tcRNA  102  alter  the  secondary  structure  of  mRNA.  Some  kind  of 
specificity  is  involved  in  this  RNA-RNA  interaction  because  tcRNA  has 
shown  no  tendency  to  associate  with  ribosomal  RNA  or  globin  mRNA 
(McCarthy  et  al,  1983).  This  may  suggest  a  certain  degree  of  control  at 
the  translational  level. 
1.2.5  Control  at  the  Level  of  DNA  Methylation 
Modified  purine  and  pyrimidine  bases  in  DNA  have  been  observed 
for  more  than  three  decades  (reviewed  by  Razin  &  Riggs,  1980;  Adams  & 
Burdon,  1982).  The  most  significant  of  these  modifications  is  the 
methylation  of  cytosine  at  position  number  five  (m5C)  and  to  a  lesser 
extent  6-methylaminopurine  (m6  A). 
The  methyl  group  in  5-methylcytosine  is  located  in  the  major 
groove  of  DNA  helix  and  does  not  change  the  base  pairing  characteristics 
of  cytosine  (Razin  &  Riggs,  1980).  The  methylated  base  m5C  has  been 
found  in  2-7%  of  mammalian  DNA  (Vanyushin  et  al,  1970).  Methylation 
occurs  enzymatically  after  DNA  synthesis  by  methyl  transfer  from 
S-adenosylmethionine  (Burdon  &  Adams,  1969). 
The  studies  on  methylated  sites  have  become  intensified  since 
the  discovery  of  the  inverse  relationship  between  the  sites  of  digestion 
of  many  bacterial  endonucleases  and  the  methylated  sites  of  the  genome 
(Razin  &  Riggs,  1980).  Many  bacterial  restriction  enzymes  have  shown  a 
strong  affinity  for  unmethylated  restriction  sites  but  they  have  low 
affinity  and  no  activity  on  methylated  sites  (Smith,  1979;  Roberts, 
1978). 
The  location  of  the  methylated  cytosine  is  non-random.  About 
90%  of 
m5C 
residues  in  eukaryotic  DNA  are  found  in  the  dinucleotide 
sequence  CpG.  Several  restriction  enzymes  include  CpG  in  their -  22  - 
recognition  sequence  (Roberts,  1978)  and  most  of  these  enzymes  do  not 
digest  the  DNA  if  the  CpG  sequence  is  methylated  (Van  der  Ploeg  & 
Flavell,  1980). 
The  preliminary  indication  that  gene  activity  was  associated 
with  undermethylation  was  reported  by  Christman  et  al  in  1977.  This 
finding  has  been  supported  later  by  the  work  of  Jones  and  Taylor  (1980). 
However,  Rogers  and  Wall  (1981)  working  on  immunoglobulin  heavy 
chain  genes  in  relation  to  methylation  and  class  switching,  have  noted 
that  the  p,  Yi,  and  8  genes  are  allJ2methylated  when  they  are  expressed. 
Numerous  reports  correlating  hypo-  and  hyper-methylation  with 
the  state  of  gene  activation  have  been  published  recently.  The 
restriction  sites  of  digestion  of  some  endonucleases  are  similar  but  can 
differentiate  between  the  methylated  and  unmethylated  CG  sequence  (Jones 
et  al,  1981;  Piekarwicz,  1982).  In  assessing  the  relationship  between 
the  state  of  methylation  and  gene  activation,  some  groups  have  concluded 
that  in  mammalian  sperm,  RBCs,  and  early  embryog  ,  the  DNA  is  highly 
methylated  and  undermethylation  is  associated  with  gene  activity 
(Waalwijk  &  Flavell,  1978;  Mandel  &  Chambon,  1979;  Jones  et  al,  1981; 
Bird  et  al,  1981)  while  in  contrast,  unmethylation  at  the  HpaII  sites  in 
a  variety  of  tissues  including  sperm  has  been  noted  (Bower  et  al, 
1983).  However,  co-existance  of  methylated  and  unmethylated  sequences 
in  the  same  genome  has  been  observed  in  a  wide  range  of  eukaryotes.  In 
addition,  the  presence  of  unmethylated  sequences  in  the  otherwise  heavily 
methylated  genomes  of  vertebrates  suggests  that  methylation  compartments 
are  a  general  feature  of  eukaryotic  genomes  (Cooper  et  al,  1983). 
Naveh-Many  &  Cedar  (1981)  have  suggested  that  transcribed 
sequences  in  the  chicken  are  undermethylated  compared  to  those  in  the 
genomic  DNA.  However,  analysis  of  individual  chicken  genes  has  shown  a 
rather  complex  picture  with  methylation  patterns  that  vary  for  different 
genes.  Moreover,  Weintraub's  group  has  shown  a  correlation  between  the -  23  - 
DNase-I  sensitivity,  the  presence  of  HMG-14  and  -17  and  acetylated 
histones,  a  deficiency  of 
m5C 
at  certain  sites  and  the  expression  of 
globin  genes  during  the  development  of  the  chick  (Groudine  &  Weintraub, 
1981;  Weintraub  et  al,  1981).  Weintraub  et  al  (1981)  have  analysed  the 
chromosome  structures  and  expression  of  cc-gene  cluster  in  developing 
chicken  embryos  and  have  shown  that  adjacent  regions  at  both  5'-  and  3'- 
sides  of  the  active  a-genes  are  methylated  and  relatively  insensitive  to 
DNase-I.  As  a  general  conclusion  a  correlation  between  regions  of  the 
chromosomes  that  are  undermethylated  and  regions  that  are  expressed  seems 
to  be  favoured. 
1.2.6  Control  at  the  Level  of  Chromatin  Structure 
It  is  now  widely  accepted  that  active  genes  are  packaged  into  an 
altered  nucleosome  structure.  The  chromatin  structure  of  the 
transcribed  genes  is  different  from  that  of  the  bulk  of  DNA.  The 
difference  reflects  an  essential  feature  in  explaining  some  aspects  of 
gene  expression,  especially  with  respect  to  nuclease  digestion.  Other 
variations  which  may  dictate  special  function  in  gene  activity  stems  from 
the  role  of  some  non-histone  proteins  and  variant  histone  components. 
1.2.6.1  Nuclease  Sensitivity 
The  use  of  DNases  has  helped  a  great  deal  in  understanding  and 
differentiating  the  areas  of  actively  transcribed  gene  from  the  inactive 
ones.  Weintraub  &  Groudine  (1976),  studying  transcribed  and 
non-transcribed  genes  have  demonstrated  that  the  globin  gene  in  chick 
erythrocyte  nuclei  is  preferentially  sensitive  to  digestion  by  pancreatic 
DNAse-I.  They  have  also  shown  that  the  gene  is  resistant  to  micrococcal 
nuclease  which  suggests  that  it  is  packaged  into  nucleosome-like 
particles  that  are  different  from  most  other  nucleosomes.  TheDNase-I 
sensitivity  has  been  found  to  be  tissue  specific  (Weintraub  &  Groudine, 
1976;  Garel  &  Axel,  1976).  DNase-I  sensitivity  of  actively  transcribed 
genes  seems  to  be  a  general  phenomenon  (Garel  &  Axel,  1976;  Flint  & -  24  - 
Weintraub,  1977;  Groudine  et  al,  1978;  Storb  et  al,  1981).  However, 
the  micrococcal  nuclease  sensitive  fraction  of  calf  thymus  nucleosomes 
have  also  been  found  to  be  enriched  in  transcriptionally*active  DNA 
(Davie  &  Saunder,  1981).  In  a  similar  fractionation  technique  and  using 
micrococcal  nuclease,  it  has  been  possible  to  separate  actively 
transcribed  genes  and  genes  which  are  transcribed  at  different  rates. 
Results  obtained  by  this  method  have  been  difficult  to  substantiate 
(Weisbrod,  1982). 
Recently,  Nicolas  et  al  (1983)  have  demonstrated  that  higher 
order  chromatin  structures  might  be  responsible  for  nuclease  sensitivity 
of  active  genes.  Gottschling  et  al  (1983)  have  reported  that  the 
transcribed  region  of  rRNA  genes  in  Tetrahymena  has  a  shorter  nucleosome 
repeat  compared  with  the  non-transcribed  central  spacer  of  bulk 
chromatin.  However,  the  transcribed  region  has  been  found  to  display  an 
increased  sensitivity  to  micrococcal  nuclease  in  rapidly  growing  cells 
which  suggests  an  altered  chromatin  structure  during  transcription.  In 
an  extension  to  the  previous  finding,  Palen  and  Cech  (1983)  have 
concluded  that  transcriptional  activation  is  accompanied  by  major  changes 
in  the  structure  of  the  ribosomal  gene  chromatin  and  that  the  extent 
and/or  type  of  structural  alteration  differs  in  each  functionally  defined 
region  of  the  rDNA. 
DNase-I  sensitivity  as  a  property  of  active  gene  regions  has 
been  correlated  with  under-methylation  of  DNA  (Razin  &  Riggs,  1980). 
This  correlation  has  been  noted  in  the  chicken  globin  gene  (Weintraub  et 
al,  1981),  ovalbumin  (Kuo  et  al,  1979)  and  in  other  systems  (for  review 
see  Adams  &  Burdon,  1982). 
DNase-I  hypersensitive  regions  have  also  been  observed.  These 
are  located  in  specific  positions  of  the  genome.  In  Drosophila,  they 
are  located  in  the  vicinity  of  the  heat  shock  genes  (Wu,  1980)  adjacent 
to  the  5'-ends  of  the  coding  regions.  Similarly,  DNase-I  hypersensitive -  25  - 
sites  have  been  found  in  other  systems  (Stadler  et  al,  1980;  Weintraub 
et  al,  1981),  also  situated  adjacent  to  the  coding  sequences  of  the 
genes.  Tissue  specificity  of  DNase-I  hypersensitivity  has  been  found  in 
rat  preproinsulin-II  gene  system,  predominant  in  insulinoma  and  absent  in 
nonexpressing  tissues  such  as  kidney,  spleen  and  brain  (Wu  &  Gilbert, 
1981).  The  structural  basis  and  the  functional  significance  of  DNase-I 
hypersensitivity  are  not  well  understood  (see  Igo-Kemenes  et  al,  1982). 
1.2.6.2  Histone  H1 
Chromatin  is  usually  undergoing  extensive  transient  alterations 
in  structure  during  the  cell  cycle.  During  (S)  phase,  the  DNA  must  be 
made  accessible  in  such  a  way  to  be  presented  to  DNA-polymerases.  Later 
during  mitosis,  the  DNA  is  folded  and  compacted  to  form  the  mitotic 
chromosomes.  Several  structural  and  functional  protein  changes  must 
accompany  this  sequential  organisation.  H1  histone  is  believed  to 
play  a  role  in  the  higher  order  structure  of  chromatin  (see  section 
1.1.1.2).  The  occurrence  of  precisely  timed  stage-specific  changes  in 
histone  subtypes  during  development  suggests  that  they  are  important  in 
differentiation  (Cohen  et  al,  1979).  Direct  evidence  for  the  specific 
exchange  of  one  histone  subtype  for  another  has  been  demonstrated  in 
fertilised  sea  urchin  eggs  (Poccia  et  al,  1981).  The  switch  in  histone 
Hl  occurs  almost  immediately  while  the  core  histones  are  replaced  at 
specific  intervals. 
Post-synthetic  histone  modification  by  phosphorylation, 
acetylation,  methylation  and  poly  ADP  ribosylation  is  a  well  studied 
feature  of  chromatin  structure  and  metabolism.  Attempts  have  been  made 
to  link  these  modifications  to  transcriptional  activation.  Correlations 
between  an  increase  in  histone  acetylation  and  increased  RNA  synthesis 
have  been  observed  (Weisbrod,  1982).  Special  attention  has  been 
focu  sed  on  linking  the  enrichment  of  histone-acetylation  to 
transcriptionally  active  chromatin  (Weisbrod  &  Weintraub,  1981). -  26  - 
Phosphorylation  of  H1  histone  has  been  implicated  in  gene  activation. 
H1  is  generally  present  in  2-5  subtypes  differing  from  one  another  in 
the  N-terminal  region  of  the  molecules  (for  review  see  Cartwright  et  al, 
1982).  H1  histone  undergoes  cell  cycle  related  phosphorylation  at 
several  sites,  principally  during  (S)  phase  and  mitosis  (Hohmann  et  al, 
1976;  Ajiro  et  al,  1981a,  1981b).  These  observations  have  suggested 
that  Hl  phosphorylation  plays  a  part  in  some  of  the  conformational 
alterations  of  chromatin  during  the  cell  cycle.  It  has  also  been  shown 
that  within  a  single  cell  type  there  are  differences  between  H1 
subtypes  with  respect  to  the  extent  of  phosphorylation  during  the  cell 
cycle  (Hohmann  et  al,  1976;  Ajiro  et  al,  1981a,  1981b).  However,  H1 
subtypes  differ  from  each  other  functionally  (Lennox  et  al,  1982).  It 
has  also  been  demonstrated  that  there  are  qualitative  differences  between 
the  H1  complement  of  undifferentiated  embryonal  carcinoma  cells  and 
differentiated  endodermal  cells,  raising  the  possibility  that  such 
changes  may  play  a  role  in  the  process  of  jell  differentiation  (Lennox  et 
al,  1982). 
1.2.6.3  High  Mobility  Group  (HMG)  Proteins 
High  mobility  group  proteins  are  low  molecular  weight 
non-histone  chromosomal  components.  They  have  been  found  to  possess 
common  features  in  a  number  of  chromatin  preparations  of  various  origins 
(Goodwin  et  al,  1973;  Alfageme  et  al,  1976;  Spiker  et  al,  1978).  The 
most  important  proteins  of  this  group  are  HMG-1,  -2,  -14  and  -17.  Their 
importance  stems  from  the  possible  structural  and  functional  roles  of 
these  proteins.  Analysis  of  nucleosome  preparations  has  shown  that 
HMG-17  and  -14  are  found  in  association  with  mononucleosomes  (Mathew  et 
al,  1979),  in  particular  binding  DNA  sequences  between  145-160  bp  as  well 
as  within  the  145  bp  core  particle  (Goodwin  et  al,  1979).  However, 
Sandeen  et  al  (1980)  have  shown  that  major  sites  of  HMG-14  and  -17 
binding  are  located  near  the  termini  of  the  core  particle  DNA.  It  has -  27  - 
also  been  reported  that  HMG-14  and  -17  bind  to  a  well  defined  nucleosomal 
structure  rather  than  to  DNA  (Weisbrod  et  al,  1980). 
Chromatin  fractionation  and  nuclear  digestion  have  been  used  to 
differentiate  between  proteins  associated  with  active  and  inactive 
genes.  Rapidly  released  and/or  soluble  nucleosomes  are  generally 
reported  to  be  enriched  in  transcribed  DNA  sequences  and  in  HMG-14  and 
HMG-17  (Levy-Wilson  &  Dixon,  1978;  Mathew  et  al,  1979),  and  small 
amounts  of  HMG-1  and  HMG-2  are  also  found  (Jackson  &  Rill,  1981;  Goodwin 
et  al,  1979;  Nicolas  et  al,  1983).  However,  several  reports  have 
correlated  the  association  of  HMG  proteins  with  the  maintenance  of 
actively  transcribing  regions  in  chromatin  (Levy-Wilson  et  al,  1977; 
Vidali  et  al,  1977). 
The  functional  connection  between  HMG-14  and  -17  and  the  active 
genes  has  been  well  demonstrated  by  the  experiment  of  Weisbrod  and 
Weintraub  (1979).  In  this  experiment  it  has  been  shown  that  DNase-I 
sensitivity  of  globin  genes  in  erythrocyte  chromatin  was  lost  on  the 
removal  of  HMG  proteins  with  0.35M  NaCl.  Similar  findings  have  been 
reported  by  Nicolas  et  al  (1983)  working  on  chick  embryonic  red  blood 
cells.  The  sensitivity  to  DNase-I  has  been  restored  by  reconstitution 
with  HMG-17  and  HMG-14  (Weisbrod  &  Weintraub,  1979;  Gazit  et  al,  1980; 
Nicolas  et  al,  1983).  Weisbrod  et  al  (1980)  have  studied  the 
interaction  of  HMG-14  and  -17  with  actively  transcribed  genes  by 
monitoring  the  sensitivity  of  specific  genes  to  DNase-I  after 
reconstitution  of  HMG-depleted  chromatin  with  HMG-14  and  HMG-17.  They 
have  observed  that  the  most  actively  transcribed  genes  become  sensitised 
to  DNase-I  by  HMG-14  and  HMG-17.  Both  HMGs  have  activity  which  can  be 
reconstituted  onto  isolated  nucleosome  core  particles.  Furthermore, 
HMG-14  and  HMG-17  have  been  found  to  bind  equally  well  to  genes 
transcribing  large  amounts  of  mRNA  and  to  genes  that  are  transcribed 
rarely. -  28  - 
Further  evidence  supporting  the  correlation  of  the  presence  of 
HMG-14  and  HMG-17  with  gene  activity,  stems  from  the  altered  rate  of 
phosphorylation  at  different  stages  of  cell  cycle.  Bhorjee  (1981),  has 
demonstrated  a  seven  fold  increase  in 
32P 
incorporation  into  HMG-14  in 
(G2)  phase  of  the  cell  cycle  compared  with  (Gl),  and  a  two  fold  increase 
in  incorporation  into  HMG-17  in  early  (S)  phase.  This  report  has  also 
concluded  that  the  differential  phosphorylation  of  HMG-14  and  -17  at 
specific  stages  of  the  cell  cycle  suggests  that  they  may  well  play  a  role 
in  tissue-specific  maintenance  of  the  altered  chromatin  structure 
characteristic  of  potentially  active  or  actively  transcribed  chromatin 
domains. 
In  another  significant  finding,  the  stage-specific 
phosphorylation  of  HMG-14  has  been  found  to  be  parallel  to  that  of 
histone  H1,  and  this  adds  weight  to  the  theory  that  HMG-14  and  HMG-17 
substitute  for  H1  in  active  regions  of  chromatin  (Weisbrod,  1982). 
1.3  Nonhistone  Chromosomal  Proteins 
The  nonhistone  chromosomal  (NHC)  proteins  are  a  class  of  highly 
heterogeneous  proteins  in  eukaryotic  nuclei.  Some  of  them  are  assumed 
to  play  a  crucial  role  in  the  mechanism  of  gene  activity.  They  can  be 
divided  into  three  groups,  based  on  their  affinity  for  DNA,  the  low, 
intermediate  and  high-affinity  proteins.  The  high  mobility  group  (HMG) 
proteins  fall  within  the  DNA-low  affinity  group.  The  comparatively 
straight  forward  methodology  of  their  isolation  and  purification,  coupled 
with  their  abundance  has  led  to  fairly  detailed  characterisation  of  the 
principal  members  of  this  group  and  tentative  structural  and  functional 
roles  have  been  suggested.  In  contrast,  the  high-affinity  proteins  have 
proved  difficult  to  isolate  and  characterise  and  therefore  little  is 
known  regarding  their  roles.  However,  attempts  have  been  made  to 
determine  the  role  of  some  isolated  proteins  which  have 
intermediate-affinity  for  DNA.  Amongst  these  proteins  are  enzymes  and  a -  29  - 
number  of  cofactors.  In  addition,  a  number  of  chromosomal  proteins  with 
no  known  enzymatic  or  enzyme-associated  activity  have  been  identified  and 
resolved  from  the  bulk  of  chromosomal  proteins  by  electrophoresis.  The 
lack  of  known  enzymatic  functions  and  the  large  amounts  of  each  present 
in  a  given  cell,  suggest  that  these  proteins  are  involved  in  structural 
organisation.  Another  group  of  proteins  are  found  to  be  species-, 
tissue-  and  cell-specific.  Quantitative  variation  of  a  number  of  these 
has  been  associated  with  genetic  activity  in  some  cells.  These  groups 
of  proteins  are  analysed  in  greater  detail  in  the  following  sections. 
1.3.1  Enzymes  and  Co-factors 
A  number  of  enzymes  essential  for  the  metabolism  of  nucleic 
acids  and  protein  modification  have  been  localised  in  the  nonhistone 
fraction  of  chromosomal  proteins.  These  include  enzymes  involved  in 
DNA,  RNA,  histone  and  nonhistone  protein  metabolism  and  modifications. 
Examples  of  the  different  components  with  their  assigned  functions  are 
summarised  in  Table  (1). 
Initial  attempts  to  examine  the  role  of  NHCPsin  the  regulation 
of  transcription  were  made  by  assessing  the  effects  of  these  proteins  on 
DNA-dependent  RNA  synthesis.  Results  from  several  laboratories  indicate 
that  NHCPs  added  directly  to  histone-DNA  complexes  of  various  chromatin 
preparations,  increase  the  availability  of  DNA  as  a  template  for  RNA 
transcription  (Kaniyam  &  Wang,  1971;  Spelsberg  &  Hnilica,  1971a  &  b). 
A  protein  co-factor  which  stimulates  RNA  polymerase  I  has  been  found  to 
be  crucial  for  transcription  of  native  calf  thymus  DNA  (Goldberg  et  al, 
1977).  Le  Graverend  and  Glazer  (1980)  have  characterised  a  nonhistone 
chromosomal  protein  from  rat  liver  nuclei  which  stimulates  RNA  synthesis 
in  vitro. 
In  addition,  isolation  of  RNA  polymerase  II  stimulatory  factors 
from  calf  thymus  chromatin  (Benson  et  al,  1978),  lamb  thymus  (Revie  & 
Dahmus,  1979),  Ehrlich  ascites  tumour  (Natori  et  al,  1973),  rat  liver -4 
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(Seifart  et  al,  1973)  and  mouse  myeloma  cells  (Lentfer  &  Lezius,  1972) 
has  also  been  reported.  Recently,  an  NHCP-fraction  has  been 
chromatographically  isolated  and  found  to  contain  a  large  amount  of 
nascent  RNA  chains  (Ferraro  et  al,  1982). 
Three  factors  associated  with  RNA  polymerase  III  have  been 
purified  from  human  KB  cells  (Segall  et  al,  1980),  and  Xenopus  (Pelham  & 
Brown,  1980).  Factors  from  KB  cells  have  also  been  found  to  stimulate 
accurate  initiation  of  transcription  at  the  major  late  promoter  of 
Adenovirus-2  (Matsui  et  al,  1980). 
1.3.2  Structural  Proteins 
HMG  proteins  -14  and  -17  have  been  found  to  bind  to  the  core 
nucleosome  and  have  a  major  effect  on  nucleosome  structure  (Mathew  et  al, 
1979).  Reconstitution  experiments  have  indicated  that  both  HMG-14  and 
-17  bind  readily  to  the  145-base  pair  core  particle  at  a  stoichiometry  of 
1  and  2  molecules  per  core,  respectively,  in  a  manner  that  does  not 
exclude  binding  of  H1  (Albright  et  al,  1980).  Another  protein  of  this 
group  is  HMG-20  (Ubiquitin)  (Schlesinger  et  al,  1975)  which  has  been 
suggested  to  reside  on  linker  DNA,  between  the  core  particles,  in  the 
transcriptionally  active  chromatin  (Watson  et  al,  1978).  Ubiquitin, 
however,  is  found  as  a  constituent  of  the  conjugate  protein  A24  which 
consists  of  H2A  histone  and  HMG-20  (Goldknopf  &  Busch,  1977).  HMG-20 
is  covalently  linked  via  a  glycyl-glycine  peptide  at  its  C-terminal  end 
to  the  amino  group  of  lysine  -119  in  histone  H2A.  The  absence  of 
ubiquitin  in  mitotic  chromatin,  has  led  to  the  suggestion  that  it  plays  a 
structural  role  within  the  chromatin  components  preventing  condensation 
to  higher-order  structures  in  metaphase  (Matsui  et  al,  1979).  Recently, 
A24  has  been  found  to  be  associated  with  mononucleosomes  containing 
transcriptionally  inactive  sequences  (Levinger  et  al,  1981). 
Detke  and  Keller  (1982),  in  their  comparison  between  the 
interphase  nucleoskeleton  and  metaphase  chromosome  scaffolds  in  HeLa -32- 
cells,  have  found  that  the  major  proteins  of  both  preparations  are 
similar.  They  have  also  distinguished  the  nucleoskeletal  proteins  from 
the  major  nuclear  laminar  proteins.  Although  the  nucleoskeletal 
components  comprise  only  a  small  subset  of  the  total  nuclear  proteins,  it 
has  been  suggested  that  they  are  responsible,  at  least  in  part,  for  the 
gross  morphology  of  the  nucleus  (Riley  et  al,  1975). 
Another  group  of  proteins  which  may  play  a  part  in  the 
structural  interconversions  of  chromatin  as  well  as  in  the  regulation  of 
cell  proliferation  are  the  contractile  proteins  (LeStourgeon  et  al, 
1975).  These  proteins  have  been  found  in  the  NHCP-fraction,  and 
suggested  to  be  involved  in  intranuclear  contractile  functions. 
The  structure  of  metaphase  chromosomes  is  stabilised  by  another 
class  of  NHC-proteins,  the  tightly-bound  scaffold  proteins  (Adolph  et  al, 
1977  a&  b).  Accumulated  evidence  suggests  that  both  metaphase 
chromosomes  and  nuclei  contain  a  residual  skeleton  or  scaffold  which 
maintains  the  DNA  in  a  compact,  looped  arrangement  (Laemmli  et  al, 
1978).  Two  types  of  scaffold  protein  fractions  have  been  characterised, 
based  on  their  method  of  preparation  (Lebkowski  &  Laemmli,  1982).  The 
type-I  structure  has  been  shown  to  be  stabilised  by  the  Ca++  ion. 
This  stabilisation  can  be  altered  by  the  addition  of  2-mercaptoethanol 
which  disrupts  the  metalloprotein  interaction  to  give  a  type-II 
structure.  The  metalloprotein  interaction  involved  is  suggested  to  be 
important  for  DNA  folding.  DNA  binding  studies  have  revealed  that 
twelve  proteins  of  type-I  and  four  of  type-II  scaffolds  bind  DNA  in  vitro 
(Lebkowski  &  Laemmli,  1982).  However,  it  has  been  shown  that  following 
treatment  with  cupric  ion,  the  scaffold  residue  shows  a  simple  protein 
composition  comprising  two  high  molecular  weight  (135K  &  170K) 
proteins.  They  are  designated  as  scaffold  1  and  2  (Scl  &  Sc2) 
respectively  (Lewis  &  Laemmli,  1982).  More  recently,  Earnshaw  and 
Laemmli  (1983)  have  visualised  a  nonhistone  protein  residual  scaffold  by -  33  - 
electron  microscopy.  This  protein  scaffold  has  been  obtained  from 
nuclease  digested  chromosomes  under  conditions  of  low  salt  protein 
extraction.  It  is  suggested  that  the  extremely.  simple  composition  of 
the  residual  scaffold  proteins,  is  fibrous  in  nature  and  determines  the 
dimensions  of  the  chromosomes.  Evidence  has  been  presented  to 
demonstrate  that  the  scaffolding  network  plays  a  dynamic  role  in 
chromosome  condensation  at  mitosis  (Earnshaw  &  Laemmli,  1983). 
1.3.3  Tissue  and  Cell  Specific  Proteins 
Several  attempts  have  been  made  to  correlate  the  presence  of 
nonhistone  chromosomal  proteins  with  certain  specific  tissues  or  cell 
types.  Comparison  between  the  chromosomal  proteins  of  a  number  of 
tissues  and  cells  has  been  performed  by  immunological  criteria  or 
electrophoretic  profiles.  A  fraction  of  nonhistone  proteins  has  been 
found  necessary  for  the  in  vitro  transcription  of  tissue-specific  RNA 
species  (Spelsberg  et  al,  1971).  A  dehistonised  chromatin  fraction  from 
Novikoff  hepatoma  has  been  shown,  by  immunological  criteria,  to  be  tissue 
specific  (Chytil  &  Spelsberg,  1971),  and  to  require  and  recognise  only 
homologous  DNA  (Wakabayashi  &  Hnilica,  1973)  for  its  immunoactivity.  In 
comparison  between  tumour  and  normal  tissues,  Fujitani  et  al  (1978),  have 
localised  a  protein  antigen  (45K  -  60K)  to  the  chromatins  of  embryonic 
liver  and  several  transplantable  tumours  but  not  of  normal  tissues. 
Further  immunological  studies  on  the  Novikoff  hepatoma  antigens  have 
revealed  the  presence  of  two  proteins  (P39  &P  49)  specific  for  Novikoff 
hepatoma.  These  antigens  have  been  localised  in  chromatin  as  well  as  in 
the  cytoplasm  (Schmidt  et  al,  1981).  A  similar  approach  has  been  used 
on  the  nonhistone  chromosomal  protein  fraction  from  HeLa  cells.  The 
HeLa  antigens  have  been  identified  in  the  DNA-tightly-bound  proteins  in 
the  scaffold  area  (Campbell  et  al,  1979).  This  group  of  antigens  has 
been  found  by  immunological  criteria  to  be  cell  specific  (Briggs  et  al, 
1979)  and  species  specific  (Dunn  et  al,  1980).  However,  a  different -34- 
110K  nonhistone  phosphoprotein  purified  from  the  0.35M  NaCl  nuclear 
extract  has  also  been  found  common  to  four  cell  lines  including  Novikoff 
hepatoma  and  HeLa  cells  but  failed  to  be  traced  in  normal  tissues  (Durban 
et  al,  1981). 
Electrophoresis  has  been  used  to  demonstrate  and  characterise 
specific  proteins  in  different  chromatin  preparations.  Yaneva  et  al 
(1980)  have  shown,  by  electrophoretic  comparison,  the  presence  of  at 
least  one  unique  band  in  each  tissue  examined.  Quantitative  and 
qualitative  differences  in  the  electrophoretic  profiles  have  also  been 
noted.  Two  dimensional  gel  electrophoresis  has  been  used  by  Wu  et  al 
(1981)  to  demonstrate  differences  in  the  pattern  of  proteins  of  several 
human  tumours  and  normal  cells.  Two  proteins  (140K  &  54K)  have  been 
found  in  four  types  of  tumour  cell  but  not  in  the  four  normal  cell  types 
examined,  whereas  another  two  proteins,  of  56K  but  different  isoelectric 
points,  have  been  shown  to  occur  only  in  the  normal  cells  and  not  in  the 
tumour  cells.  Qualitative  and/or  quantitative  differences  in  the  two 
dimensional  gel  patterns  of  NHCPs  have  also  been  observed  in  closely 
related  mouse  cell  lines  (Plasmacytomas)  which  were  known  to  differ  in 
their  ability  to  express  known  genes  (Lincoln  &  Stott,  1983).  These 
differences  were  correlated  with  gene  expression. 
1.4  Characterisation  of  Nuclear  and  Nucleolar  Components  by 
Immunological  Approaches 
1.4.1  Antibodies  to  Nucleic  Acids 
Antibodies  to  purified  nucleic  acids  are  obtained  with  great 
difficulty.  Several  reports  have  described  successful  immunisation  with 
RNA  preparations.  Antisera  obtained  from  rabbits  immunised  with  yeast 
RNA  have  shown  reactivity  towards  yeast,  human,  rabbit  and  rat  RNA  (Lamon 
&  Bennett,  1970).  Hernandez  et  al  (1968)  have  shown  that  after 
immunisation  of  four  rabbits  with  tRNA,  believed  to  be  free  from  protein 
carriers,  and  twenty  nine  rabbits  with  oligonucleotides  prepared  by -  35  - 
partial  enzymatic  digestion  of  RNA,  almost  all  antisera  obtained  from 
both  types  react  in  the  complement  fixation  assay  with  RNA  of  high 
molecular  weight  as  well  as  with  oligonucleotides  prepared  from  tRNA. 
However,  one  antiserum  out  of  33  reacts  specifically  with  tRNA  itself. 
On  the  other  hand,  antisera  obtained  after  immunisation  with  free  tRNA 
have  failed  to  react  with  tRNA  (Bonavida  et  al,  1970). 
Despite  the  difficulties  experienced  by  immunisation  of 
experimental  animals,  anti-RNA  antibodies  are  commonly  detected  in 
autoimmune  diseases  in  man  and  animals.  Anti  snRNA  antibodies  have  been 
detected  in  sera  from  patients  with  SLE  (Lerner  et  al,  1980,1981). 
Successful  hybridomas  with  reactivity  against  rRNA  have  been  produced 
from  autoimmune  mice  (Eilat  et  al,  1980).  One  of  these  monoclonal 
antibodies  derived  from  NZB/NZW  (F1)  mouse  lymphocytes  fused  with  the 
myeloma  cell  line  MPC-11,  has  shown  specific  binding  to  rRNA  and  failed 
to  bind  significantly  to  DNA,  tRNA  and  synthetic  single-  and 
double-stranded  polynucleotides.  Similarly,  monoclonal  antibodies 
derived  from  MRL  mice  have  shown  specific  reactivity  towards  rRNA  (Lerner 
et  al,  1981).  Eilat  et  al  (1982)  produced  a  sequence  specific  anti-RNA 
monoclonal  antibody  which  recognise  a  G/C-rich  ribonucleotide. 
Antibodies  to  DNA  have  been  proved  difficult  to  raise  in 
laboratory  animals.  Antisera  from  animals  immunised  with  purified  DNA 
from  calf  thymus,  salmon  sperm,  E.  coli  and  rat  liver  have  also  failed  to 
show  immunoreactivity  towards  DNA  (Levine  &  Stollar,  1968;  Barnett  & 
Vaughan,  1966;  Yachin,  1962).  This  led  Stollar  (1973)  to  conclude  that 
native  DNA  is  not  immunogenic. 
However,  spontaneous  antibodies  reacting  with  native  DNA  have 
been  reported  in  almost  all  patients  with  Systemic  Lupus  Erythromatosus 
(Tan  et  al,  1966).  Evidence  for  the  presence  of  antisera  which  react 
with  ss-DNA  in  patients  with  SLE  and  other  autoimmune  diseases  has  been 
presented  (Koffler  et  al,  1973,1974).  Specific  antisera  which  react -  36  - 
only  with  double-stranded  DNA  and  others  that  bind  both  ds-  and  ss-DNA 
have  also  been  demonstrated  in  SLE  patients  (Gilliam  et  al,  1980). 
Antisera  which  react  with  ds-poly  d(AT)  have  been  shown  to  bind  well  to 
ss-DNA  (Gilliam  et  al,  1980).  Peripheral  blood  lymphocytes  from 
patients  with  no  autoimmune  disease  show  no  production  of  anti-DNA 
antibodies  but  after  EBV  transformation  (Epstein-Barr  Virus),  anti-DNA 
antibodies  producing  cells  have  been  detected  (Hoch  et  al,  1983).  In 
addition,  it  has  also  been  shown  that  normal  mice  can  produce  anti-DNA 
antibodies  if  their  B-lymphocytes  undergo  mitogen-stimulated  polyclonal 
activation  (Fish  &  Ziff,  1982;  Dziarski,  1982).  Moreover,  production 
of  autoantibodies  by  human-human  hybridomas  has  been  reported  from  many 
laboratories.  Shoenfeld  et  al  (1982)  using  the  ELISA  technique  have 
demonstrated  the  feasibility  of  producing  anti-ss-DNA  monoclonal 
antibodies  using  peripheral  blood  cells  from  a  number  of  patients  with 
autoimmune  diseases  such  as  SLE  and  Atopic  Allergy.  Recently,  Shoenfeld 
et  al  (1983)  have  managed  to  fuse  a  human  lymphoblastoid  cell  line 
derived  from  patient  with  multiple  myeloma  with  lymphocytes  from  an  SLE 
patient.  Among  the  thirty  monolconal  antibodies  produced  against 
denatured  DNA,  eighteen  of  them  react  with  additional  polynucleotide  such 
as  native  DNA,  left  handed  double  helical  DNA  (Z-DNA),  poly(I)  and 
poly(dT).  Ten  of  these  monoclonal  antibodies  showed  reactivity  towards 
nucleic  acids  and  cardiolipin  phosphlipid.  Accordingly,  this  report 
suggests  that  DNA  itself  need  not  be  the  immunogenic  stimulus  for 
autoantibody  formation  in  this  type  of  disease. 
Laboratory  animals  such  as  NZB/NZW  mice  have  also  been  found  to 
make  antibodies  to  DNA  (Stollar,  1973).  Lee  et  al  (1981)  have  produced 
six  hybridomas  which  secrete  extremely  specific  monoclonal  antibodies  to 
deoxyribonucleic  acids  from  NZB/NZW  mice.  It  has  been  shown  that 
various  RNAs  failed  to  react  with  these  monoclonal  antibodies.  In 
addition,  the  ss-DNAS  tested  showed  higher  reactivity  than  ds-DNA.  Some -  37  - 
of  these  monoclonal  antibodies  exhibit  sequence  preferences  which  make 
them  a  powerful  tool  for  distinguishing  between  similar  nucleic  acids. 
Other  groups  have  succeeded  in  producing  a  number  of  hybridomas  that 
secrete  monoclonal  anti-DNA  autoantibodies  from  NZB/NZW  (Hahn  et  al, 
1980;  Jacobs  &  Tron,  1982)  or  MRL  mice  (Lerner  et  al,  1981).  Hahn  et 
al  (1980)  in  their  studies  using  murine  anti-DNA  monoclonals  have  shown 
that  these  antibodies  exhibit  specificity  towards  ds-DNA  and  ss-DNA  but 
not  ss-RNA  or  poly(I-C).  Jacobs  and  Tron  (1982)  and  Andrzejewski  et  al 
(1981)  produced  10  anti-DNA  monoclonal  antibodies  with  identical 
specificity  to  a  conformational  determinant  of  the  B-helical  form  of 
ds-DNA.  Other  anti-nucleic  acid  monoclonal  antibodies  have  recently 
been  reported  (Kioke  et  al,  1982).  These  monoclonals  were  produced  from 
hybrids  of  (MRL  1)  X  NZB-NZW  (F1)  mouse  lymphocyte  fused  with  653 
myeloma  cell  line.  Twelve  clones  have  shown  specific  reactivity  with 
ss-DNA  only  while  another  two  react  with  both  ss-  and  ds-DNAs.  Studies 
with  mouse  anti-DNA  monoclonal  autoantibodies  have  revealed  that  a  single 
antibody  can  bind  to  multiple  nucleic  acid  antigens  of  different  base 
composition  (Andrzejewski,  1981;  Pisetsky,  1982;  Kioke  et  al,  1982). 
Structural  differences  in  polynucleotide  backbones  can  explain  individual 
variations  in  binding  specificities  among  the  monoclonal  antibodies.  In 
addition,  phosphodiester-containing  epitopes  also  account  for  the  ability 
of  some  monoclonal  anti-DNA  autoantibodies  to  bind  to  certain 
phosphlipids  such  as  cardiolipin  (Lafer  et  al,  1981c).  Immunisation  of 
normal  rabbits  (Guarnieri  &  Eisner,  1974)  or  mice  (Rauch  et  al, 
unpublished  data)  with  cardiolipin  has  been  found  to  stimulate  the 
production  of  both  anti-cardiolipin  and  anti-DNA  antibodies.  Moreover, 
MCAs  derived  from  these  cardiolipin-immunised  mice,  bind  to  cardiolipin, 
DNA,  poly(I)  and  poly(dT).  The  polyspecificities  of  some  MCAs  signify 
that  it  is  not  possible  to  imply  the  origin  of  spontaneously  produced 
autoantibodies  from  serum  analyses  only. - 
In  contrast  to  most  other  nucleic  acids,  left-handed-DNA  (Z-DNA) 
is  a  strong  immunogen  which  elicits  Ab  production  in  both  mouse  and 
rabbit.  The  anti-left  handed-DNA  Abs  react  with  only  Z-DNA  and  show  no 
reactivity  with  native  B-DNA  (Lafer  et  al,  1981a).  However,  nuclei  of 
many  rat  cells  exhibit  Z-DNA  immunoactivity  with  anti-Z-DNA  which 
suggests  that  Z-DNA  may  exist  naturally  in  mammalian  chromatin  (Morgenegg 
et  al,  1983).  In  Drosophila,  fluorescent  staining  with  these  Abs  has 
shown  specific  binding  to  polytene  chromosomes  especially  in  the 
interband  regions  (Lafer  et  al,  1981b).  Monoclonal  antibodies  to  Z-DNA 
have  also  been  produced  recently  and  shown  to  exhibit  high  specificity 
(Pohl  et  al,  1982). 
1.4.2  Antibodies  to  Histones 
Most  of  the  amino  acids  sequences  of  histone  proteins  are 
similar  in  different  species  reflecting  the  conserved  primary  structures 
of  these  proteins.  As  a  result  of  this  fact,  these  proteins  are  in 
general  weak  antigens. 
Antisera  raised  against  total  rat  liver  chromatin  have  shown  no 
reactivity  towards  pure  histone  fractions,  while  antisera  to  purified 
histones  failed  to  interfere  with  the  reaction  between  antibodies  to 
chromatin  and  chromatin  itself  as  judged  by  C'F  assay  (Goldblatt  & 
Bustin,  1975).  Antisera  raised  against  calf  thymus  H2  A,  H2B  and 
H4  histones  have  failed  to  distinguish  between  these  histones  and  those 
obtained  from  chicken  erythrocytes,  frog  liver  and  human  spleen  (Stollar 
&  Ward,  1970).  Pothier  et  al  (1975)  managed  to  raise  antisera  against 
the  major  histones  of  calf  thymus.  These  antisera  have  been  used  to 
localise  the  distribution,  by  immunofluorescence  of  various  proteins 
during  the  cell  cycle,  and  also  to  follow  their  reactivity  on  chromosomes 
of  different  cells.  Cross  reactivity  is  common  among  all  but  Hl 
histone.  Antibodies  elicited  against  Hl  and  H2B  histones  of 
Drosophila  have  also  been  used  coupled  to  fluorescent  labels  in  order  to -  39  - 
localise  their  positions  on  polytene  chromosome  (Alfageme  et  al,  1976). 
Both  H1  and  H2B  have  been  found  in  most  chromosomal  regions. 
In  contrast  to  antibodies  to  the  four  other  histones,  those 
elicited  against  unfractionated  H1  derived  from  calf  thymus  (Bustin  & 
Stollar,  1972)  or  rat  tissues  (Hekman  &  Sluyser,  1973)  have  shown  both 
species  and  organ  specificity  in  this  histone  class.  Similarly, 
specific  antisera  against  H1-subfractions  have  been  used  to  detect 
species-  and  tissue-specificity  (Sluyser  &  Bustin,  1974)  as  well  as 
changes  in  conformational  determinants  and  changes  due  to  chemical 
modifications  (Bustin  &  Stollar,  1973). 
High  levels  of  antibodies  to  histones  have  been  found  in  many 
patients  with  autoimmune  diseases.  This  makes  the  specific  antisera  a 
potentially  useful  diagnostic  tool  in  such  diseases.  Anti-histone 
antibodies  from  sera  of  patients  with  various  rheumatic  diseases  have 
been  shown  to  react  predominantly  with  histone  complex  H3-H4  (Rubin 
et  al,  1982). 
1.4.3  Antibodies  to  Nonhistone  Chromosomal  Proteins 
NHC  proteins  are  the  most  heterogeneous  group  of  nuclear 
proteins.  The  DNA-low  affinity  proteins  are  relatively  easy  to 
fractionate.  A  wide  variety  of  antisera  specific  to  components  of  this 
group  has  been  reported.  These  have  in  general  been  used  to  locate  the 
corresponding  antigen  in  different  subtractions  or  cell  types.  Bustin 
and  Neihart  (1979)  have  raised  a  rabbit  antiserum  to  calf  thymus  HMG-1 
and  shown  that  it  reacts  with  both  the  chromatin  itself  and  also 
cytoplasmic  components  of  Chinese  hamster  V-79,  rat  liver  TR-12  and 
bovine  trachea  EBTr-NBL-4  cells.  Another  antiserum  raised  against  chick 
oviduct  HMG-1  has  been  used  in  a  limited  study  of  the  effect  of  oestrogen 
stimulation  on  HMG-1  distribution  in  cells  (Teng  &  Teng,  1981). -  40  - 
Antibodies  to  HMG-1  and  HMG-2  proteins  have  also  been  detected 
by  ELISA  in  antisera  from  patients  with  SLE  and  other  autoimmune  diseases 
(Bustin  et  al,  1982).  However,  the  immune  response  to  HMG-14  and  HMG-17 
proteins  appears  to  be  stronger. 
The  distribution  of  nonhistone  proteins  of  a  variety  of 
molecular  weights  in  polytene  chromosomes  of  Drosophila  salivary  glands 
was  visualised  some  years  ago  by  the  use  of  antisera  raised  to 
chromosomal  antigens  eluted  from  SDS-PAGE  (Stumph  et  al,  1974).  More 
detailed  information  on  the  location  of  a  particular  NHCP  in  the  same 
polytene  chromosome  was  later  obtained  using  antiserum  raised  against 
purified  Dl  nonhistone  protein  (Alfageme  et  al,  1976).  Similarly, 
antisera  raised  against  other  purified  individual  NHCP  from  Drosophila 
have  been  used  to  assess  the  selectivity  of  distribution  patterns,  and 
two  of  these  have  shown  that  the  corresponding  protein  distribution  is 
limited  on  the  polytene  chromosome  (Silver  &  Elgin,  1978).  On  the  other 
hand,  an  antiserum  raised  against  a  21K  protein  has  shown  prominent 
immunofluorescent  staining  at  dense  chromomeres  and  the  chromocentre  in  a 
pattern  mimicking  DNA  distribution  (Silver  &  Elgin,  1978). 
The  high  affinity  NHC  protein  group  has  proved  more  difficult  to 
fractionate.  This,  together  with  the  unknown  function  of  most  of  these 
proteins,  makes  the  isolation  and  identification  of  individual  proteins 
more  difficult.  However,  antiserum  to  a  chromosomal  protein  fraction 
specific  for  HeLa  cells  has  been  elicited  in  rabbit.  Although  this 
antiserum  has  not  been  shown  to  react  with  a  single  protein,  it  has  been 
useful  to  localise  the  immunoactivity  to  the  transcriptionally  inactive 
region  of  log  phase  chromatin  (Campbell  et  al,  1979).  Further  studies 
have  suggested  that  some  of  the  antigenic  proteins  in  the  scaffold  area 
are  both  tight  binding  and  cell-specific.  It  has  been  shown  that  the 
specific  antigens,  of  this  chromatin  fraction,  are  a  complex  of  human  or 
HeLa  DNA  only  and  the  tightly  bound  NHC  proteins.  In  addition, -  41  - 
immunochemical  tests  have  revealed  that  the  antigens  are  continuously 
present  throughout  the  cell  cycle  (Briggs  et  al,  1979). 
Another  DNA:  NHCP  complex  immunogen  has  been  detected  in  Novikoff 
hepatoma  (Wakabayashi  &  Hnilica,  1973).  This  immunogen  has  been  shown 
to  have  species-  and  tissue-specificity  (Fujitani  et  al,  1978). 
However,  more  recently  antisera  against  three  partially  purified  Novikoff 
hepatoma  antigens  from  the  same  group  have  been  used  to  localise  their 
distribution  in  various  subcellular  fractions  by  immunoblotting 
techniques  (Schmidt  et  al,  1981).  These  proteins,  of  39K,  49K  and  56K 
molecular  weights  have  been  found  in  cytoplasmic  fractions  as  well  as  in 
isolated  chromatin. 
In  an  early  approach,  Chytil  and  Spelsberg  (1971)  showed  that 
the  antigeneity  of  NHCPs  of  chick  oviduct  chromatin  was  associated  with 
DNA  and  was  species-specific.  In  addition,  the  differential 
distribution  of  this  antigen  complex  in  different  tissues  indicated  a 
tissue-specificity. 
Species-specificity  of  another  NHCP:  DNA  complex  from  chick 
reticulocytes  have  also  been  investigated  by  immunological  criteria 
(Krajewska  et  al,  1979).  Further  immunological  evidence  for  tissue-, 
species-  and  cell-specificity  of  this  NHCP  group  have  emerged  from  more 
recent  studies.  Erythroid  cell-specific  antisera  detecting  the 
tightly-bound  DNA:  NHCP  complex  from  dehistonised  chicken  reticulocyte 
chromatin  have  shown  no  cross  reactivity  with  chromatin  of  thrombocytes 
(Krajewska  &  Klyszejko-Stefanowics,  1982)  although  thrombocytes  are 
closely  related  to  erythroid  cells.  In  addition,  antisera  to  the 
tightly  bound  NHCP:  DNA  complex  of  thrombocytes  have  shown  no 
immunological  similarity  with  those  raised  against  erythrocyte 
DNA-tightly  bound  chromatin.  More  recent  studies  have  confirmed  that 
antisera  raised  in  mice  to  chromatin  from  different  tissues  of  the -  42  - 
chicken  reacted  preferentially  with  the  chromatin  type  that  was  used  for 
immunisation  (Vanderbilt  &  Anderson,  1983). 
Antisera  against  a  single  NHCP  of  predefined  function  have  also. 
been  used  to  determine  the  presence  of  such  protein  in  different 
subcellular  preparations.  Watson  and  Moudrianakis  (1982)  have  elicited 
an  antiserum  to  an  NHC  protease.  Antiserum  against  a  nonhistone 
chromosomal  phosphoprotein  (B2)  that  is  specifically  associated  with  the 
nucleosome  structure  has  also  been  reported  (Zhao  &  Liew,  1982). 
Monoclonal  antibodies  to  NHCPs  will  be  discussed  in  section 
(1.5.3). 
1.4.4  Antibodies  to  Nucleolar  Antigens 
The  nucleolus  is  the  site  of  synthesis  of  28S,  18S  and  5.8S 
ribosomal  RNAS  (Wellauer  &  Dawid,  1973).  In  addition  to  ribosomal  RNA 
precursors,  the  nucleolus  contains  a  small  species  of  RNA,  U3  (for 
review  see  Ro-Choi  &  Busch,  1974).  This  species  of  RNA  is  of  interest 
because  of  its  unique  and  specific  localisation  in  the  nucleoli 
(Prestayko  et  al,  1971)  and  its  hydrogen  bonding  to  nucleolar  35S  and  28S 
RNA  (»restayko  et  al,  1970).  Other  small  RNAs  can  also  be  detected  in 
nucleoli  (reviewed  by  Busch  et  al,  1982).  The  assembly  of  ribosomes 
begins  in  the  nucleolus.  Therefore,  it  is  likely  that  many  of  the 
molecular  associations  found  in  cytoplasmic  ribosomes  may  also  be  present 
in  nucleolar  precursors. 
Nucleolar  immunofluorescent  staining  has  been  found  in  some  SLE 
patients  whose  antisera  contain  antibodies  against  cytoplasmic  antigen 
with  rRNA  characteristics  (Miyachi  &  Tan,  1979).  On  the  other  hand, 
Homberg  et  al  (1974)  have  described  another  type  of  distinctive 
immunofluorescent  pattern  found  in  some  antisera  of  patients  with  SLE  and 
other  collagenous  diseases.  These  sera  which  are  of  anti-ribosomal 
character  have  failed  to  react  with  nucleolar  ribosomes  (Bianchi  et  al, 
1974). -  43  - 
In  general,  anti-nucleolar  antibodies  are  more  common  in 
Scleroderma  than  in  other  SLE  and  Rheumatic  diseases.  Although  earlier 
reports  showed  an  11-21%  incidence  of  anti-nucleolar  antibodies  in 
Scleroderma  patients  (Fennell  et  al,  1962;  Beck  et  al,  1963;  Burnham  et 
al,  1966),  a  higher  percentage  has  been  described  in  a  later  report 
(Ritchie,  1969).  Anti-nucleolar  antibodies  have  also  been  detected  in 
Sjögren's  Syndrome  (Tan  &  Lerner,  1972)  as  well  as  in  response  to 
malignant  melanoma  (McBride  et  al,  1972). 
Nucleolar  specific  antibodies  have  been  raised  in  rabbits 
immunised  with  whole  nucleoli  from  Novikoff  hepatoma  ascites  cells  or 
from  normal  rat  liver.  Of  the  fourteen  antigens  detected,  ten  reacted 
with  both  kinds  of  antisera  (Davis  et  al,  1978).  In  addition, 
comparison  of  the  nucleolar  antigens  of  human  liver  and  HeLa  cells  has 
shown  a  54K  immunogen  in  HeLa  but  not  in  normal  liver  cells  (Chan  et  all 
1980).  However,  in  a  more  detailed  comparison,  antisera  raised  against 
a  nuclear  0.01M  tris-HC1  (pH  8)  extract  or  nucleolar  preparation  of  HeLa 
S3  cells,  have  shown  a  wide  range  of  nucle  olar  immunofluorescence  in  61 
out  of  63  human  adenocarcinomas,  squamous  cell  carcinomas,  sarcomas, 
haematological  neoplasms  and  other  malignant  tumours  (Busch  et  al, 
1979).  With  these  antibodies,  nucleolar  immunofluorescence  has  not  been 
visualised  in  23  normal  tissue  specimens.  In  similar  studies,  Davis  et 
al  (1979)  have  also  described  the  presence  of  a  nucleolar  antigen  which 
was  found  in  several  human  tumours  but  not  in  non-tumour  tissues.  These 
reports  suggest  that  such  specific  antisera  may  be  a  useful  tool  for 
differentiating  malignant  from  normal  tissues. 
1.5  Monoclonal  Antibodies 
1.5.1  History  and  Background 
In  1975,  Köhler  and  Milstein  showed  that  somatic  cell 
hybridisation  could  be  induced  in  culture  between  antibody-producing 
B-lymphocytes  which  are  mortal  in  tissue  culture  and  myeloma  cells  which -  44  - 
continue  to  grow  in  appropriate  conditions.  The  hybrid  cell  which 
results  from  such  fusion  has  the  ability  to  grow  continuously  and  produce 
the  B-lymphocyte  specified  antibody  in  selective  culture  media. 
The  two  pathways  of  nucleotide  biosynthesis  in  eukaryotic  cells 
are  the  "De  Novo"  synthesis  and  the  "Salvage"  pathways.  The  De  Novo 
synthesis  of  purines  and  pyrimidines  can  be  blocked  by  the  folic  acid 
antagonist;  Aminopterin.  However,  the  cell  can  still  synthesise  DNA 
via  the  so  called  Salvage  pathways,  if  it  possesses  the  required  enzymes, 
Thymidine  Kinase  (TK)  for  the  pyrimidines,  and  Hypoxanthine  Guanosine 
Phosphoribosyl  Transferase  (HGPRT)  for  the  purines.  When  the  De  Novo 
synthesis  of  DNA  is  blocked,  the  cells  which  contain  these  enzymes  can 
survive  if  exogenous  hypoxanthine  and  thymidine  are  provided  in  the 
culture  media  (Littlefield,  1964).  After  the  fusion  event,  three  kinds 
of  cells  are  mixed  in  the  selective  media,  HAT  media.  The  spleen  cells 
which  have  the  ability  to  synthesise  the  antibodies  die  in  culture  after 
a  few  days,  while  the  myeloma  cells  which  are  usually  either  producer  of 
irrelevant  antibodies  or  non-producers,  lack  the  enzyme  HGPRT  and  thus 
cannot  survive  in  aminopterin-supplemented  media.  Only  the  hybrid  cells 
have  the  ability  to  survive  in  HAT  medium  since  they  have  acquired  the 
ability  to  make  HGPRT  from  the  spleen  cells.  The  antibody  produced  by 
such  a  hybrid  cell  clone  is  monoclonal  (see  Figure  3). 
Since  the  beginning  of  monoclonal  antibody  technology  in  1975, 
several  modifications  have  been  introduced  aiming  at  optimising  the 
product  of  this  useful  technique.  The  first  attempt  by  Köhler  and 
Milstein  utilised  Sendai  virus  as  the  fusing  agent  (Fusogen). 
Polyethylene  glycol  (PEG)  has  been  introduced  as  a  good  and  conventient 
fusogen  of  mammalian  cells  (Pontecorvo,  1975).  Galfre  et  al  (1977)  have 
successfully  used  PEG  to  produce  mouse  hybrids  secreting  monoclonal 
antibodies  of  choice.  The  addition  of  dimethyl  sulfoxide  (DMSO)  to  PEG 
solution  was  shown  to  enhance  the  PEG-mediated  cell  fusion  (Norwood  et -  45  - 
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al,  1976).  A  large  number  of  chemicals  as  well  as  different  grades  of 
PEG  have  been  tried  to  promote  fusion  events,  but  low  molecular  weight 
PEG  (1000-4000)  proved  to  be  superior  in  producing  high  number  of  growing 
somatic  cell  hybrids  (Klebe  &  Mancuso,  1981). 
Pardue  et  al  (1983)  have  reported  a  successful  in  vitro 
immunisation  of  spleen  cells  using  recently  developed  technqiues  (Luben  & 
Mohler,  1980;  Reading,  1982).  Mouse  spleen  cells  from  an  unimmunised 
animal  have  been  incubated  in  thymocyte  culture  conditioned  medium  with 
the  required  antigen.  Five  days  later,  these  spleen  cells  have  been 
fused  with  myeloma  cells  using  PEG  solution.  This  technique  is 
specially  useful  in  situations  where  very  small  amounts  (nanograms)  of 
antigen  are  available. 
Another  useful  development  has  been  the  introduction  of 
non-secretary  myeloma  cells.  After  fusion  with  these  cells,  the  hybrids 
secrete  only  the  antibody  from  B-lymphocytes.  The  desired  monoclonal 
antibody  secretion  seems  to  be  amplified  (Köhler  et  al,  1977;  Schulman 
et  al,  1978;  Kearney  et  al,  1979). 
In  addition  to  mouse-mouse  fusions,  many  attempts  have  been  made 
to  produce  hybridomas  by  rat-rat  fusions  (Galfre  et  al,  1979), 
human-human  fusions  (Cote  et  al,  1983;  Olsson  &  Kaplan,  1980;  Croce  It 
al,  1980)  and  mouse-human  fusions  (Levy  &  Dilley,  1978;  Schlom  et  al, 
1980;  Cote  et  al,  1983).  However,  permanent  cultures  of 
antibody-producing  human  B-lymphocytes  have  also  been  obtained  by 
transformation  with  Epstein  Barr  (EBV)  virus  (Steinitz  et  al,  1977; 
Crawford  et  al,  1983  a&  b). 
Other  developments  such  as  the  use  of  reliable  and  quick 
screening  assays,  including  Solid-Phase  Radioimmunoassay,  ELISA, 
Fluorescence  Microscopy  and  Fluorescence-Activated  Cell  Sorting  (FACS) 
techniques  have  led  to  the  stream  lining  of  monoclonal  antibody 
technology  (for  more  detailed  information  regarding  the  use  of  these -  47  - 
assays,  see  Current  Topics  in  Microbiology  &  Immunology  (1978)  vol.  81, 
ed.  Melchers,  Potter  &  Warner). 
1.5.2  Properties  and  Limitations  of  Monoclonal  Antibodies 
The  main  advantages  of  monoclonal  antibodies  over  conventional 
sera  lie  in  the  fact  that  antibodies  of  chosen  specificity  and  affinity 
may  be  produced  indefinitely  in  large  and  standard  amounts.  This  has 
major  implications  for  diagnostic,  therapeutic  and  preparative  applied 
research  and  also  makes  them  a  powerful  tool  in  basic  research. 
1)  Diagnostic  Applications 
Undoubtedly  the  main  advantage  of  MCAs  in  diagnosis  lies  in  the 
fact  that  large  amounts  of  antibody  of  the  chosen  specificity  may  be 
produced  indefinitely.  Many  clinical  assays  have  in  the  past  relied  on 
rabbit  sera  which  are  variable  in  titre,  specificity,  bleed  and  animal. 
Standardisation  of  any  particular  assay  is  now  possible. 
The  high  specificity  gives  the  advantage  of  fine  diagnosis 
between  two  similar  strains  of  the  same  virus  or  bacterium  or  two  similar 
polypeptide  hormones.  The  antibodies  may  also  be  used  to  find  tumour 
associated  antigens  and  to  dissect  out  the  aberrant  immune  response  in 
autoimmune  diseases. 
2)  Therapeutic  Applications 
Monoclonal  antibodies  have  considerable  potential  in  the  field 
of  tumour  therapy  and  have  already  been  used  for  this  purpose.  Their 
high  specificity  makes  it  possible,  in  principle,  for  antibodies  to 
tumour-associated  antigens  to  be  targetted  to  tumour  cells  leaving  normal 
tissues  unaffected.  The  antibody  can  either  be  used  by  itself,  with 
reliance  on  the  complement  system  to  potentiate  the  immune  response,  or 
associated  with  drugs  or  toxins. 
While  MCAs  may  also  have  potential  in  the  treatment  of 
autoimmune  disease  via  anti-idiotype  therapy  or  specific  suppression  of 
the  immune  response,  this  field  is  at  an  early  stage  of  development. -  48  - 
3)  Preparative  Applications 
The  most  successful  preparative  use  to  date  of  MCAs  has  been  in 
the  purification  of  alpha-interferon  (Secher  &  Burke,  1980).  The  major 
advantages  of  monoclonal  antibodies  in  this  area  lie  in  that  the  material 
used  for  immunisation  need  not  be  pure,  though  the  assay  must  be 
specific.  It  is  possible,  at  least  in  theory,  to  isolate  a  pure 
component  from  a  very  heterogeneous  mixture.  In  practice  the  response 
is  dominated  by  major  Ags  and  some  degree  of  prepurification  is  highly 
desirable. 
The  ability  to  select  affinity  of  Ab  is  also  occasionally  an 
advantage  in  preparative  techniques.  Thus  it  is  possible  to  select  an 
antibody  of  comparatively  low  affinity  (Mason  &  Williams,  1980)  for 
affinity  purification  of  a  readily  denatured  antigen. 
4)  Applications  in  Basic  Research 
The  ability  of  MCAs  to  react  with  a  single  epitope  has  extensive 
implications  in  many  fields  of  basic  research.  It  is,  at  least  in 
theory,  possible  to  contemplate  a  detailed  analysis  of  the  distribution 
within  and  among  cell  types  of  any  chosen  Ag,  to  investigate  its  detailed 
function  by  inhibition  with  Abs  directed  to  different  epitopes,  to  purify 
it  in  substantial  quantities  for  detailed  structural  analysis  and 
potentially  to  isolate  the  genes  coding  for  its  production.  In  this 
last  point  it  has  been  suggested  that  the  DNA  coding  for  the  antibody  may 
even  be  altered  so  that  an  Ab  of  chosen  specificity  unobtainable  from 
eukaryotic  systems  may  be  produced  in  bacteria. 
The  work  described  in  this  thesis  was  directed  towards  some 
aspects  of  these  basic  applications  with  chromosomal  proteins. 
While  in  theory  MCAs  have  the  potential  to  perform  many  of  the 
functions  outlined  above,  they  have  limitations  relating  to  their 
monoclonal  nature.  Amongst  these  limitiations  are  firstly,  their 
over-specificity,  for  example  they  may  not  always  react  with  all  strains -  49  - 
of  virus.  Secondly  they  may  also  exhibit  under-specificity  due  to  their 
reaction  with  single  and  possibly  common  epitope  such  as  a  carbohydrate 
moiety.  A  third  disadvantage  may  be  that  it  has  not  yet  proved  possible 
in  practice  to  emplsy  monoclonal  antibodies  to  dissect  a  complex  array  of 
antigen.  Fourthly,  functions  dependent  on  the  binding  of  two  Abs  in 
close  proximity  like  C'F  may  not  always  perform.  More  detailed  accounts 
of  the  properties  and  limitations  of  monoclonal  antibodies  are  given  in 
recent  reviews  (Edwards,  1981;  Goding,  1980;  Staines  &  Lew,  1980, 
Yelton  &  Scharff,  1981;  Fazekas  de  St.  Groth  &  Scheidegger,  1980). 
1.5.3  Monoclonal  Antibodies  to  Chromosomal  Proteins 
There  is  considerable  interest  in  the  specific  association  of 
certain  nonhistone  chromosomal  proteins  with  actively  transcribed  DNA  and 
the  possible  role  of  these  proteins  in  chromosome  structure  and  gene 
expression.  The  complex  and  heterogeneous  nature  of  this  group  means 
that  MCAs  have  great  potential  to  play  a  major  role  in  dissecting  and 
characterising  such  proteins.  The  use  of  immunofluorescent  methods  has 
helped  to  locate  some  such  antigens  on  chromosomes.  Saumweber  et  al 
(1980)  have  used  the  indirect  immunofluoresc2nce  technique  to  demonstrate 
that  amongst  a  number  of  MCAs  raised  against  the  total  nuclear  fraction 
from  Kc  cells  of  D.  melanogaster,  fifty  eight  have  shown  a  highly 
selective  staining  pattern  on  polytene  chromsomes  of  the  salivary 
glands.  Three  distinct  staining  patterns  have  been  recognised. 
Staining,  of  the  transcriptionally  active  regions,  of  the  phase  dark 
bands  and  of  most  interbands,  have  been  noted  clearly.  The  molecular 
weights  of  the  individual  proteins  that  react  with  the  monoclonal 
antibodies  have  been  determined.  These  antibodies  have  shown  reactions 
with  wide  range  of  proteins  of  different  molecular  weights.  In  another 
work,  Howard  et  al  (1981)  have  produced  a  monoclonal  antibody  that 
recognises  a  single  nonhistone  protein  of  62K  molecular  weight  in 
Drosophila.  The  antibody  preferentially  stains  the  induced  heat  shock -  50  - 
loci.  This  study  demonstrates  that  MCAs  can  be  used  successfully  to 
verify  the  hypothesis  that  specific  individual  NHC  proteins  are 
preferentially  associated  with  the  set  of  loci  that  includes  both  active 
sites  and  those  scheduled  to  be  active  at  some  time  during  development. 
Among  other  MCAs  produced  by  Saumweber  et  al  (1980),  one  has  been  used  in 
further  investigation.  HUgle  et  al  (1982)  have  applied  this  antibody 
(T7),  which  is  known  to  react  with  transcriptionally  active  regions,  to 
stain  HeLa  and  PTK2  cells.  Using  T7;  positive  immunofluorescent 
staining  on  interphase  nuclei  of  HeLa  and  PTK2  cells  has  been  noted.  In 
an  attempt  to  localise  the  antigen  for  this  MCA,  three  polypeptides  of 
molecular  weights  (44K,  63K  and  70K)  have  been  identified.  It  has  been 
concluded  that  these  polypeptides  are  probably  components  of  two 
different  RNP  structures.  One  of  these  structures  is  sensitive  and  the 
other  is  resistant  to  RNAse  treatment.  Also  among  the  monoclonal 
antibodies  reported  by  Saumweber  et  al  (1980),  are  many  whose  antigens 
have  been  found  associated  with  pulse  labelled-RNA  (Risau  et  al,  1982). 
The  distribution  pattern  of  these  antigens  has  been  determined  in 
comparison  with  that  of  RNA  polymerase  B  by  double  labelling 
immunofluorescence  using  as  a  reference  a  MCA  directed  towards  subunit 
one  of  Drosophila  RNA  polymerase  B.  The  results  have  indicated  the 
existence  of  two  types  of  RNA-associated  particles  (Kabisch  &  Boutz, 
1983).  This  Ab  can  prove  very  useful  in  locating  those  NHC  proteins 
which  have  been  suggested  to  play  an  important  role  in  gene  activation 
and  are  associated  with  RNA  forming  particles  (Yang  et  Al,  1981). 
Another  group  of  MCAs  directed  against  a  nuclear  protein  of  53K 
(P53)  have  been  reported.  MCAs  to  (P53)  produced  by  Crawford  et  al 
(1981)  have  shown  selective  reactivity  with  human  cell  lines  derived  from 
spontaneous  tumours  or  transformed  in  vitro  with  simian  virus  40.  In 
contrast,  this  phosphoprotein  has  not  been  detected  in  normal  human 
cells.  Othek  groups  of  workers  have  also  described  the  production  of -  51  - 
MCA  against  a  53K  transformation-related  nuclear  protein  (De  Leo  et  al, 
1979;  Dippold  et  al,  1981).  Dippold  et  al  (1981)  have  noted  that 
expression  of  (P53)  in  human  cells  correlates  with  the  growth  level. 
High  levels  of  P53  have  been  found  associated  with  rapid  cell 
proliferation.  However,  recently  Bosslet  et  al  (1983)  have  described 
another  murine  MCA  reactive  with  cell  nuclei  which  is  not  exclusively 
against  DNA  nor  P53  in  transformed  cells  but  towards  a  nucleo-protein 
complex. 
Another  group  of  MCAs  have  been  produced  against  avian  red  cell 
nuclear  proteins  (Kane  et  al,  1982).  Although  some  of  them  have  shown 
cross-reactivity  with  a  number  of  polypeptides  which  may  reflect  a  common 
protein  domain,  the  others  provided  an  interesting  specificity  for  the 
identification  and  isolation  of  tissue-  and  species-specific  nuclear 
components.  In  more  recent  studies,  Vanderbilt  and  Anderson  (1983)  have 
been  able  to  produce  MCAs  from  mice  immunised  with  erythrocyte 
chromatin.  Tissue  specificity  has  been  noted  in  the  immunoreactivity  of 
a  number  of  these  Abs.  Three  protein  antigens  have  been  localised  as 
nuclear  while  another  three  proteins  are  found  in  the  cytoplasm.  On  the 
other  hand  another  group  of  MCAs  derived  from  mice  injected  with 
chromatin  from  hen  oviduct,  react  strongly  with  hen  oviduct  chromatin 
(Vanderbilt  &  Anderson,  1982).  All  of  these  Abs  react  with  chromosomal 
proteins  in  the  absence  of  nuclear  DNA  while  a  large  fraction  of  them 
reacts  specifically  with  oviduct  chromatin  but  not  with  other  tissues. 
Another  MCA  against  NHC  protein  has  been  reported  recently  (Kuo  et  al, 
1982). 
Teng  et  al  (1982)  have  raised  a  highly  specific  anti  HMG-17 
MCA.  No  cross-reactivity  with  even  the  closely  related  HMG  proteins 
(-1,  -2  and  -14)  has  been  detected.  Turner  (1981)  has  successfully 
produced  another  group  of  MCAs  to  chromatin-associated  proteins  from 
human  liver,  rat  liver  and  a  human  lymphoblastoid  cell  line.  The -  52  - 
subcellular  location  of  target  antigens  has  been  examined  by 
immunofluorescence.  Three  of  these  Abs  have  given  staining  patterns 
consistent  with  the  in  vivo  association  of  the  target  Ag  with  chromatin 
recognising,  respectively,  the  interphase  nucleus  and  metaphase 
chromsomes,  the  nuclear  per'phery,  and  the  mitotic  spindle  and  other 
microtubule-containing  structures.  Moreover,  another  four  MCAs  have 
recognised  Ags  associated  with  the  intermediate  filament  network  possibly 
due  to  cytoplasmic  contamination. 
.' -  53  - 
Concluding  Remarks  and  Aim  of  the  Project 
As  is  outlined  in  the  introduc(ion,  gene  expression  is  a  very 
complex  process  which  involves  the  participation  of  many  components, 
including  nucleic  acids  and  various  types  of  nuclear  protein.  Many  of 
these  components  are  present  in  very  small  amounts  which  makes  their 
characterisation  and  purification,  as  well  as  the  assignment  of  any 
specific  role  for  each  one  of  them,  an  extremely  difficult  task  with  the 
limited  capacity  of  the  available  biochemical  techniques.  Moreover, 
understanding  of  the  structural  assembly  of  chromosomes  in  metaphase  or 
interphase  nuclei,  and  the  forces  responsible  for  bringing  about  the 
fundamental  changes  in  these  structures  during  the  cell  cycle  is  limited. 
Many  nonhistone  nuclear  proteins  which  are  involved  in  different 
aspects  of  metabolism  are  still  unpurified  and  uncharacterised.  In 
addition,  proteins  involved  in  the  control  of  gene  expression  of  cells 
are  still  largely  unidentified.  Consequently,  highly  specific 
antibodies  may  be  a  useful  tool  in  the  characterisation  of  individual 
chromosomal  components. 
Specific  antibodies  could  be  employed  in  the  following  ways: 
(1)  In  basic  research,  specific  antibodies  to  minor  proteins  or 
proteins  that  share  common  biochemical  features  which  make  them 
inseparable  or  very  difficult  to  purify,  could  be  used  to 
characterise  and  purify  them. 
(2)  While  cell  surface  antigens  are  more  commonly  used  as  markers  to 
classify  and  type  cells  in  culture  there  are  many  situations  in 
which  the  cell  surface  antigens  are  not  readily  resolved. 
Chromosomal  antigens  may  provide  better  antigenic  resolution  in 
such  cases. 
(3)  Monospecific  antibodies  to  proteins  associated  with  the  control 
of  gene  expression  could  obviously  be  of  great  value  in  the 
elucidation  of  this  complex  process. -  54  - 
(4)  Highly  specific  antibodies  against  tumour  or  other 
disease-associated  antigens  could  play  a  valuable  role  in 
diagnosis  and  possibly  in  treatment. 
Consequently,  the  research  undertaken  and  presented  in  this 
thesis  is  aimed  at  producing  specific  antisera  and  monoclonal  antibodies 
to  chromosomal  components  at  the  basic  level  of  research  but  with  the 
anticipation  of  possible  long  term  clinical  significance. Materials  &  Standard  Solutions -  55  - 
2.  Materials  and  Standard  Solutions 
2.1  Materials 
The  materials  used  during  the  course  of  this  project  are  listed 
below  with  their  suppliers  names  and  addresses. 
2.1.1  Cell  Culture  Materials 
Aminopterin  ) 
RPMI-1640  medium  ) 
Foetal  Calf  Serum  (FCS)  ) 
Penicillin/Streptomycin 
Flow  Laboratories,  Irvine, 
Scotland 
Glaxo  Pharmaceutical,  London 
Gentamycin  )  Sigma  Chemical  Co.,  Dorset 
Hypoxathine  )  England 
Thymidine 
Non  Essential  amino  acids  (NEAA)  )  Gibco  Europe,  Paisley, 
Fungizone  )  Scotland 
GMEM  medium 
2.1.2  Disposable  Plasticware 
(1)  All  tissue  culture  plasticware  and  disposable  plastic  bottles 
were  supplied  by  Sterilin,  Teddington,  England 
(2)  Costar  plates  (24-well  and  96-well)  were  supplied  by 
Costar-Inc.,  Northumbria  Biological  Ltd.,  England 
(3)  ELISA  plates  were  obtained  from  Dynatech  Laboratories  Ltd., 
Sussex,  England 
(4)  Flexible  microtitre  plates  for  radioimmunoassay  were  supplied  by 
Flow  Laboratories,  Scotland 
2:  1.3  Radiochemicals 
L-[ 
35S]Methionine, 
specific  activity  5000i/mmoleand 
125  125 
[  I]iodine  (carrier-free  Na  I),  1.9-2.6Ci/mmole  were  supplied  by 
the  Radiochemical  Centre,  Amersham,  England. -56- 
2.1.4  X-ray  and  Photographic  Materials 
X-ray  films  (Kodak  X-Omat  S)  were  supplied  by  Kodak-Pathe-France 
400ASA  Photographic  films  (Kodak)  were  purchased  from  a 
photographic  retailer,  Glasgow,  Scotland. 
2.1.5  Enzymes 
Staphylococcal  nuclease  (EC  3.1.4.7)  was  purchased  from  BCL, 
Bell  Lane,  Lewes,  East  Sussex,  England. 
Ribonuclease  A  (EC  3.1.4.22);  Bovine  Pancrease,  and  DNAse  I  (EC 
3.1.21.1)  were  obtained  from  Sigma  Chemical  Co.,  Dorset,  England. 
Trypsin  1:  250  (EC  3.4.21.4);  Difco,  was  supplied  by  Difco 
Laboratories,  PO  Box  14B,  Central  Av.,  East  Molesey,  Surrey. 
2.1.6  Chemicals 
The  following  chemicals  were  supplied  by  Sigma  Chemical  Co., 
England. 
O'-phenyldiamine  (OPD),  8-azaguanine  (AG),  digitonin, 
deoxycholic  acid,  polyoxyethylene  sorbiton  monopalmitate  20  (Tween  20), 
N,  N,  N'N'-tetramethylene  diamine  (TEMED),  tris  (hydroxymethyl)  aminoethane 
(Trizma  Base),  N-desacetyl-N-methyl  colchicine  (Democolcine), 
O'-dianisidine,  spermine,  spermidine,  N-2-hydroxyethylpiperazine 
N'-2-ethane  sulfonic  acid  (HEPES),  Coomassie  Blue  (G-250). 
Other  chemicals  were  supplied  as  listed  below: 
dimethyl  sulfoxide  (DMSO) 
2-mercaptoethanol  )  Koch  Light  Laboratories, 
dithiothreitol  (DTT)  )  Bucks,  England 
NaCl  and  KC1 
2,5-diphenyloxazole  (PPO) -  57  - 
Polyethylene  glycol  1500  (PEG  1500)  Serva,  Heidelberg,  Germany 
Triton  X-100 
Pristane  (2,6,10,14-tetra- 
methyl  pentadecane) 
PMSF  (phenyl  methyl  sulfonyl 
fluoride) 
Rohm  &  Haas,  Tyne  &  Wear, 
Eng  land. 
Aldrich  Chemical  Co.  Ltd., 
Gillingham,  Dorset,  England 
Boehringer,  West  Germany 
All  other  reagents  were  "Analar"  grade  and  were  supplied  by 
British  Drug  House  (BDH),  Dorset,  England. 
2.1.7  Cell  Lines 
2.1.7.1  Human  Cell  Lines 
The  sources  and  characteristics  of  human  cell  lines  which  were 
used  during  the  course  of  this  research  are  listed  in  Table  2a. 
2.1.7.2  Animal  Cell  Lines 
The  sources  and  characters  of  mouse  and  other  nonhuman  cell 
lines  used  during  the  course  of  this  research  are  shown  in  Table  2b. 
2.1.8  Animals 
2.1.8.1  Mice 
BALB/c  mice  were  obtained  from  the  University  of  Glasgow  Colony, 
Animal  House,  Department  of  Biochemistry.  Mice  were  propagated  by 
sibling  mating  and  entered  the  study  at  2-4  months  of  age.  Both  sexes 
were  used. 
2.1.8.2  Rabbits 
White  Albino,  English,  Dutch  F3X-F2Y  and  Half  Lop  rabbits  of 
both  sexes  entered  the  study  at  approximately  8-10  months  of  age. 
2.1.9  Serological  Materials 
Commercial  rabbit  anti-class  specific  (mouse)  immunoglobulin 
antisera  were  obtained  from  Bionetics  Laboratory  Products,  supplied  by 
Uniscience,  Ltd.,  Cambridge,  England. -  58  - 
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Peroxidase  conjugated  goat  anti-rabbit  and  rabbit  anti-mouse 
were  from  Miles  Laboratories  Ltd.,  Slough,  England. 
Affinity  purified  sheep  anti-rabbit  IgG  and  anti-mouse  IgG  were 
supplied  by  Dynatech  Laboratories,  Sussex,  England. 
Sheep  anti-mouse  (anti-Y),  donkey  anti-sheep  and  other  normal 
sera  (rabbit,  sheep  and  goat)  were  obtained  from  Scottish  Antibody 
Production  Unit  (SAPU),  Wishaw,  Scotland. 
Rabbit  haemolysin  was  purchased  from  Flow  Laboratories,  Irvine, 
Scotland. 
Guinea  pig  complement  was  obtained  from  Wellcome  Diagnostics, 
Dartford,  England. 
2.1.10  Sheep  Red  Blood  Cells  (SRBCs) 
SRBCs  were  supplied  by  Professor  Douglas  of  the  Veterinary 
School,  University  of  Glasgow. 
2.1.11  Miscellaneous 
Ficoll,  polyvinylpyrolidone  (PVP),  bovine  serum  albumin  (BSA), 
Protein  A  and  NP-40  were  supplied  by  Sigma  Chemical  Co.,  England. 
Nitrocellulose  papers  were  purchased  from  Schleicher  &  Schüll, 
West  Germany. 
Low  molecular  weight  marker  proteins  and  Sephadex  G25  were 
obtained  from  Pharmacia  Fine  Chemicals,  Uppsala,  Sweden. 
Eppendorf  tubes  (1.5m1  capacity)  were  obtained  from  Eppendorf 
Gerätebau,  Hamburg,  West  Germany. 
2.2  Standard  Solution  and  Buffers 
2.2.1  Fusion  and  Cell  Culture  Media 
2.2.1.1  RPMI-1640  medituyr 
This  was  supplied  by  Flow  Laboratories  as  a  dry  powder.  The 
content  of  the  bottle  was  dissolved  in  distilled  water  as  instructed  by 
the  supplier  and  to  it  2g/L  of  Sodium  bicarbonate  was  added.  The  pH  was 
adjusted  to  pH  7.0-7.1  with  concentrated  HC1  and  water  added  up  to  the -  61  - 
required  volume.  The  medium  was  sterilised  by  filteration  and  then 
aliquoted  and  stored  at  4°C. 
The  composition  of  RPMI  medium  is  shown  in  Table  3. 
Immediately  before  use,  fungizone,  penicillin-streptomycin  and/or 
gentamycin  and  the  required  amount  of  heat-inactivated  FCS  were  added. 
2.2.1.2  Heat-Inactivation  of  Foetal  Calf  Serum  (FCS) 
Foetal  calf  serum  was  inactivated  at  56°C  for  45-60  minutes, 
then  aliquoted  in  sterile  bottles  and  stored  at  -20°C. 
2.2.1.3  HT  and  HAT  media 
The  concentration  of  HT  and  HAT  in  medium  is  as  described  by 
Littlefield  (1964).  Hundred  fold  concentrated  HT  stock  was  prepared  by 
dissolving  hypoxanthine,  thymidine  and  glycine  in  distilled  water. 
Solubilisation  of  hypoxathine  was  assisted  by  stirring  the  mixture  at 
45-50°C  for  60  minutes  and  the  warm  solution  was  sterilised  by 
filteration  aliquoted,  and  stored  at  -20°C. 
HT  medium  was  made  up  by  diluting  1.  Oml  of  the  sterilised  stock 
with  100ml  of  complete  FCS-RPMI  medium  to  give  a  concentration  of 
3x10 
5M, 
lx10-3M  and  1.6x10-4M  for  glycine,  hypoxanthine  and 
thymidine  respectively. 
HAT  medium  was  prepared  from  HT  complete  medium  with  the 
addition,  to  each  100m1  of  this  medium,  0.4m1  of  0.1mM  stock  aminopterin 
supplied  by  Flow  Laboratories  to  give  a  final  concentration  of  4x10-7M. 
2.2.1.4  GMEM  medium 
Glasgow  modified  Eagle's  minimum  essential  medium  (GMEM)  was 
supplied  by  Flow  Laboratories.  It  was  made  up  as  IOX  concentrated 
solution  and  stored  at  4°C.  This  was  diluted  and  supplemented  with 
penicillin/streptomycin,  sodium  bicarbonate  and  calf  serum  (CS)  or  foetal 
calf  serum  (FCS)  prior  to  its  use. 
The  composition  of  GMEM  is  given  in  Table  4. -  62  - 
Table  3  Composition  of  RPMI  1640  medium 
Amino  Acids 
L-Arginine 
L-Asparagine  H2O 
L-Aspartic  acid 
L-Cystine,  disodium  salt 
L-Glutamic  acid 
L-Gluatmine 
Glycine 
L-Histidine 
L-Hydroxyproline 
L-Isoleucine 
L-Leucine 
L-Lysine  HC1 
L-Methionine 
L-Phenylalanine 
L-Proline 
L-Serine 
L-Threonine 
L-Tryptophan 
L-Tyrosine 
L-Valine 
Vitamins 
Biotin 
D-Calcium  pantothenate 
Choline  chloride 
Folic  acid 
i-Inositol 
Nicotinamide 
p-Aminobenzoic  acid 
Pyridoxine  HCl 
Riboflavin 
Thiamin  HCl 
Vitamin  B12 
Inorganic  salts 
Ca  (N03)  2 
KC1 
MgSO4.7H20 
NaCl 
NaHCO3 
Na2HPO4 
Other  Compounds 
Glucose 
Glutathione 
Sodium  phenol  red 
mg/litre 
200.00 
56.82 
20.00 
59.15 
20.00 
300.00 
10.00 
15.00 
20.00 
50.00 
50.00 
40.00 
15.00 
15.00 
20.00 
30.00 
20.00 
5.00 
20.00 
20.00 
0.20 
0.25 
3.00 
1.00 
35.00 
1.00 
1.00 
1.00 
0.20 
1.00 
0.005 
69.49 
400.00 
100.00 
6000 
2000 
800.7 
2000 
1.00 
5.00 -  63  - 
Table  4  Composition  of  Glasgow  modified  Eagle's  Medium  (GMEM) 
Amino  acids  mg/litre 
L-Arginine  HC1  42.12 
L-Cystine  disodium  salt  28.42 
L-Glutamine  584.6 
L-Histidine  HC1  H2O  21.00 
L-Isoleucine  52.46 
L-Leucine  52.46 
L-Lysine  HC1  73.06 
L-Methionine  14.92 
L-Phenylalanine  33.02 
L-Threonine  47.64 
L-Tryptophan  8.16 
L-Tyrosine  36.22 
L-Valine  46.86 
Vitamins 
D-Ca  pantothenate  2.00 
Choline  chloride  2.00 
Folic  acid  2.00 
i-Inositol  4.00 
Nicotinamide  2.00 
Pyridaxal  HC1  2.00 
Riboflavin  0.20 
Thiamine  HC1  2.00 
Inorganic  salts 
CaC12.2H20  264.9 
Fe  (N03)3.9H20  0.10 
KC1  400.00 
MgSO4.7H20  200.00 
NaCl  6400 
NaHCO3  2750 
NaH2PO4.2H20  140.00 
Other  compounds 
Glucose  4500 
Sodium  phenol  red  17.00 -  64  - 
2.2.1.5  Polyethylene  glycol  (PEG)  Solution 
2.  Og  of  polyethylene  glycol  1500  (PEG  1500)  was  autoclaved  at  15 
lb/sq.  in.  for  15  minutes,  then  cooled  down  to  45-50°C  and  added  to  it 
2m1  of  filter-sterilised  0.15M-HEPES  (N-2-hydroxyethyl  piperazine 
N'-2-ethane  sulfonic  acid)  buffer  pH  7.5  to  give  50%  w/v  sterile  PEG 
solution. 
2.2.1.6  Antibiotics 
Penicillin  105  I.  U.  /L  and  streptomycin  100mg/L  were  used  in 
routine  culture  media  from  a  100X  stock. 
For  hybridoma  production  and  cloning  media,  gentamycin  (50pg/ml) 
was  used  as  well  as  penicillin  and  streptomycin.  Fungizone,  2.51g/ml  in 
final  concentration,  was  also  added. 
2.2.1.7  Trypan  Blue  Dye  Solution 
This  solution  was  made  up  by  mixing  one  part  of  1%  (w/v)  trypan 
blue  dye  and  four  parts  of  1%  NaCl  (w/v).  The  mixture  was  diluted  with 
saline,  to  give  0.1%  solution,  immediately  before  use  for  the  Trypan  Blue 
Exclusion  Test. 
2.2.2  Chromatin  and  Dehistonised  Chromatin  Buffers  and  Solutions 
All  solutions  and  buffers  were  prepared  then  stored  at 
-20°C.  PMSF  was  added  immediately  before  use  from  X100  stock  in  DMSO. 
2.2.2.1  Solution  (1) 
0.34M  Sucrose 
10.0mM  tris-HC1  pH  7.5 
1.0mM  EDTA 
1.0mM  PMSF 
0.1%  Triton  X-100 
2.2.2.2  Solution  (2) 
80.0mM  NaCl 
20.0mM  EDTA 
l.  0mM  PMSF -  65  - 
2.2.2.3  Solution  (3) 
0.34M  NaCl 
2.2.2.4  Solution  (4) 
7.5M  Urea 
3.  OM  NaCl 
1.0mM  MgCl2 
0.15M  phosphate  buffer  pH  6.0 
2.2.2.5  2M  Salt  buffer 
2.  OM  NaCl 
10.0mM  tris-HC1  pH  6.0 
1.5mM  MgC12 
1.0mM  PMSF 
0.1%  Nonidet-P-40  (NP-40) 
2.2.2.6  Sucrose  buffer 
1.  OM  Sucrose 
2.  OM  NaCl 
10.0mM  tris-HC1  pH  6.0 
1.5mM  MgC1 
2 
1.0mM  PMSF 
0.1%  Triton  X-100 
2.2.2.7  SSC  buffer 
150.0mM  NaCl 
15.0mM  Sodium  citrate  buffer  pH  5.5 
2.3  Immunoassay  Buffers 
2.3.1  ELISA  Buffers 
2.3.1.1  Carbonate/EDTA  Buffer  (Antigen  Coating  Buffer) 
1.41mM  Na2CO3 
1.79mM  NaHCO3  )  pH  9.6 
1.00mM  EDTA 
0.02%  NaN3 -  66  - 
2.3.1.2  Citrate-phosphate  Buffer 
113.8mM  Na2HPO4 
46.45mM  Citric  acid  )  pH  5.5 
2.3.2  Complement  Fixation  Assay  Buffers 
2.3.2.1  Stock  diluent 
0.15M  MgSO4 
0.10M  CaC12 
1.40M  NaCl 
0.10M  tris  base 
approximately  6.6m1  of  concentrated  HCl  added  to  give  a  final  pH 
7.4  in  a  total  volume  of  1L 
2.3.2.2  Working  diluent  (W.  D.  ) 
100ml  Stock  diluent 
1.  Og  BSA 
Distilled  water  up  to  1  litre 
2.3.3  Saline  Buffers 
2.3.3.1  Tris-saline  (TN) 
50.0mM 
150.0mM 
2.3.3.2  phosphate  buffer-saline  (PBS) 
170.0mM 
3.4mM 
10.0mM 
1.8mM 
tris-HC1  pH  7.4 
NaCl 
NaC1 
KC1 
Na2HP04 
KH 
2PO  4  pH  7.3 Methods -  67  - 
3.  METHODS 
3.1  Preparation  of  Nuclei  and  Chromatin 
3.1.1  Preparation  of  Nuclei 
3.1.1.1  The  method  of  Chauveau  et  al 
This  was  completed  after  the  procedure  of  Chauveau  et  al  (1956) 
as  modified  in  "Methods  in  Enzymology"  (1967). 
Nuclei  were  prepared  from  human  cell  lines.  All  steps  were 
done  at  40C. 
Cells  were  washed  in  PBS  and  then  homogenised  in  0.33M  sucrose  - 
4mM  CaC12.  The  homogenate  was  centrifuged  at  600xg  for  10  minutes  to 
pellet  the  nuclei  which  were  resuspended  in  (0.25M-sucrose,  3mM-CaC12), 
homogenised  and  spun  at  1500xg  for  5  minutes.  The  pellet  was  suspended 
in  nine  volumes  of  (2.4M-sucrose,  3mM-CaC12)  and  homogenised  in  a  tight 
fitted  Teflon  pestle  in  a  mechanical  homogeniser,  then  centrifuged  at 
45,000xg  for  lh.  The  pellet  was  collected,  resuspended  in  0.25M  sucrose 
-  3mM  CaC12,  centrifuged  at  600xg  for  10  min.  The  nuclei  were 
collected  as  a  pellet  and  washed  with  PBS. 
3.1.1.2  Polyamine  method 
Nuclei  were  prepared  following  the  method  of  Blumenthal  et  al 
(1979),  as  modified  by  Lewis  and  Laemmli  (1982). 
Solution  (I) 
7.5OmM  Tris-HC1  pH  7.4 
0.10mM  Spermine 
0.25mM  Spermidine 
1.00mM  EDTA 
40.  OOmM  KCl 
Solution  (II) 
5.00mM  Tris-HC1 
0.25mM  Spermidine 
2.00mM  K-EDTA 
2.00mM  KC1 
0.1%  Digitonin 
pH  7.4 
Cells  were  collected,  washed  once  and  soaked  at  room  temperature 
for  15  min  in  100mM-tris-HC1  pH  7.4  containing  100mM-NaC1  and -6B- 
5.  OmM-MgC12.  The  mixture  was  centrifuged  at  1400xg  for  5  min.  The 
pellet  was  collected,  washed  three  times  at  25°C  in  15.  Oml  of  solution 
(I).  The  cells  were  collected  after  each  wash  by  centrifugation  at 
1400xg  or  5  min.  Swollen  cells  (pellet)  were  resuspended  at  4°C  and 
vortexed  for  15  sec  in  10.0  ml  of  twice  concentrated  solution  (I) 
containing  0.1%  digitonin  and  lOpg/ml  of  RNAase  A.  All  subsequent  steps 
were  carried  out  at  4°C.  The  cells  were  lysed  by  gentle  (5  strokes) 
and  vigorous  (5  strokes)  homogenisation  in  a  tight  fitting  pestle.  The 
homogenate  was  centrifuged  at  low  speed  (180xg)  for  5  min  and  the 
supernatant  was  collected,  layered  gently  onto  37.  Oml  of  a  15-60%  (w/v) 
sucrose  gradient  in  solution  (II)  and  centrifuged  at  4000xg  for  5  min 
then  at  1100xg  for  30  min. 
Cytoskeletal  materials  remained  on  top  and  nuclei  were  collected 
as  a  pellet. 
3.1.2  Chromatin  Preparation 
This  was  carried  out  after  the  procedure  of  Briggs  et  al  (1979) 
with  minor  modifications.  The  solutions  used  are  described  in  2.2.2  and 
all  steps  were  performed  at  4°C. 
Cells  were  washed  with  solution  (1)  and  lysed  by  gentle 
homogenisation  (1-2  strokes)  in  5  volumes  of  the  same  solution.  The 
homogenate  was  spun  at  5000xg  for  5  minutes.  The  supernatant  referred 
to  as  cytoplasmic  fraction  was  stored  at  -20°C.  The  pellet  was 
collected,  suspended  in  3  volumes  of  solution  (2)  and  homogenised  with  a 
Teflon  tight-fitting  pestle  until  the  nuclei  appeared  to  be  broken  when 
examined  under  the  microscope.  The  mixture  was  spun  at  8000xg  for  10 
minutes  and  the  pellet  was  collected,  resuspended  in  3  volumes  of 
solution  (2)  lacking  PMSF  and  homogenised  again  for  few  strokes.  The 
homogenate  was  centrifuged  at  36,000xg  for  15  min.  The  pellet  was 
extracted  by  homogenisation  in  solution  (3)  and  centrifuged  at  36,000xg -  69  - 
for  15  minutes.  The  chromatin  was  collected  as  a  pellet,  resuspended  in 
one  volume  of  100-fold  diluted  SSC  buffer  and  pelleted  by  centrifugation 
at  36,000xg  for  15  minuts. 
3.1.3  Dehistonised  Chromatin 
3.1.3.1  2M  Salt  extracted  chromatin 
The  chromatin  prepared  in  3.1.2  or  nuclei  in  3.1.1  were  further 
extracted  by  2M-salt  buffer. 
The  pellet  from  3.1.1  and  3.1.2  was  resuspended  in  3  volumes  of 
2M-salt  buffer  described  above  in  2.2.2.5  and  homogenised  for  several 
strokes  with  a  tight  fitting  pestle.  Each  2.5m1  of  the  homogenate  was 
layered  gently  on  the  top  of  2.5m1  of  sucrose  buffer  (2.2.2.6)  in  5m1 
capacity  cellulose  nitrate  centrifuge  tube.  The  tubes  were  spun  at 
140,000xg  in  SW50.1  rotor  for  90  minutes.  The  supernatant  was  decanted 
gently  and  the  pellet  washed  twice  with  double  distilled  water. 
3.1.3.2  2M  Salt  -  5M  urea  extracted  chromatin 
Chromatin  preparations  as  described  above  in  Sections  3.1.2  and 
3.1.3.1  were  further  extracted  by  2M  salt  -  5M  urea  following  the 
procedure  of  Briggs  et  al  (1979)  with  minor  modifications. 
Chromatin  or  2M  salt  extracted  chromatin  was  suspended  in 
2mM-tris-HC1  pH  7.5,  and  the  concentration  of  DNA  was  adjusted  to  give 
0.5mg/ml.  Two  volumes  of  solution  (4)  (2.2.2.4)  were  added  and  the 
solution  was  stirred  for  2h  at  4°C  then  spun  at  100,000xg  for  24-36h. 
The  supernatant  was  decanted  carefully  and  the  sides  of  the  tubes  were 
rinsed  three  times  with  double-distilled  water  containing  0.  lmM-PMSF. 
The  pellet  was  resuspended  in  2mM-tris-HC1  pH  7.5,  homogenised  then 
stirred  at  4°C  overnight.  The  suspension  was  centrifuged  at  1400xg 
for  5  minutes  and  the  dehistonised  chromatin  was  collected  as  supernatant. -  70  - 
3.1.4  Bhorjee  and  Pederson's  Method  of  Preparation  of  Nucleoli  and 
Nonhistone  Chromosomal  Proteins 
This  was  completed  after  the  procedure  of  Bhorjee  and  Pederson 
(1973).  The  experiment  was  performed  at  0-40C. 
The  cells  were  washed  once  with  PBS  buffer  and  centrifuged  at 
500xg  for  5  minutes.  The  pellet  was  suspended  in  TNM  hypotonic  buffer 
(lOmM-tris-HC1  pH  7.0,  lOmM-NaCl  and  1.5mM-MgC12).  The  suspension  was 
allowed  to  stand  for  10  minutes  then  homogenised  by  a  tight-fitting 
Teflon  homogeniser  (10  strokes).  The  nuclei  were  collected  by 
centrifugation  at  1000xg  for  3  minutes  and  washed  three  times  in  10 
volumes  of  TNM  buffer.  The  clean  nuclei  were  resuspended  at  4x107  per 
ml  in  TNM  buffer  containing  lmM-PMSF  and  disrupted  by  brief  sonication 
(4x15  seconds  at  a  current  of  1.5A1  The  sonicate  was  then  layered  on 
top  of  equal  volume  of  30%  sucrose  bed  in  TNM  buffer  and  centrifuged  at 
4500xg  for  15  minutes.  The  nucleoli  were  collected  as  a  pellet. 
The  material  which  remained  on  top  of  30%  (w/v)  sucrose  bed  was 
collected  and  aliquoted  into  10ml  portions.  Each  aliquot  was  then 
layered  gently  on  the  top  of  27m1  of  60%  sucrose  solution  (w/v)  in 
TN-EDTA  buffer  (2.5mM-tris-HC1  pH  7.2,  lOmM-NaCl  &  25mM-EDTA)  and 
centrifuged  at  131,000xg  for  90  minutes  in  SW27  Beckman  rotor.  The 
pellet  was  suspended  in  0.5-lml  of  TNM  buffer,  and  dialysed  overnight 
against  several  changes  of  TNM  buffer.  Histones  were  extracted  from  the 
dialysed  chromatin  by  adding  H2SO4  to  a  concentration  of  0.2M  and 
allowing  the  sample  to  stand  at  4°C  for  30  min.  The  extract  was  then 
centrifuged  at  37,000xg  for  15  minutes.  The  pellet  was  re-extracted 
again  with  0.2M-H2SO4  and  centrifuged.  The  nonhistone  fraction  was 
pelleted  and  resuspended  in  (2.5mM-tris-HC1  pH  7.2  and  lOmM-NaC1), 
dialysed  against  the  same  buffer  overnight. -  71  - 
3.2  Animal  Procedures 
3.2.1  Preparation  of  immunogen  in  complete  Freund's  Adjuvent  (CFA) 
Dehistonised  chromatin  obtained  by  procedure  3.1.3  was  suspended 
in  PBS.  The  required  amount  of  immunogen  in  50-100Nl  was  then  mixed 
with  equal  volume  of  CFA.  The  mixture  was  vortexed  to  make  an  emulsion 
which  was  passed  through  narrow  gauge  (G21-G23)  needle. 
3.2.2.  Injection  of  Mice 
Individuals  were  immunised  i.  p.  with  100-150pl  of  immunogen 
(measured  as  100pg  of  DNA)  as  an  emulsion  in  CFA  prepared  as  reported  in 
3.2.1.  The  immunisation  was  repeated  twice  in  CFA  with  10-14  days 
interval  in  between.  A  booster  of  100pg  immunogen  in  PBS  was  given  i.  p. 
14-18  days  after  the  second  injection.  The  animals  were  sacrificed 
under  anaesthetic  (ether)  4-5  days  after  the  booster  and  spleens  were 
collected. 
3.2.3  Injection  Protocol  of  Rabbits 
Individual  rabbits  were  given  (70-150Ng)  of  immunogen,  (measured 
as  DNA  content)  emulsified  in  CFA,  subcutaneously  (S.  C.  )  in  the  back  of 
the  animal  on  2-3  sites.  Two  S.  C.  injections  were  given  in  CFA  two 
weeks  apart,  followed  by  a  booster  of  100pg  of  immunogen  in  PBS  14-20 
days  after  the  second  injection.  The  booster  was  injected  i.  v.  in  the 
ear. 
3.2.4  Fluid  Withdrawal 
3.2.4.1  From  Mice 
3.2.4.1a  Blood  withdrawal 
Blood  from  mice  was  withdrawn  from  the  tail  3-4  days  after 
booster.  The  end  of  the  tail  was  cut  (2mm)  by  sterile  scalpel  blade 
while  the  animal  was  under  anaesthesia.  A  few  drops  of  blood  could  be 
collected  by  massaging  the  tail  gently. 
3.2.4.1b  Ascitic  Fluid  withdrawal 
Ascitic  fluids  were  withdrawn  from  the  intraperitoneal  cavity  of 
mice  by  a  syringe  attached  to  21G  gauge  needle.  The  anaesthesised  mouse -  72  - 
was  laid  on  the  back  and  carefully  a  small  incission  was  made  through  the 
skin  without  cutting  the  peritoneal  membrane.  A  sterile  needle  (G21) 
was  then  inserted  and  the  fluid  was  withdrawn  slowly  making  sure  that  the 
needle  did  not  touch  the  viscera. 
3.2.4.2  From  Rabbits 
Rabbits  were  bled  from  the  marginal  vein  on  the  ear.  The  area 
was  cleaned  and  shaved,  then  a  small  cut  was  made  in  the  vein  by  a 
sterile  scalpel  blade.  The  blood  was  drained  by  massaging  and  pressing 
on  the  vein  to  stop  the  return  blood  flow. 
3.3  Lymp  hocyte  H  ybridoma  Production  and  Tissue  Culture 
3.3.1  Pre  paration  of  Myeloma  Cells 
Myeloma  cells  653  (X63-Ag-653)  reported  by  Kearney  et  al  (1978) 
were  obtained  from  Flow  Laboratories,  Scotland. 
The  cells  were  grown  in  RPMI  1640  medium  supplemented  with  10% 
FCS,  20pg  8-azaguanine,  fungizone,  penicillin  and  strptomycin,  at  37°C 
c 
in  humidified  5%  C02  incubator.  Cells  for  fusion  were  collected  from 
culture  medium  and  examined  for  at  least  95%  viability. 
3.3.2  Preparation  of  Spleen  Cells 
Spleen  cells  as  feeder  layer  and  for  fusion  from  immunised 
BALB/c  mice  were  prepared  by  the  same  method.  Mice  were  washed  with 
alcohol  and  dissected  by  sterile  equipment.  Spleens  were  collected  from 
the  mice,  washed  twice  with  sterile  serum-free  RPMI  medium  containing 
fungizone  and  gentamycin  as  described  in  2.2.1.6.  The  spleen  cells  were 
released  by  teasing  the  spleen  with  several  injections  of  RPMI  medium. 
The  cells  were  then  washed  3-4  times  with  RPMI. 
3.3.3  Assessment  of  Cell  Viability  and  Counting 
Cell  viability  was  examined  by  Trypan  Blue  exclusion  test.  An 
aliquot  of  cell  suspension  was  mixed  with  an  equal  volume  of  trypan  blue 
dye  solution  (2.2.1.7).  The  number  of  live  and  dead  cells  were  counted 
in  a  Neubauer  Haemocytometer. 
Routine  cell  counting  was  also  done  in  a  haemocytometer. -  73  - 
3.3.4  Feeder  Layer 
Spleen  feeder  cells  were  prepared  as  described  in  3.3.2.  A 
known  number  of  cells  were  suspended  in  20%  FCS-supplemented  RPMI  medium 
(with  or  without  HT  supplements  as  described  in  3.3.5  and  3.3.6)  and 
dispensed  at  a  concentration  of  106  cells  per  ml.  0.5  ml  of  this  cell 
suspension  was  placed  in  each  well  of  2  ml  capacity  (or  0.  lml  in  0.25m1 
capacity  well)  24  hr  before  fusion  or  cloning. 
3.3.5  Fusion  Protocol 
This  was  carried  out  by  the  procedure  of  Pontecorvo  (1975)  with 
minor  modifications,  using  HEPES  buffer  as  described  by  Klebe  and  Mancuso 
(1981). 
Spleen  cells  (lxlO8)  were  mixed  with  (1x107)  myeloma  cells 
in  serum-free  RPMI  medium,  washed  and  centrifuged  at  500xg  for  5  min. 
The  supernatant  was  carefully  and  fully  aspirated,  and  the  pellet  was 
tapped  gently.  To  the  pellet,  lml  of  sterile  and  pre-warmed  (37°)  50% 
(w/v)  PEG  solution  (2.2.1.5)  was  added  slowly  over  a  period  of  60  seconds 
with  very  gentle  shaking.  The  mixture  was  incubated  at  37°C  for  60 
sec  and  then  diluted  slowly  with  5ml  of  warm  RPMI  medium  over  a  period  of 
3-5  min  with  gentle  shaking.  The  mixture  was  again  incubated  at  37°C, 
and  left  for  5  min,  after  which  5ml  of  warm  RPMI  medium  was  added  and  the 
suspension  was  spun  at  500xg  for  5  min. 
The  cells  were  then  gently  resuspended  in  RPMI  1640  medium 
containing  20%  (v/v)  FCS,  hypoxanthine,  thymidine  and  glycine  (HT 
medium).  Half  a  millilitre  of  this  suspension  was  added  to  each  well  of 
24-well  costar  plate  (2ml  capacity)  prelayered  with  a  spleen  cell  feeder 
layer  5xl05  cells  per  well  as  described  in  3.3.4,  and  the  plates  were 
incubated  at  37°C  in  humidified  CO2  incubator  at  a  density  of  5x105 
myeloma  cells/ml.  After  6-18  h  incubation  in  HT  medium,  0.5m1  of  HT 
medium  containing  three  times  concentrated  aminopterin  was  added  to  each 
well,  and  the  plate  was  again  incubated  in  the  Co2 
incubator  for  one -  74  - 
week.  The  cells  were  fed  on  days  8  and  11  by  removing  lml  of  the  medium 
without  disturbing  the  cells,  and  then  lml  of  fresh  HAT  medium  (2.2.1.3) 
was  added  slowly. 
3.3.6  Cloning  by  Limited  Dilution 
Screening  for  positive  wells  by  ELISA  was  carried  out  between 
day  15  and  18  after  fusion  as  described  in  3.4.2.  Cells  in  the  wells  of 
interest  were  cloned  (first  cloning)  by  limited  dilution  in  HT  medium  in 
a  96-well  costar  plate  prelayered  with  spleen  feeder  cells  (106 
cells/well).  The  limiting  dilution  was  performed  at  1  cell  per  well  or 
less.  The  plates  were  examined  under  the  microscope  after  5-7  days. 
Wells  containing  single  foci  were  marked  and  tested  on  day  15-20  after 
cloning.  The  positive  clones  were  recloned  again  (second  cloning). 
The  positive  clones  from  the  second  cloning  again  either  expanded  or 
recloned  for  3rd  or  4th  cycle. 
Positive  single  clones  at  this  stage  were  considered  monoclonal 
and  propagated  in  FCS-supplemented  RPMI. 
3.3.7  Freezing  of  Cells 
Cells  were  suspended  in  1.0ml  aliquots  containing  2x106  cells 
per  ml  in  RPMI-1640  supplemented  with  10%  (v/v)  FCS,  10%  (v/v)  DMSO  in 
1.5m1  capacity  sterile  bottles.  The  aliquots  were  frozen  at  -70° 
overnight,  then  transferred  to  Gas-phase  liquid  nitrogen  freezer. 
3.3.8  Thawing  of  cells 
Frozen  cells  were  quickly  thawed  in  a  37°C  water  bath  and  then 
layered  onto  the  top  of  5.  Oml  of  50%  (v/v)  FCS  in  RPMI  in  a  sterile 
bottle.  The  bottle  was  centrifuged  at  300xg  for  5  min,  and  the  cells 
were  collected  and  grown  in  30-40%  (v/v)  FCS-RPMI.  Half  the  medium  was 
changed  after  24-48  hr  with  20%  (v/v)  FCS-RPMI  and  then  the  cells  were 
fed  with  10%  (v/v)  FCS-RPMI  as  necessary. -  75  - 
3.3.9  Propagation  of  Monoclonal  Antibodies 
3.3.9.1  In  Vivo 
In  order  to  establish  the  monoclonal  hybridoma  cell  lines  as 
tumours  in  BALB/c  mice,  the  animals  were  given  a  primary  injection  of 
0.4m1  of  Pristane  (2,6,10,14-tetramethyl  pentadecane)  per  mouse 
intra-peritoneally  (i.  p.  )  at  least  seven  days  before  the  cells  were 
injected. 
_ 
106-107  Myeloma  cells  were  suspended  in  50-100pl  of  PBS 
and  injected  intra-peritoneally  (i.  p.  )  into  each  mouse.  '  The  animals 
were  examined  daily  after  14  days  for  the  development  of  Ascites 
tumour.  Ascitic  fluid  was  drained  as  described  in  Section  3.2.4.1b 
3.3.9.2  In  vitro 
Hybridoma  (or  Myeloma)  cells  were  grown  in  complete  RPMI-10% 
(v/v)  FCS  medium  in  sterile  flasks  at  370C  in  a  humidified 
C02  incubator  and  were  subcultured  when  required  before  fully 
confluent.  Supernatant  (MCA)  was  collected  and  stored  at  -20°C. 
3.3.10  Routine  Culture 
Other  cell  lines  were  grown  in  large  scale  cultures  in  2.5L 
sterile  roller  bottles.  The  bottles  containing  the  cultures  were  gassed 
to  give  5-7%  (v/v)  CO20  sealed  and  placed  on  a  mechanical  rolling 
device  in  a  37°C  hot  room. 
The  appropriate  culture  media  for  each  cell  line  is  shown  in 
Table  2. 
3.4  Assays  of  Monoclonal  Antibodies  and  Other  Antisera 
3  .  4.1  Radioimmunoassay 
125 
Affinity  purified  sheep  antiglobulins  were  labelled  with  1 
using  the  chloramine  T  method  as  described  in  3.5.3.  Flexible 
microtitre  plates  were  used  and  the  procedure  was  carried  out  in 
duplicate.  Protocol: 
1)  l00N1  (100pg/ml)  of  chromatin  in  carbonate-EDTA  buffer 
(2.3.1.1),  was  placed  in  each  well  and  left  overnight  at  4°C.  The 
plate  was  then  washed  twice  with  TN  buffer. -  76  - 
2)  150pl  of  5%  (v/v)  goat  serum  plus  3%  (v/v)  BSA  in  TN  buffer 
(GS-BSA-TN)  was  added  to  each  well  to  saturate  any  remaining  non-specific 
binding  sites  and  the  plate  was  left  at  room  temperature  for  lh,  then 
washed  with  TN  buffer, 
3)  80pl  of  culture  fluid  (supernatant)  or  the  required  dilution  of 
antisera  or  ascitic  fluid  in  (GS-BSA-TN)  was  added  to  each  well.  The 
plates  were  incubated  at  4°C  overnight  (o.  n.  ),  washed  3-4  times  with  TN 
buffer. 
4)  70pl  of 
1251-anti-gamma-globulin 
(106  c.  p.  m.  /ml)  in 
GS-BSA-TN  buffer  was  added  to  each  well  and  the  plate  was  incubated  at 
room  temperature  for  two  hours  (or  overnight  at  4°C),  wash  4-5  times  in 
TN  buffer.  The  wells  then  dried,  cut,  and  counted  in  an  LKB  minigamma 
counter. 
5)  Controls:  Antigen,  antibody  and  blank  (GS-BSA-TN)  controls  were 
run  simultaneously  on  the  same  plate. 
3.4.2.  Enzyme  Linked  Immunosorbent  Assay  (ELISA) 
The  ELISA  technique  which  was  first  outlined  by  Engvall  and 
Perlman  (1971)  and  then  modified  for  the  optimal  conditions  as  described 
by  Engvall  (1980)  was  adopted.  The  reaction  was  performed  in  a 
specially  coated  ELISA  plate  (Dynatech). 
The  protocol  was  as  described  for  radioimmunoassay  in  Section 
3.4.1,  except  after  step  three;  70p1  of  peroxidase  linked  anti-mouse  IgG 
in  GS-BSA-TN  buffer  (1/500)  was  added  and  the  plate  was  incubated  for  2h 
at  4°C  (or  lh  at  room  temperature)  and  washed  4-5  times  with  TN 
buffer.  To  the  wells,  5Opl  of  o-phenyl-diamine  (OPD),  as  a  substrate 
(0.4mg/ml)  in  citrate-phosphate  buffer  (2.3.1.2)  containing  0.01%  fresh 
H2O21  was  added  and  the  plate  was  kept  in  the  dark  for  10-20  minutes 
or  till  the  colour  developed  in  the  wells.  The  reaction  was  terminated 
by  the  addition  of  100pl  of  4M  H  2SO4  and  the  A492  of  the  solution 
was  read  in  a  Multiskan  (Flow)  microtitre  reader.  Controls  as  described 
in  3.4.1  were  also  prepared  on  the  same  plate. -  77  - 
3.4.3  Complement  Fixation  Assay  (C'F  Assay) 
This  was  completed  following  the  method  of  Wasserman  and  Levine 
(1961)  with  minor  modifications. 
3.4.3.1  Preparation  of  complement  (C') 
Guinea  pig  Lyophilised  complement  (Wellcome)  was  used.  The 
contents  of  each  bottle  were  dissolved,  as  recommended  by  the  supplier  in 
5m1  of  chilled  distilled  water  at  0°C,  then  aliquoted  in  cold  (0°C) 
Eppendorf  tubes  and  stored  at  -700  for  a  maximum  period  of  three  months. 
When  needed,  the  aliquots  were  thawed  at  0°C  and  diluted  with 
chilled  working  diluent  (2.3.2.2)  and  kept  at  0°C  for  up  to  lh.  The 
dilution  required  was  estimated  by  incubating  the  dilute  complement 
(0.6m1)  with  0.2ml  of  activated  SRBCs  (3.4.3.3.  )  at  37°C  with 
shaking.  The  maximum  dilution  of  complement  which  gave  full  cell  lysis 
within  15-20  mins  was  selected.  The  maximum  dilution  was  routinely 
found  1/500. 
3.4.3.2  Preparation  of  Antibody-Antigen-Complement  Mixture  (Ab-Ag-C') 
All  steps  were  carried  out  at  0-4°C. 
Plastic  tubes  contained  serial  dilution  of  antisera  (O.  lml  each) 
in  working  diluent  were  set  up  in  a  duplicate  samples.  Chromatin 
samples  as  prepared  in  3.1.2  were  suspended  in  working  diluent  to  give 
100pg  of  DNA  per  ml  and  O.  lml  of  this  suspension  was  added  to  each 
tube.  To  this  mixture,  0.6ml  of  1/500  dilution  of  complement  was  added 
and  the  mixture  was  incubated  at  4°C  for  18-20h. 
Antibody  control  for  each  dilution,  chromatin  controls  (Ag), 
working  diluent,  and  complement  controls  were  prepared  and  incubated  at 
the  same  time. 
3.4.3.3  Activation  of  Sheep  Red  Blood  Cells  (SRBCs) 
Fresh  sheep  red  blood  cells  (supplied  routinely  every  28  days) 
were  washed  2-3  times  with  working  diluent,  centrifuged  at  300g  for  5 
mins.  The  cells  were  then  suspended  in  working  diluent  (approximately -  78  - 
1/100)  so  that  0.2m1  of  this  suspension  when  lysed  with  0.8m1  of  water 
gave  an  A413  of  0.9-1.1. 
To  this  cell  suspension  rabbit  antisheep  haemolysin  was  added  to 
t 
a  concentration  of  ipl/ml  of  suspension.  The  mixture  was  incubated  at 
37°C  for  30  min  with  occasional  shaking,  then  cooled  and  used  the  same 
day. 
3.4.3.4  Determination  of  the  percentage  of  complement  fixed  by  the 
Antibody-Antigen  Complex 
After  18-20h,  the  tubes  in  3.4.3.2  were  put  on  ice  and  0.2m1  of 
activated  SRBCs  was  added  to  each  one.  The  tubes  were  incubated  in  a 
shaking  water  bath  at  37°C  and  watched  for  complete  cell  lysis  in 
complement  control  tubes. 
The  incubation  was  then  extended  for  another  2-3  min,  and 
terminated  by  placing  the  tubes  on  ice-bath.  The  tubes  were  spun  at 
500g  for  5  mins  at  4°C.  The  supernatants  were  collected  and  read  at 
A413. 
The  percentage  of  Complement  Fixation  (%  C'F)  is  calculated  as 
follows: 
A413  Complement  Control  Complete  Lysis  -  A413  test  sample 
CIF  x  100 
A413  Complete  Lysis 
3.4.4  Determination  of  the  pH  Effect  on  Monoclonal  Antibody  in  ELISA 
This  was  completed  as  described  in  3.4.2,  except  that  serial 
dilutions  of  Ab  were  added  in  different  pH  ranges.  A  range  of  pH  3  to 
pH  12  was  selected  using  the  Universal  Buffer  described  by  Britton  and 
Welford  (1937)  added  to  it  NaCl  to  give  saline  concentration. 
The  universal  buffer  was  made  0.02857M  with  respect  to  boric 
acid,  citric  acid,  5,5'-diethyl  barbituric  acid,  potassium  dihydrogen 
phosphate,  buffered  with  NaOH.  To  this  buffer  NaCl  was  added  to  give  a 
concentration  of  0.14M. -  79  - 
3.4.5  Competition  Assay 
The  competition  assay  was  carried  out  to  allow  two  (or  more) 
different  or  homologous  antigens  to  compete  with  each  other  for  the 
antibody  binding  site. 
In  small  volumes  (150pl)  of  TN  buffer  containing  0.2%  BSA, 
serial  dilution  of  different  concentrations  of  antigen  (Agl)  were 
incubated  with  fixed  amounts  of  antiserum  or  monoclonal  antibody  in  small 
glass  tubes  at  4°C  for  18-24h.  The  tubes  were  centrifuged  briefly  at 
500xg  for  3  min.  The  unabsorbed  antibody  (supernatant)  was  then 
collected  gently  and  50pl  from  each  tube  was  added  to  the  wells  of  ELISA 
plate.  The  plate  was  precoated  10.  ONg  of  HeLa  chromatin  (Ag2)  and 
blocked  with  GS-BSA-TN  buffer  as  described  in  Section  3.4.2.  The 
procedure  was  continued  as  in  Section  3.4.2. 
3.4.6  Enzyme  Treatment  of  HeLa  Chromatin  Reacting  with  Monoclonal 
Antibody 
The  procedure  of  Turner  (1981)  was  adopted  with  minor 
modifications.  On  an  ELISA  plate,  different  concentrations  of  HeLa 
chromatin  were  immobilised  as  described  under  Section  3.4.2.  The  plate 
was  then  washed  with  TN  buffer.  Enzymes  (50pl)  were  added  to  the  wells 
in  the  appropriate  concentrations  and  buffer  systems.  The  wells  were 
incubated  at  25°C  for  60  min  (except  for  RNAase-A  which  was  incubated 
at  370C)  in  a  humid  atmosphere.  The  wells  were  then  washed  5  times 
with  TN  buffer  and  blocked  with  BSA-GS-TN  buffer  for  lh  at  room 
temperature.  The  plate  was  washed  twice  with  TN  buffer  and  a  fixed 
amount  of  monoclonal  antibody  was  added  to  each  well.  The  procedure  was 
continued  as  described  under  Section  3.4.2. 
Enzyme-untreated  control  was  also  run  simultaneously. -  80  - 
The  enzyme  concentrations  and  the  appropriate  buffers  are  shown 
below: 
1)  DNase-I  (EC  3.1.2.1.1) 
500pg  per  ml  in: 
50mM  acetate  buffer  (pH  5.0) 
4.2mM  MgCl 
2 
1.0mM  PMSF 
2)  RNase-A  (EC  3.1.4.22) 
200pg  per  ml  in: 
10.  OmM  tris-HC1  (pH  7.5) 
Boiled  for  10  min  and  cooled  down  immediately  before  use. 
3)  Trypsin  (EC  3.4.21.4) 
200pg  per  ml  in: 
10.0mM  tris-HC1  (pH7.6) 
3.5  Immunological  and  Immunochemical  Methods 
3.5.1  Chemical  Fractionation  of  Antibodies 
Ammonium  sulphate  precipitation  was  carried  out  using  the  method 
outlined  in  the  EMBO  Laboratory  Manual  (1979). 
Saturated  ammonium  sulphate  solution  was  prepared  by  mixing  75g 
of  solid  on  a  total  volume  of  100ml  of  distilled  water.  The  mixture  was 
stirred  for  1-2h  at  room  temperature  then  stored  at  4°C. 
Culture  supernatants  (or  a  known  volume  of  ascitic  fluid  or 
antiserum,  diluted  4  times  with  PBS)  were  placed  on  ice  for  10  min.  an 
equal  volume  of  saturated  ammonium  sulphate  was  added  dropwise  with 
constant  stirring  at  0-40C  over  a  period  of  several  minutes.  The 
mixture  was  left  on  ice  for  30-60  min  and  then  centrifuged  at  5000xg  for 
10  min.  The  pellet  was  collected  in  a  small  volume  of  buffer  A  (10mM 
tris-HC1  pH  7.8  -  40mM  NaCl),  and  transferred  into  deionised  dialysis- 
tubing.  Dialysis  was  carried  out  agäinst  100  volumes  of  buffer  B(20mM 
tris-HC1  pH  7.8  -  20mM  NaCl).  The  buffer  was  changed  every  3h  and  a -  81  - 
total  dialysis  of  at  least  9h  was  allowed,  after  which  the  sample  was 
collected  and  spun  at  15000x9  for  10  min.  The  supernatant  was  collected 
and  its  A280  measured. 
3.5.2  Analysis  of  Biosynthetically  Radiolabelled  Immunoglobulin 
3.5.2.1  Radiolabelling 
Cells  for  labelling  were  healthy  with  a  viability  range  of 
95-100%.  Hybrid  cells  1.5x106  per  millilitre  were  suspended  in 
methionine  free-RPMI  medium  supplemented  with  10%  dialysed 
heat-inactivated  FCS.  [ 
35 
S]-methionine  solution  was  evaporated  to 
dryness  using  a  stream  of  nitrogen  in  a  fume  hood  or  under  vacuum.  The 
dry  amino  acid  was  redissolved  in  10-20N1  of  methionine-free  RPMI  and 
added  to  the  cell  suspension  to  give  a  final  concentration  of  150NCi/ml. 
The  cells  were  grown  in  CO-humid  incubator  at  37°C.  Complete 
RPMI-10%  FCS  (50pl)  was  added  to  the  cell  suspension  5h  after  the  start 
of  incubation  which  was  continued  for  a  further  11-19h.  The  cell 
suspension  was  then  centrifuged  at  500xg  for  5  min.  The  pellet  was 
collected  for  the  analysis  of  the  internally  labelled-Ig.  The 
supernatant  was  either  frozen  at  (-70°C)  or  used  for 
immunoprecipitation. 
Foetal  calf  serum  was  dialysed  against  several  changes  of  PBS  at 
4°C  for  18h. 
3.5.2.2  Cell  Lysis  and  Immunoprecipitation 
3.5.2.2a  Cell  lysis 
The  cell  pellet  was  suspended  in  0.4ml  of  cold  TKM  (100mM 
tris-HC1  pH  8.0,100mM  KC1  and  5mM  MgC12)  buffer.  Triton  X-100  (10% 
in  TKM),  50N1,  was  then  added  and  the  mixture  was  left  at  0-40C  (with 
occasional  gentle  shaking  for  10  min  to  allow  cytoplasmic  lysis  to 
occur.  The  lysate  was  then  centrifuged  at  500xg  for  10  min  to  pellet 
nuclei  and  debris.  To  the  collected  supernatant,  5011  of  10% -  82  - 
deoxycholate,  5%  SDS  in  TKM  was  added.  The  cell  lysate  was  used 
immediately  for  immunoprecipitation. 
3.5.2.2b  Immunoprecipitation 
Supernantant  (250pl)  from  3.5.2.1  was  added  to  250x1  of  TKM 
buffer  containing  2%  triton  X-100,2%  deoxycholate  and  1%  SDS.  To  90N1 
of  this  mixture  (or  cell  lysate  mixture  in  3.5.2.2a),  1-2p1  of  rabbit 
anti-mouse  antiserum  was  added.  The  mixture  was  incubated  at  40C  for 
30-60  min,  then  10pl  of  goat  anti-rabbit  antiserum  was  added  and  the 
mixture  was  incubated  overnight  at  4°C.  Control  samples  containing 
normal  rabbit  serum  were  also  run  simultaneously. 
After  the  overnight  incubation,  50N1  of  0.75M  sucrose  in  TKM 
containing  1%  triton  X-100,1%  deoxycholate  and  0.5%  SDS  (TKMD)  was  added 
and  the  mixture  was  layered  gently  on  top  of  a  0.6m1  of  two  step  sucrose 
gradient  (1M  -  0.5M)  in  TKMD.  The  gradient  was  centrifuged  at  4000xg 
for  10  min  at  4°C,  and  the  top  layer  was  then  aspirated  gently  leaving 
the  pellet  which  was  washed  with  TKM  and  collected  again. 
3.5.2.3  Polyacrylamide  Gel  Electrophoresis  Analysis 
The  pellet  collected  from  3.5.2.2b  was  dissolved  in  the 
appropriate  volume  of  sample  buffer  described  in  3.6.1,  boiled  for  5  min 
then  cooled  and  applied  to  10%  gel.  The  gel  contains  0.8:  30  acrylamide 
mixture  and  was  run  at  constant  current  of  l5mA,  stained  and  destained  as 
described  in  Section  3.6.2. 
3.5.2.4  Fluorography 
This  was  carried  out  after  the  procedure  of  Bonner  and  Laskey 
(1974)  with  minor  modifications. 
The  destained  gel  which  contains  the  radiolabelled  proteins  was 
soaked  in  DMSO  (5  times  the  volume  of  the  gel)  for  30  min  with  gentle 
rocking.  This  was  repeated  3  times  with  fresh  DMSO.  The  gel  was  then 
impregnated  (with  gentle  rocking)  in  four  volumes  of  scintillation 
solution  of  20%  w/w  2,5-diphenyloxazole  (PPO)  in  DMSO  for  45-60  min. -  83  - 
After  this  immersion  in  scintillator,  the  gel  was  washed  with  several 
changes  (10  volumes)  of  deionised  (or  distilled)  water  over  a  period  of 
lh.  The  gel  was  then  dried  under  vacuum  in  a  gel  dryer  (Bio-Rad). 
In  a  dark  room,  X-ray  film  (X-Ornat)  was  placed  in  contact  with 
the  dry  gel  and  exposed  at  -700C  for  4-18h  in  a  dark  wrap.  The  film 
was  developed  and  fixed  in  the  dark  according  to  the  instruction  of  the 
developer  supplier. 
3.5.3  Antibody  Radiolabelling 
The  methods  of  Greenwood  et  al  (1963)  were  adopted  with  minor 
modifications. 
Affinity  purified  sheep  anti 
'y-globulin 
(Dynatech)  was  diluted 
in  0.5M  phosphate  buffer  pH  7.5  to  give  a  concentration  of  200Ng  IgG  per 
200p1.  Sodium  iodide  (125I),  lmCi  (carrier-free)  was  added  followed 
immediately  by  100Ng/100Nl  of  freshly  prepared  chloramine  T  in  0.5M 
phosphate  buffer.  The  mixture  was  shaken  frequently  over  a  period  of  60 
sec.  The  reaction  was  stopped  by  the  addition  of  125pg  of  sodium 
metabisulphite  in  100p1  of  0.05M  phosphate  buffer  pH  7.5  and  the  mixture 
again  left  for  60  sec  with  shaking.  Potassium  iodide  2mg  in  200pl  of 
0.05M  phosphate  buffer  was  added  as  a  carrier  for 
125I 
ions  followed  by 
400111  of  0.2%  BSA  in  0.05M  phosphate  buffer.  The  mixture  was  then 
passed  through  1.5xlOcm  pre-equilibrated  sephadex  G25  column  and  the 
sample  was  eluted. 
Pre-equilibration  and  elution  were  performed  by  passing  0.1%  BSA 
in  0.05M  phosphate  buffer  through  the  column.  Fractions  of  0.5  -  0.7m1 
were  collected. 
PMSF  was  added  to  the  phosphate  buffer  immediately  before  use  to 
give  a  final  concentration  of  0.1mM. 
A  typical  elution  profile  is  shown  in  Figure  4. -  84  - 
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3.5.4  Immunoblotting 
3.5.4.1  ELISA  Technique 
Antigens  (proteins)  transferred  to  nitrocellulose  paper  (3.6.3) 
were  detected  by  Enzyme  Linked  Immunoassay  (ELISA)  as  described  by  Towbin 
et  al  (1979). 
Nitrocellulose  paper  after  blotting  was  washed  with  TN  buffer, 
and  the  paper  was  then  incubated  with  3%  BSA  -  5%  GS  in  TN  buffer 
(GS-BSA-TN)  for  lh  at  room  temperature  to  block  the  nonspecific  sites. 
The  paper  was  washed  with  TN  buffer  and  incubated  with  the  first  antibody 
(antiserum,  ascitic  fluid  or  culture  medium)  diluted  in  GS-BSA-TN  buffer 
at  40C  overnight.  The  paper  was  then  washed  3  times  with  TN  buffer 
and  incubated  for  2h  at  room  temperature  with  peroxidase  conjugated 
second  antibody  (anti-gamma-globulin)  diluted  1/500  -  1/700  in  GS-BSA-TN 
buffer  and  washed  4-5  times  with  TN  buffer.  To  visualise  the  antibody 
reaction  the  nitrocellulose  paper  was  incubated  in  the  dark  with 
o-dianisidine  0.0025%  w/v  (  as  a  substrate)  in  TN  buffer  containing  0.01% 
H202.  The  colour  developed  within  10-20  min  and  the  reaction  was 
stopped  by  washing  the  paper  in  a  large  volume  of  TN  buffer  or  deionised 
water. 
3.5.4.2  Immunoblotting  by  Radiolabelled  Antibody 
The  practical  principle  was  essentially  the  same  as  that 
described  in  3.5.4.1  except  that  the  second  Ab  was 
125I-labelled 
affinity  purified  antiglobulin  (3.5.3). 
The  nitrocellulose  paper  was  incubated  with  the  second  antibody 
at  106c.  p.  m. 
125I 
per  ml  of  GS-BSA-TN  for  2h  at20C.  The  paper  was 
then  washed  4-5  times  with  TN  buffer,  dried  by  blotting  between  filter 
papers  and  then  autoradiographed  using  Kodak  X-ray  (X-Omat  S)  film. 
3.5.4.3  Immunoblotting  by 
125I-Protein  A  Method 
This  was  performed  after  the  procedure  of  Battiger  et  al  (1982) 
using  Tween  20  as  blocking  agent  as  modified  in  our  laboratory 
(A.  M.  Campbell,  personal  communication). -86- 
The  nitrocellulose  paper  after  protein  transfer  was  washed 
several  times  in  (20mM  tris-HC1  pH7.2,0.15M  NaCl,  0.5mg/ml  NaN3,0.5% 
Tween  20)  for  30-60  min  to  block  non-specific  sites.  The  blot  was  then 
incubated  (at  4°C  overnight)  with  first  antibody  (the  mouse  monoclonal) 
diluted  in  the  same  buffer.  The  paper  was  washed  5  times  (for  30  min) 
with  the  blocking  buffer  and  then  incubated  (for  4h/at  room  temperature) 
again  with  second  antibody  (anti-mouse  IgM  H+L)  diluted  1/100  in  the  same 
buffer.  The  nitrocellulose  paper  was  washed  again  5  times  as  described 
above  and  then  allowed  to  react  with 
125I-protein 
A  (2x107  cpm/ml) 
for  lh,  washed  (5-10  times  over  30-60  min  in  the  blocking  buffer),  dried 
by  blotting  between  filter  papers  then  autoradiographed  using  Kodak  X-ray 
(X-Omat  S)  film. 
3.6  Gel  Electrophoresis  and  Protein  Blotting 
3.6.1  Slab  Gel  Electrophoresis 
This  was  completed  after  the  method  of  Laemmli  (1970)  with  minor 
modifications. 
1) 
2) 
3) 
Separating  gel  buffer 
Stacking  gel  buffer 
Running  (Reservoir)  buffer 
3M  tris-HC1  pH  8.8 
0.5M  tris-HC1  pH  6.8 
4)  Sample  buffer 
(0.025M  tris  base) 
(0.192M  Glycine 
(0.1%  SDS  ) 
pH  8.3 
(0.0625M  tris-HC1  pH  6.8 
2%  SDS 
(  10%  glycerol  ) 
5%  2-mercapto-ethanol) 
(0.001%  bromophenol  blue  ) -  87  - 
5)  30%  Acrylamide  mixture 
a)  0.8:  30  (the  ratio  of  bisacrylamide  to  the  total) 
29.2g  acrylamide 
0.8g  bisacrylamide 
Upto  100m1  of  distilled  water 
The  mixture  was  filtered  then  stored  at  4°C  and  used  only 
as  indicated  in  the  text. 
b)  1.2:  30 
28.8g  acrylamide 
1.2g  bisacrylamide 
Upto  100ml  of  distilled  water 
This  mixture  was  used  routinely  unless  otherwise  stated  in 
the  text. 
6)  10%  Separating  gel  mixture  lOml  30%  acrylamide  mixture 
3.75m1  separating  gel  buffer 
1.50m1  1%  ammonium  persulfate 
1.67m1  9M  urea 
15N1  TEMED 
upto  30m1  Water 
This  10%  gel  mixture  was  used  routinely  unless  otherwise  stated. 
7)  3%  Stacking  gel  mixture  2.  Oml  acrylamide  mixture 
S.  Oml  stacking  gel  buffer 
0.5m1  ammonium  persulfate 
1.13  ml  9M  urea 
10  N1  TEMED 
upto  20m1  distilled  water 
The  separating  gel  mixture  was  poured  between  two  glass  plates 
(22x30cm)  held  apart  by  1.2mm  diameter  silicone  tubing  in  addition  to 
1.1mm-thick  spacers  on  each  side.  The  glass  plates  were  held  vertically 
and  the  gel  allowed  to  polymerise.  The  stacking  gel  was  then  poured  on -  88  - 
the  top  of  the  separating  gel  with  a  Teflon  "comb"  in  place  to  provide 
sample  slots.  After  polymerisation,  the  sample  slots  were  washed 
thoroughly  with  the  reservoir  buffer  to  remove  the  unpolymerised  gel 
solution. 
Before  loading  the  samples,  the  gel  was  pre-run  for  30-60  min  at 
200V.  Samples  (15-30pg  proteins  per  20-50pl  of  sample  buffer)  were 
dissolved  in  sample  buffer,  boiled  for  3-5  min,  cooled  and  loaded  in  the 
sample  slots.  The  gels  were  normally  run  at  200V  till  the  dye  entered 
the  separating  gel,  then  the  run  was  carried  out  at  constant  current  of 
14-15mA  overnight. 
The  run  was  terminated  when  the  dye  front  reached  2cm  from  the 
bottom  of  the  gel. 
3.6.2  Staining  and  Destaining  of  Gels 
Slab  gels  were  stained  with  0.25%  w/v  coomassie  blue  R250 
(Sigma)  in  45:  10:  45  methanol:  acetic  acid:  water  overnight  at  room 
temperature  or  for  lh  at  37°C. 
Gels  were  destained  in  several  changes  of  45:  10:  45  methanol: 
acetic  acid:  water.  The  percentage  of  methanol  was  decreased  gradually 
up  to  20%. 
3.6.3  Protein  Blotting 
3.6.3.1  Electroblotting 
This  was  completed  after  the  method  of  Towbin  et  al  (1979). 
The  assembly  of  the  gel  and  nitrocellulose  paper  is  illustrated  below. 
Basically,  a  plastic  grid  followed  by  foam  pad  (Scotch-Brite  pad)  and 
then  wet  filterpaper  3mm  (Whatman)  were  laid  flat  underneath  the  slab 
gel.  On  the  top  of  the  gel,  buffer-soaked  nitrocelluose  paper  was  laid 
carefully  excluding  any  air  bubble  which  might  be  formed  between  the  gel 
and  paper.  The  paper  was  followed  by  wet  filter  paper  and  another  foam 
pad  and  plastic  grid.  The  assembly  was  tied  tightly  by  rubber  bands  and -  89  - 
then  immersed  vertically  in  an  electrophoretic  destainer  tank  containing 
20%  methanol  in  24mM  tris-192mM  glycine  pH  8.3.  The  nitrocellulose 
paper  was  placed  facing  towards  the  anode  (+ve)  and  the  gel  facing  the 
cathode  (-ve).  The  electrophoretic  run  was  at  300mA  for  2.5-3h. 
The  plastic  grids  contained  many  holes  to  allow  the  current  to 
flow  freely. 
000000000000000000 
plastic  grid  A^  AA  AAA  AA  AAA  AA  nitrocellulose  paper 
foam  .....  gel 
.......  .......... 
filter  paper---ý----  AAAAAAAAAAAA^A^  filter  paper 
0000000000000000000 
plastic  grid  foam 
3.6.3.2  Blotting  by  Diffusion 
The  procedure  of  Bowen  et  al  (1980)  was  adopted. 
Transfer  Buffer 
50.0mM  NaCl 
2.0mM  EDTA 
0.1mM  DTT  (fresh) 
10.0mM  tris-HC1  pH  7.0 
Urea  Pretransfer  Buffer 
4M  urea  in  transfer  buffer 
Before  blotting,  the  gels  were  immersed  in  urea  pretransfer 
buffer  and  agitated  for  3h.  The  assembly  of  gel  for  blotting  was 
basically  as  described  in  3.6.3.1  except  that  nitrocellulose  papers  were 
put  on  each  side  of  the  gel  and  the  transfer  was  performed  by  immersing 
the  whole  assembly  in  transfer  buffer  for  36-48h. 
3.6.3.3  Staining  of  Blots 
Protein  on  nitrocellulose  paper  was  stained  by  0.1%  freshly 
prepared  amidoblack  (Naphthalene  -  blue  black  -  Sigma),  made  up  in 
45:  10:  45  methanol:  acetic  acid:  water,  for  10  min. 
3.6.3.4  Destaining  of  Blots 
Nitrocellulose  papers  were  destained  immmediately  after  staining 
by  several  changes  of  90:  2:  8  methanol:  acetic  acid:  water. -  90  - 
3.6.3.5  DNA  Binding  on  the  Blot 
The  method  of  Bowen  et  al  (1980)  was  employed: 
(  10.0mM  tris-HC1  pH  7.0 
(  1.0mM  EDTA 
(  0.02%  BSA 
DNA-binding  buffer  (  0.02%  Ficoll 
0.02%  polyvinyl  pyrollidone 
(PVP) 
(  50.0mM  NaCl 
To  determine  whether  the  antigenic  determinants  of  the  proteins 
transferred  on  nitrocellulose  paper  are  DNA-dependent  or  not,  the 
proteins  on  the  paper  were  reconstituted  with  DNA.  After  blotting,  the 
paper  was  washed  with  DNA  binding  buffer  and  incubated  with  100rg/ml  DNA 
in  the  same  buffer  at  37-40°C  for  2h  with  continuous  shaking.  The 
paper  was  washed  with  TN  buffer  and  treated  as  described  in  3.5.4. 
3.7  Immunofluorescence 
3.7.1  Preparation  of  Monolayer  Cells 
Round  glass  coverslips  were  washed  with  dilute  chloros  solution, 
rinsed  with  distilled  water  then  dried  and  sterilised  in  a  hot  air  oven 
at  400  °C.  The  coverslips  were  cooled  down  and  4-5  of  them  were  placed 
in  a  sterile  60mm  plastic  petridish.  Cells  at  105/5011  were  placed  on 
the  top  of  coverslips  and  grown  for  48h  in  the  appropriate  medium  in  a 
CO2  incubator. 
3.7.2  Preparation  of  Mitotic  Cells 
Metaphase  cells  were  prepared  exactly  as  described  in  3.7.1. 
except  that  the  medium  was  supplemented  with  0.5pg/ml  final  concentration 
of  Democolcine  (N-desacetyl-N-methyl  colchicine)  845h  before  collecting 
the  cells. -  91  - 
3.7.3.  Lysis  and  Fixation  of  Cells  to  Preserve  Keratins 
Hypotonic  buffer  Fluorescence  Buffer  (F) 
5.0mM  MgC12  130  mM  KC1 
2.0mM  EGTA  5.0mM  NaCl 
1.0mM  DTT  1.0mM  NaN3 
5.0mM  NaN3  5.0mM  MgCl2 
0.5mM  PMSF  1.0mM  EGTA 
5.  omM  tris-HC1  pH  7.5  20.0mM  potassium  phosphate 
buffer  pH  7.5 
Cells  were  lysed  on  coverslips  according  to  the  procedure  of 
Granger  and  Lazarides  (1982)  with  minor  modifications. 
Cells  attached  to  coverslips  were  washed  with  PBS  and  lysed  by 
immersion  in  several  changes  of  cold  hypotonic  buffer  at  0-4°C  for  10 
min.  The  coverslips  then  were  held  face-up  position  in  the  bottom  of  a 
beaker  filled  with  hypotonic  buffer  up  to  a  height  of  3-4cm.  The  cells 
were  further  disrupted  by  sonication.  The  sonicator  probe  tip  was 
positioned  3-4cm  overhead  and  sonication  was  at  1.5  -  1.7V  for  15-20  sec 
using  6.0mm  diameter  Ti  probe.  Disrupted  cells  on  coverslips  were  then 
fixed  with  3%  gluteraldehyde  (Electron  Microscopy  Grade)  in  buffer  (F) 
for  30-60  min  at  room  temperature. 
After  fixation,  the  cells  were  made  permeable  by  immersion  in 
cold  acetone  (-10°C)  for  10  min. 
3.7.4  Cells  Preparation  on  Coverslips  for  General  Immunofluorescence 
Staining 
The  procedure  of  Stenman  et  al  (1975)  was  adopted.  The  cells 
were  grown  on  coverslips  as  described  in  section  3.7.1,  washed  once  with 
cold  PBS  and  treated  with  ice-cold  hypotonic  medium  (10mM  tris-HC1  pH 
7.4,40mM  glycerol,  20mM  NaCl,  5mM  KC1,1mM  CaC12  and  0.5mM  MgC12) 
for  10  min.  The  excess  of  buffer  on  coverslips  was  blotted  gently  and -  92  - 
the  coverslips  were  air-dried.  The  cells  were  fixed  in  ethanol:  acetone 
(1:  1)  at  -20°C  for  10  min,  airdried  and  then  treated  with  antibodies  as 
described  under  Section  3.7.5  except  that  the  dilutions  of  antisera  were 
performed  in  0.2%  BSA  in  PBS. 
3.7.5  Treatment  of  cells  with  Antibodies 
Acetone  treated  cells  were  washed  with  PBS  and  incubated  for 
30-45  min  at  room  temperature  with  first  antibody  (antisera  or  MCA) 
diluted  in  TN  buffer.  The  coverslips  were  washed  3  times  with  PBS  then 
incubated  for  20  min  at  room  temperature  with  second  antibody  (goat  anti 
mouse  -  or  rabbit  -  IgG  H+L)  coupled  to  FITC  (Miles)  diluted  lA0-1/30  in 
PBS.  The  coverslips  were  washed  3-4  times  with  PBS  and  mounted  with-90% 
glycerol  in  (85mM  NaHCO3  and  15mM  Na2CO3  pH  8.9)  and  viewed  by 
"Leitz"  fluorescent  microscope. 
3.7.6  Chromosome  Spread  Preparation 
Healthy  cells  were  grown  in  plastic  tissue  culture  bottles  for 
48h  in  the  appropriate  medium.  Democolocine  (N-desacetyl-N-methyl 
colchicine)  was  added  to  a  final  concentration  of  5pg/ml  and  the  cells 
were  incubated  for  45-60  min.  The  mitotic  cells  were  then  harvested  by 
gentle  rocking  of  the  plastic  bottle  and  the  cells  were  washed  with  PBS 
and  centrifuged  at  500xg  for  5  min.  The  cells  were  resuspended  in 
0.075M  KC1  and  allowed  to  stand  for  10-12  min  then  centrifuged  at  500xg 
for  5  min.  All  the  KC1  solution  was  sucked  off  except  0.25-0.5m1.  The 
cells  were  resuspended  very  gently  in  the  remainder  of  KC1  solution  and 
then  fixed  in  cold  3:  1  methanol:  acetic  acid  fixative  mixture  by  pouring 
5ml  slowly  dropwise  and  another  5m1  quickly.  The  cells  were  left  in  the 
fixative  mixture  for  at  least  30  min  (up  to  24h)  then  centrifuged  at 
500xg  for  5  min.  The  pellet  was  resuspended  in  10ml  of  fixative  mixture 
and  centrifuged  again.  The  collected  pellet  was  resuspended  in  1-2ml  of 
fixative  mixture.  From  this  suspension  5-6  drops  were  dropped  from  a 
height  of  100cm  onto  a  slide  (prewashed  with  chromic  acid  for  at  least  2h 
then  dried). -  93  - 
3.7.7  Chromosome  Staining 
Chromosomes  which  were  spread  on  a  slide  as  described  in  Section 
3.7.6  were  either  treated  with  antibodies  as  in  3.7.4  for 
immunofluorescent  staining  or  stained  with  Giemsa  stain  as  follows. 
The  chromosomes  fixed  on  the  slides  were  stained  with  Giemsa 
stain  (10%)  in  Gurr's  buffer  (BDH)  pH  6.8.  The  staining  was  performed 
for  30  min  at  room  temperature  and  the  slides  were  washed  thoroughly 
under  tap  water  and  dried. 
3.7.8  Photography 
Cells  or  chromosomes  were  viewed  in  Fluorescence  Microscope 
(Leitz)  using  different  magnifications  or  an  oil  immersion  lens  with 
magnification  of  X2000.  Photographs  were  taken  using  400ASA  film 
(Kodak)  attached  to  an  Orthomat  camera. 
3.8  Miscellaneous 
3.8.1  DNA  Preparation 
The  procedure  of  Flint  et  al  (1976)  was  adopted  with  minor 
modifications. 
Cells  were  washed  in  solution  (1)  (2.2.2.1),  vortexed  and 
homogenised  gently  (one  stroke),  then  spun  at  500xg  for  5  min.  The 
pellet  was  collected,  resuspended  in  hypotonic  buffer  (10.0mM  tris-HC1, 
1.0mM  EDTA,  0.5%  SDS  pH  7.9)  and  vortexed.  The  suspension  was  extracted 
twice  with  phenol  saturated  with  hypotonic  buffer  lacking  SDS.  The 
aqueous  layer  was  collected  each  time  and  then  extracted  further  with 
isoamylalcohol:  chloroform  1:  24  and  the  aqueous  phase  collected.  Sodium 
acetate  3M  (1/10th  volume)  was  then  added  to  give  a  final  concentration 
of  0.3M.  Cold  ethanol  (2  volumes)  was  then  added  and  nucleic  acids  were 
precipitated  at  -200  overnight. -  94  - 
The  precipitate  was  collected,  added  to  20-25m1  of  tris-HC1  pH 
7.9  and  incubated  with  50Ng/ml  of  ribonuclease  A  (boiled  for  10  min  and 
cooled  on  ice  immediately  before  use)  at  370C  for  60  min.  The  mixture 
was  then  extracted  twice  with  saturated  phenol  and  once  with 
isoamylalcohol-chloroform.  Two  volumes  of  cold  ethanol  was  added  to  the 
aqueous  layer  to  precipitate  DNA  at  -200C. 
3.8.2  DNA  Digestion 
Chromatin  or  dehistonised  chromatin  was  suspended  in  digestion 
buffer  (10mM  tris-HC1,40mM  NaCl,  1.0mM  CaC12,1mM  PMSF  pH  7.5)  at  a 
concentration  of  0.60mg  DNA/mi.  Staphyloccocal  nuclease  (Boehringer) 
15,000U  in  lml  of  digestion  buffer  was  then  added  and  the  mixture  was 
vortexed  and  incubated  at  37°  for  90-120  min  in  a  shaking  water  bath. 
The  reaction  was  terminated  by  the  addition  of  EDTA  to  a  final 
concentration  of  2.0mM. 
3.8.3.  DNA  Reconstitution 
The  nuclease  digested  chromatin  was  reconstituted  in  the 
following  manner. 
The  digested  chromatin  (100Ng)  was  dialysed  against  500m1  of  (5M 
urea,  2mM  EDTA,  2.5M  NaCl  and  50mM  tris-HC1  pH  7.5)  at  4°C  for  18h. 
The  dialysing  buffer  was  changed  four  times  over  a  period  of  36-48h 
bringing  the  concentration  of  NaCl  down  to  40mM  then  urea  was  dialysed 
out  (3-4  changes)  against  (40mM  NaCl,  1mM  EDTA  and  50mM  tris-HC1  pH  7.5) 
overnight  at  4°C. 
If  the  digested  chromatin  was  prepared  for  C'F  assay,  further 
dialysis  (2  changes)  against  working  diluent  was  necessary.  To 
reconstitute  native  DNA  with  the  digested  chromatin,  the  required  amount 
of  DNA  (homologous  or  heterologous)  was  added  to  the  chromatin  before  the 
last  change  of  dialysis. -  95  - 
3.8.4  DNA  Estimation 
The  procedure  of  Burton  (1956)  was  used  with  minor  modification. 
A  duplicate  series  of  test  tubes  were  prepared  containing  20, 
40,60  and  100Ng  per  10011  of  standard  calf  DNA  solution  (from  a  stock 
lmg/ml  distilled  water).  HC1O4  0.5M  solution  (0.5m1)  was  added  to 
each  tube  and  the  mixtures  were  incubated  at  700C  for  30  min,  cooled  to 
room  temperature  and  centrifuged  at  600xg  for  10  min.  The  supernatant 
was  collected,  2.  Oml  of  diphenylamine  reagent  was  added  to  each 
supernatant  and  the  solutions  were  kept  in  the  dark-at  room  temperature 
for  20-24h.  The  A600  of  the  solution  was  read  and  plotted  on  graph 
paper.  A  typical  straight  line  was  obtained  within  the  range  of 
concentrations  used  as  shown  in  Figure  S.  Any  unknown  DNA  sample  was 
treated  in  the  same  way  and  its  concentration  was  obtained  from  the 
standard  curve. 
Diphenylamine  (DPA)  reagent  was  prepared  by  dissolving  1.5g  of 
DPA  in  100ml  of  glacial  acetic  acid  added  to  1.5m1  of  concentrated 
sulphuric  acid  and  the  reagent  was  stored  in  the  dark  at  room 
temperature.  Before  this  reagent  was  used,  a  20m1  aliquot  was  withdrawn 
and  O.  lml  of  aqueous  acetaldehyde  (16mg/ml)  added  to  it.  For  routine 
measurement  of  DNA  concentration,  1  A260  unit  was  found  to  be 
equivalent  to  50Ng/ml. 
3.8.5  Protein  Estimation 
The  procedure  of  Bradford  (1976)  was  adopted. 
A  duplicate  series  of  test  tubes  containing  10,20,30,40  and 
50pg/O.  lml  of  standard  BSA  solution  (from  a  lmg/ml  stock)  were  prepared 
in  150mM  NaCl.  The  volume  in  the  test  tubes  was  kept  constant  at 
0.  lml.  Bradford's  reagent  (3.  Oml)  was  then  added  and  the  tubes  were 
vortexed  and  left  to  stand  for  10  min  to  complete  the  reaction.  The 
A595 
of  the  coloured  solution  obtained  was  read  and  a  standard  curve 
was  drawn. -96- 
Figure(5):  Standard  Curve  For  DNA  Estimation 
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To  estimate  an  unknown  protein  sample  concentration,  the  protein 
was  treated  exactly  in  the  same  way  as  for  the  standard  and  its 
concentration  was  obtained  from  the  standard  curve.  The  standard  curve 
is  shown  in  Figure  6. 
Bradford's  reagent  was  freshly  prepared  by  dissolving  100mg  of 
Coomassie  Brilliant  Blue  G-250  (Sigma)  in  50m1  of  95%  ethanol.  This 
solution  was  mixed  with  100ml  of  85%  w/v  phosphoric  acid,  diluted  with 
distilled  water  to  a  volume  of  1L,  and  filtered. 
3.8.6  Intermediate  Filaments  Preparation  (IF) 
This  was  completed  after  the  procedure  of  Schmidt  et  al  (1982) 
with  minor  modification. 
The  cells  (1-2g)  were  lysed  by  homogenisation  (15  strokes)  in  a 
tight-fitting  pestle  in  lysis  buffer  (0.3M  KC1,0.15M  potassium  phosphate 
buffer  pH  6.5).  The  homogenate  was  stirred  gently  for  20  min  at  40C 
and  homogenised  again,  diluted  with  4  volumes  of  cold  distilled  water, 
centrifuged  at  800xg  for  10  min.  The  pellet  was  then  suspended  in  4 
voluems  of  0.4%  NaHCO3  at  4°C,  stirred  gently  for  10  min,  centrifuged 
at  very  low  (180xg)  speed  for  3  min.  The  pellet  was  collected, 
resuspended  in  0.05M  NaHCO3  -  0.05M  Na2CO3  (1g  pellet/ml),  stirred 
for  10  min,  diluted  with  10  volumes  of  0.5mM  CaCl  2  and  centrifuged  at 
800xg  for  10  min. 
To  make  acetone  powder  of  IF,  the  pellet  was  added  to  three 
volumes  of  acetone,  mixed  and  spun  at  180xg  for  5  min.  The  residue  was 
collected,  mixed  with  one  volume  of  acetone  containing  0.5mM  Na2CO3 
and  air  dried. 
3.8.7  Nuclear  Lamina  Protein-Matrix  Preparation 
The  method  of  McKeon  et  al.  (1983)  was  followed  with  minor 
modifications. -98__ 
Figure  6:  Standard  Curve  For  Protein  Estimation 
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HeLa  cells  (20x106)  were  washed  and  extracted  by  four  strokes 
in  a  tight-fitting  pestle  (Teflon)  in  2.  Oml  of  PBS  (section  2.3.3.2) 
lacking  KC1  but  containing  0.1%  Nonidet  P-40,15.0mM  2-mercaptoethanol 
and  1.0mM  PMSF.  The  mixture  was  then  centrifuged  at  1000xg  for  10  min 
and  the  pellet  was  resuspended  in  2.  Oml  of  the  same  buffer  containing 
5.0mM  CaCl  2  and  exposed  to  10  units/ml  of  micrococcal  nuclease  for  10 
min  at  220C.  The  reaction  was  stopped  by  the  addition  of  EDTA  to  a 
concentration  of  3.0mM  and  the  mixture  was  centrifuged  at  1000xg  for  10 
min.  The  pellet  was  extracted  by  1.0ml  of  3M  NaCl  (4  strokes  in  glass 
homogeniser)  in  a  buffer  containing  80mM  KC1,5mM  EDTA,  0.1%  triton  X-100 
and  15.0mM  Pipes  (1,4-piperazinediethane  sulfonic  acid,  pH7.4).  The 
homogenate  was  then  centrifuged  at  2000xg/10  min  and  the  pellet  was 
collected. -  100  - 
4.  Results  and  Discussion -  101  - 
4.1  Results  Obtained  Using  R3.1  Antiserum 
Results 
R3.1  is  a  polyclonal  antiserum  obtained  after  immunising  a  (Half 
Lop)  rabbit  with  two  subcutaneous  injections  of  histone-depleted  HeLa 
chromatin  (150Jg  of  DNA)  extracted  with  2M  salt  and  5M  urea,  prepared  as 
described  in  Section  3.1.3.2.  A  booster  injection  of  the  antigen  (150pg) 
was  given  intravenously  six  days  before  bleeding  of  the  animal. 
The  antiserum  shows  a  high  titre  of  immunoreactivity  towards 
HeLa  chromatin  even  at  a  dilution  of  1/1200.  This  has  been  shown  by  C'F 
assay  and  ELISA  (Figures  4.1.1,4.1.11  &  4.1.12). 
Using  ELISA,  the  antiserum  (R3.1)  reacted  in  a  similar  pattern, 
when  between  2-18pg  of  HeLa  chromatin  was  layered  in  each  well  of  the 
ELISA  plate  (Figure  4.1.1).  If  the  amount  of  chromatin  plated  in  each 
well  was  reduced  to  lpg/well  or  less,  the  immunoreactivity  of  R3.1  fell 
drastically.  This  gives  an  indication  of  the  limited  amount  of  antigen 
which  could  be  immobilised  in  each  well  of  the  ELISA  plate. 
The  target  antigen  requires  the  presence  of  DNA  for  its 
immunoreactivity  with  R3.1  antiserum.  This  is  demonstrated  by  the  great 
loss  of  activity  on  micrococcal  nuclease  digestion  as  seen  in  ELISA 
(Figure  4.1.2)  and  C'F  assay  (  Figure  4.1.3).  Since  micrococcal 
nuclease  digests  both  DNA  and  RNA,  it  is  possible  that  the  complex 
antigen  may  require  RNA  to  determine  the  configuration  of  the  antigenic 
determinants  and  to  make  them  accessible  for  the  antibody  recognition. 
The  immunoactivity  of  the  complexed  antigen  was  almost  completely 
restored  upon  reconstituting  the  nuclease-digested  chromatin  with  HeLa 
DNA  alone  (Figures  4.1.2  &  4.1.3).  As  the  HeLa  DNA  was  prepared  in  a 
way  which  eliminates  the  presence  of  RNA  by  digestion  with  large  amounts 
of  RNAase  A,  as  described  in  Section  3.8.1,  DNA  rather  than  RNA  is 
therefore  required  for  the  immunoreactivity  of  R3.1  antiserum  with  HeLa 
chromatin.  In  order  to  demonstrate  whether  the  immunoreactivity  of  the -  102  - 
Figure  4.1.1  ELISA  of  R3.1  Antiserum  with  HeLa  chromatin 
Enzyme  linked  immunosorbent  assay  of  different 
concentrations  of  R3.1  antiserum  reacted  with  various 
amounts  of  HeLa  chromatin  layered  in  the  wells  of  ELISA 
plate.  (Antibody  and  antigen  controls  were  subtracted) 
0  18pg  chromatin 
p  2pg  chromatin 
p  lpg  chromatin 
X  lOng  chromatin 
The  highest  antibody  control  was  0.07  A492  unit  at  1/150  dilution  while  the 
highest  antigen  control  was  found  to  be  0.15  A492  at  l8ug  of  chromatin. 
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Figure  4.1.2  ELISA  of  R3.1  Antiserum  with  HeLa  Digested-  and 
Undigested-chromatins 
Enzyme  linked  immunosorbent  assay  of  R3.1  antiserum 
(1/250)  allowed  to  react  with  different  concentrations 
of  HeLa  antigen  immobilised  on  an  ELISA  plate.  The 
Chromatins  measured  as  total  protein  content  and  the 
DNA  values  estimated  as  total  DNA  applied  on  the  ELISA 
plate.  (Antibody  and  antigen  controls  have  been 
subtracted). 
O  Undigested  HeLa  chromatin 
0  Micrococcal  nuclease-digested  HeLa  chromatin 
reconstituted  with  HeLa  DNA 
0  Micrococcal  nuclease-digested  HeLa  chromatin 
V  HeLa  DNA  alone 
Antibody  control  was  found  to  be  0.04  A492  unit,  while  antigen  controls  were 
all  between  0.14-0.1  A492  unit. Figure  4.1.2 
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Figure  4.1.3  C'F  Assay  of  R3.1  Antiserum  with  HeLa  Digested-  and 
Undigested-chromatins 
Complement  fixation  assay  of  R3.1  antiserum  (1/200) 
fixed  with  various  concentrations  of  HeLa  DNA, 
chromatin  and  micrococcal  nuclease-digested  chromatin 
before  and  after  reconstitution  with  HeLa  DNA.  All 
chromatin  preparations  were  measured  as  total  protein 
content  except  DNA  alone  estimated  as  total  DNA. 
(Antibody  and  antigen  controls  were  subtracted). 
O  HeLa  chromatin 
Q  Micrococcal  nuclease-digested  HeLa  chromatin 
reconstituted  with  HeLa  DNA 
Micrococcal  nuclease-digested  HeLa  chromatin 
0  HeLa  DNA  alone 
Antigen  controls  showed  less  than  3%  C'F  and  antibody  control  exhibited  on  1y  1%  C'F. Figure  4.1.3 
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target  antigen  lies  with  the  DNA  itself  or  not,  HeLa  DNA  alone  was 
allowed  to  react  with  R3.1  antiserum.  Figures  4.1.2  and  4.1.3  show  asmall 
amount  of,  immunoreaction  between  R3.1  antiserum  and  HeLa  DNA,  when 
assayed  by  complement  fixation  and  ELISA.  This  indicates  that  the 
target  antigen  is  not  the  DNA  alone  but  a  complex  of  DNA  and  chromosomal 
proteins. 
These  data  were  substantiated  by  using  the  competition  assay 
described  in  Section  3.4.5.  R3.1  antiserum  was  absorbed  either  by  HeLa 
chromatin  or  by  micrococcal  nuclease-digested  chromatin  prior  to  its 
application  to  an  ELISA  plate  coated  with  HeLa  chromatin.  The  results 
shown  in  Figure  4.1.4  demonstrate  that  a  great  deal  of  immunoreactivity 
of  R3.1  antiserum  (diluted  1/250)  was  absorbed  by  micrococcal 
nuclease-undigested  HeLa  chromatin  even  at  a  small  amount  of  0.625Ng  of 
chromatin  in  50111  of  the  reaction  mixture.  The  nuclease-digested 
chromatin  failed  to  absorb  large  amounts  of  R3.1  antiserum.  These  data 
are  presented  clearly  when  plotted  as  a  percentage  of  the  absorbed 
chromatin  in  relation  to  the  freely  reacted  R3.1  antiserum  shown  in 
Figure  4.1.4b. 
In  order  to  further  characterise  the  protein  antigens,  HeLa 
chromatin  and  dehistonised  chromatin  together  with  cytoplasmic  fractions 
were  resolved  on  an  SDS-polyacrylamide  gel  electrophoresis  and  then 
transferred  onto  nitrocellulose  paper  as  described  in  Section  3.6.4.1. 
The  antibody-antigen  reaction  was  monitored  by  enzyme  linked 
immunoblotting  as  outlined  in  Section  3.5.4.1  and  shown  in  Figure  4.1.5 
(the  bands  are  very  faint  on  the  photograph  so  a  diagramatic 
representation  is  traced  from  the  original  blot).  R3.1  antiserum 
(1/200)  did  not  show  any  reaction  with  cytoplasmic  fraction  (lanes  7& 
10)  while  faint  colouring  was  noted  corresponding  to  bands  of  Mr  45,000 
and  43,000  on  both  dehistonised  and  chromatin  fractions  (lanes  5,8, 
6&  9).  Another  faint  band  could  be  seen  on  the  immunoblot  in -  106  - 
Figure  4.1.4a  Competition  ELISA  of  HeLa  Chromatins  Reaction  with  R3.1 
Antiserum 
Enzyme  linked  immunoassay  of  R3.1  (1/250)  absorbed  with 
various  concentrations  of  micrococcal  nuclease-digested 
(as  described  in  Section  3.8.2)  and  undigested  HeLa 
chromatins,  50xl  of  this  mixture  then  allowed  to  react 
with  HeLa  chromatin  (layered  as  lOpg/well)  immobilised 
on  an  ELISA  plate.  (Antigen  and  antibody  controls  were 
subtracted). 
O  Micrococcal  nuclease-undigested  HeLa  chromatin 
A  Micrococcal  nuclease-digested  HeLa  chromatin 
The  dotted  line  represents  the  average  of  50pl  of 
unabsorbed  R3.1  (1/250)  reacted  with  HeLa  chromatin 
(layered  as  lOpg/well)  immobilised  on  ELISA  plate. 
Figure  4.1.4b  Percentage  of  Competition  ELISA  of  HeLa  Chromatins 
Reaction  with  R3.1  Antiserum 
The  amount  of  R3.1  (1/250)  antiserum  absorbed  by 
micrococcal  nuclease-digested  and  -undigested  HeLa 
chromatin  expressed  as  a  percentage  of  free  R3.1 
reaction  with  immobilised  HeLa  chromatin  (10pg/well). 
Q  Micrococcal  nuclease-undigested  chromatin 
O  Micrococcal  nuclease-digested  chromatin Figure  4.1.4a 
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Figure  4.1.5  Immunoblots  of  HeLa  Subcellular  Fractions  Reacted  with 
R3.1  and  Normal  Rabbit  Antisera 
Protein  immunoblot  of  R3.1  (1/200)  antiserum  (Strips  B 
&  C)  and  normal  rabbit  serum  (1/200)  (Strip  D)  reacted 
with  cytoplasmic  fraction  (lanes  7,10  &  13),  chromatin 
(lanes  6,9,  &  12)  and  2M-salt  extracted  chromatin 
(lanes  5,8,  &  11)  preparations  from  HeLa  cells 
visualised  by  using  the  immunoperoxidase  method 
described  in  Section  3.5.4.1.  Strip  (C)  was  incubated 
with  HeLa  DNA  as  described  in  Section  3.6.3.5  prior  to 
its  reaction  with  R3.1  antiserum.  Lanes  2,3,  &4 
represent  the  amido  black-stained  proteins 
corresponding  to  2M-salt  extracted  chromatin,  chromatin 
and  cytoplasmic  preparations.  Lane  (1)  is  the 
molecular  weight  marker.  Phosphorylase  b  94,000; 
Bovine  serum  albumin  67,000;  Ovalbumin  43,000; 
Carbonic  anhydrase  30,000;  Soybean  trypsin  inhibitor 
20,100;  M  -Lactalbumin  14,400.  The  proteins  were  run 
in  a  10%  Laemmli  gel  containing  0.5M  urea. - 
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lanes  5  and  6  which  represent  the  dehistonised  chromatin  and 
chromatins.  This  band  is  at  an  approximate  molecular  weight  of 
67,000.  Increasing  the  concentration  of  the  antiserum  (R3.1)  used, 
failed  to  show  any  increase  in  colour  intensity  on  the  immunoblot. 
Furthermore,  normal  rabbit  serum  (1/200)  from  unimmunised  animal  showed 
no  visible  immunoreaction  on  the  blot  (Strip  D). 
Since  the  antigens  in  HeLa  chromatin  require  the  presence  of  DNA 
for  its  reactivity  with  R3.1  antiserum,  and  the  DNA  itself  is  too  large  a 
molecule  to  enter  the  high  percentage  polyacrylamide  gel,  incubating  the 
blot  with  DNA  may  enhance  or  change  the  antigenic  determinants  on  the 
blot  and  make  them  accessible  to  the  antibody  recognition.  The  blot  was 
incubated  with  HeLa  DNA  (100pg/ml)  prior  to  its  reaction  with  R3.1 
antiserum  as  described  in  Section  3.6.3.5.  The  pattern  seen  after  DNA 
treatment  did  not  significantly  affect  the  distribution  of  the  reactive 
proteins  except  for  the  appearance  of  one  faint  band  (Mr  70,000)  in  the 
dehistonised  fraction  and  two  faint  bands  at  Mr  70,000  and  68,000  in  the 
chromatin  lane  (Lane  9).  The  latter  may  be  the  same  as  the  67,000  seen 
in  lanes  5  and  6. 
By  inspecting  the  immunoblot  in  Figure  4.1.5,  it  is  possible  to 
categorise  the  proteins  which  reacted  with  R3.1  antiserum  into  two 
groups.  The  first  comprises  the  67,000-70,000  proteins  seen  in 
chromatin  and  the  dehistonised  fractions  in  the  DNA-treated  blot.  The 
second  group  comprises  the  43,000-45,000  proteins  detected  in  the 
chromatin  and  dehistonised  chromatin,  respectively,  of  both  the 
DNA-treated  and  untreated  blots.  This  group  is  therefore 
immunologically  detectable  in  all  chromatin  and  dehistonised  chromatin 
except  those  which  were  allowed  to  react  with  normal  rabbit  serum. 
It  is  interesting  to  see  the  appearance  of  68,000  and  70,000 
protein  bands  in  the  DNA-treated  blot  (Lanes  8&  9)  which  indicates  the 
necessity  of  DNA  for  the  antibody-antigen  reaction  of  these  proteins. -  109  - 
It  is  worth  mentioning  that  the  immunoreactivity  of  HeLa 
chromatin  with  R3.1  was  greatly  affected  by  SDS-treatment.  It  was 
observed  that  this  reactivity  reduced  drastically  when  chromatin 
preparation  was  incubated  with  1%  SDS  in  TN  buffer  for  90  minutes  at  room 
temperature  then  applied  onto  a  nitrocellulose  paper  and  allowed  to  react 
with  R3.1  in  the  same  way  as  for  the  electroblot.  The  reactivity 
decreased  further  upon  increasing  the  SDS  concentration  until  it  was 
completely  abolished  at  10%  SDS  treatment.  This  was  monitored  visually 
by  looking  at  the  intensity  of  the  substrate  colour  on  the  reacted 
chromatin. 
To  determine  the  localisation  and  distribution  of  the  antigen 
using  R3.1  antiserum  as  first  antibody,  an  indirect  fluorescein 
isothiocyanate  (FITC)  staining  of  HeLa  cells  was  performed  (Figure 
4.1.6).  The  staining  is  seen  mainly  in  the  nuclei  with  more  intensity 
at  the  periphery  (perinuclear  area).  A  cons  iderable  amount  of  staining 
could  also  be  noted  in  the  cytoplasm. 
Pure  nuclei  were  also  prepared  as  described  in  Section  3.1.1.1 
and  then  fixed  on  the  slide  and  treated  with  R3.1  antiserum  followed  by 
FITC-conjugated  second  antibody  in  the  same  manner  as  the  treatment  of 
the  cells.  Again  all  the  nuclei  were  stained  with  more  intensity  at  the 
nuclear  periphery  (Figure  4.1.7).  In  comparable  experiments  using  the 
same  technique,  Chang  liver  and  FL  cells  failed  to  show  significant 
nuclear  reaction  with  R3.1.  A  small  amount  of  cytoplasmic  reaction  was 
again  observed  (Figure  4.1.8).  Moreover,  normal  rabbit  serum  used  at 
the  same  dilution  as  R3.1  antiserum  showed  no  significant  reaction  with 
HeLa  cells  (Figure  4.1.9). 
As  is  observed  in  Figure  4.1.6a,  fluorescein  stained  cells 
showed  more  staining  intensity  on  the  periphery  of  the  nuclei.  This 
suggests  that  part  of  the  reaction  antigen  may  be  associated  with  nuclear 
matrix  or  nuclear  envelope.  This  observation,  together  with  the  fact -  110  - 
Figure  4.1.6  FITC-staining  of  HeLa  Cells  Reacted  with  R3.1  Antiserum 
(a,  b.  c)  Immunofluorescent  staining  of  HeLa  cells 
reacted  with  1/100  R3.1  antiserum  (X2000). -  111  - 
Figure  4.1.7  FITC-staining  of  HeLa  Nuclei  Reacted  with  R3.1  Antiserum 
(a)  Indirect  immunofluorescent  staining  of  HeLa  nuclei 
reacted  with  R3.1  antiserum  (X2000). 
(b)  Phase  contrast  of  the  nuclei  in  (a). 
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Figure  4.1.8  FITC-staining  of  Human  Cells  Reacted  with  R3.1  Antiserum 
Indirect  immunofluorescent  staining  of  human  cells 
allowed  to  react  with  R3.1  antiserum  (X2300). 
(a)  Chang  liver  cells 
(b)  Phase  contrast  of  (a) 
(c)  FL  cells 
(d)  Phase  contrast  of  (c) 
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Figure  4.1.9  FITC-staining  of  HeLa  Cells  Reacted  with  Normal  Rabbit 
Serum 
Indirect  immunofluorescent  staining  of  normal  rabbit 
serum  (1/100)  allowed  to  react  with  HeLa  cells  (X2000), 
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that  protein  bands  of  Mr  68,000-70,000  showed  some  degree  of  reactivity 
with  R3.1  antiserum  in  the  presence  of  DNA  suggests  that  nuclear  matrix 
or  pore  complex-lamina  proteins  may  be  the  dominant  antigens  since  these 
lie  in  the  molecular  weight  range  of  68,000-70,000.  Therefore,  the 
protein  fraction  from  a  nuclear  pore  complex-lamina  matrix-enriched 
preparation  (prepared  as  described  in  Section  3.8.7)  was  allowed  to  react 
with  R3.1  antiserum  (1/250).  Equal  amount  of  proteins  from  chromatin 
and  nuclear  laminar  preparations  layered  on  an  ELISA  plate  showed 
different  reactivity  towards  R3.1  antiserum  (Figure  4.1.10).  Nuclear 
lamina-matrix  proteins  exhibited  only  about  half  of  the  reactivity  seen 
with  a  chromatin  preparation  tested  simultaneously.  It  is  worth  noting 
that  the  lamina-matrix  preparation  involved  the  use  of  small  amounts  of 
micrococcal  nuclease  digestion. 
The  specificity  of  R3.1  antiserum  was  tested  with  human  and 
non-human  chromatins  (Figure  4.  l.  lla  &  b)  using  C'F  assay.  The 
antiserum  showed  more  than  95%  complement  fixation  at  a  dilution  of  1/200 
when  reacted  with  HeLa  chromatin,  while  little  (less  than  10%)  of  the 
complement  was  fixed  on  its  reaction  with  other  human  chromatins. 
Approximately  15-20%  fixation  was  noted  with  Chang  liver  and  FL  cells. 
Similarly,  no  significant  complement  fixation  was  observed  when  R3.1 
antiserum  was  allowed  to  react  with  non-human  chromatins  (Figure  4.  l.  llb). 
In  the  enzyme  linked  immunoassay  (Figure  4.1.12a  &  b),  R3.1 
antiserum  showed  a  reaction  with  HeLa  chromatin  relatively  higher  than 
its  reactivity  with  other  human  and  non-human  chromatins.  Again,  Chang 
liver  and  FL  cells  showed  rather  high  reactivity  with  R3.1.  This 
reactivity  is  even  higher  than  that  detected  by  C'F  assay.  The 
difference  in  the  reactivity  between  ELISA  and  C'F  assays  will  be 
discussed  later. 
It  is  worth  noting  that  the  human  cell  lines  used  for  the 
microcomplement  fixation  and  ELISA  assays  were  from  various  tissues, -  115  - 
Figure  4.1.10  ELISA  of  R3.1  Antiserum  with  HeLa  Lamina  Preparation 
An  enzyme  linked  immunosorbent  assay  comparing  the 
reactivity  of  HeLa  chromatin  and  HeLa  nuclear-lamina- 
matrix-enriched  preparation  towards  R3.1  (1/250) 
antiserum.  (Antibody  and  antigen  controls  were 
subtracted). 
O  HeLa  chromatin 
0  HeLa  nuclear  pore  complex-lamina-matrix 
preparation 
Antibody  control  was  found  to  be  0.04  A492  unit  while  the  highest  antigen  control  was  0.14  A492  unit. Figure  41.10 
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Figure  4.1.11a  C'F  Assay  of  R3.1  Antiserum  With  Human  Chromatin 
Complement  fixation  assay  of  various  human  chromatins 
(20Ng  of  protein)  from  different  tissues  (see  Table  2a) 
fixed  with  different  concentrations  of  R3.1 
antiserum.  (Antibody  and  antigen  controls  were 
subtracted). 
O  HeLa 
D  Chang  liver 
K562 
V  KB 
1  FL 
0  HT1080 
Antigen  control  showed  between  2-3%  C'F  while  antibody  controls  exhibited  only 
1%  C'F  at  1/200  dilution  and  a  -1%  C'F  at  1/1600  diltuion  of  antibody. Figure  4.1.  lla 
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Figure  4.1.11b  C'F  Assay  of  R3.1  Antiserum  with  Non-human  Chromatins 
Complement  fixation  assay  of  HeLa  chromatin  compared 
with  various  non-human  chromatins  (20pg  of  protein), 
from  different  tissues  (see  Table  2b)  fixed  with 
different  concentrations  of  R3.1  antiserum.  (Antibody 
and  antigen  controls  were  subtracted). 
O  HeLa 
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Figure  4.1.12a  ELISA  of  R3.1  Antiserum  with  Human  Chromatins 
An  enzyme  linked  immunosorbent  assay  of  different 
concentrations  of  R3.1  antiserum  reacted  with  fixed 
amounts  of  human  chromatins  (10Ng  chromatin  layered  in 
each  well)  immobilised  on  an  ELISA  plate.  (Antibody 
and  antigen  controls  were  subtracted). 
O  HeLa 
   H.  Ep-2 
Q  Chang  liver 
K562 
v  KB 
A  FL 
0  HT1080 
Antigen  controls  were  as  follows:  HeLa  0.149,  H.  Ep-2,0.18,  Chang  liver  0.1  6 
K562  0.145,  KB  0.15,  FL  0.15  and  BT1080  0.16  A492  unit.  Antibody  controls  were  less  than  0.05  A492  unit. Figure  4.1.12a 
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Figure  4.1.12b  ELISA  of  R3.1  Antiserum  with  Non-human  Chromatins 
An  enzyme  linked  immunosorbent  assay  of  different 
concentrations  of  R3.1  antiserum  reacted  with  non-human 
chromatins  (10pg  layered  in  each  well)  immobilised  on 
an  ELISA  plate.  The  reactivity  simultaneously 
compared  with  equal  amount  of  HeLa  chromatin. 
(Antibody  and  antigen  controls  were  subtracted). 
O  HeLa 
0  BSC-1 
L929 Figure  4.1.12b 
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while  the  non-human  chromatins  were  not  only  from  different  tissues  but 
also  from  three  kinds  of  animals;  rat,  monkey  and  mouse  (see  Table  2a  & 
b). 
Since  FL  and  Chang  liver  cells  have  shown  relatively  higher 
immunoreactivity  with  R3.1  compared  with  other  human  cell  lines,  and  in 
addition,  some  kind  of  complex  association  between  the  DNA  and  HeLa 
chromatin  has  been  found  necessary  for  the  immunoreactivity  with  R3.1 
antiserum,  it  is  obviously  important  to  compare  the  DNA  content  of  each 
chromatin  preparation  with  the  degree  of  its  reactivity  with  R3.1 
antiserum.  Table  (5)  shows  the  ratio  of  DNA:  protein  in  the  human 
chromatins  which  were  subjected  to  reaction  with  R3.1.  Chang  liver  and 
FL  cells  have  a  higher  ratio  of  DNA:  protein  than  HeLa  chromatin,  yet  they 
show  lower  reactivity  than  HeLa  cells.  Other  human  chromatins  (H.  Ep-2  & 
K562),  which  have  similar  ratio  of  DNA:  protein  as  that  of  HeLa  cells, 
exhibited  very  little  reactivity  with  R3.1.  This  suggests  no  direct 
correlation  between  the  amount  of  DNA  content  and  the  immunoreactivity  of 
any  human  chromatin  with  R3.1  antiserum. 
Treatment  of  HeLa  cells  with  colcemid  (Democolcine)  resulted  in 
variable  immunofluorescent  patterns.  The  differences  may  reflect  the 
various  stages  of  the  cell  cycle.  This  is  shown  in  Figure  4.1.13  and 
4.1.14.  The  fluorescent  staining  was  predominantly  found  in  the  whole 
cell  with  more  intensity  at  the  cytoplasmic  boundaries  with  nuclei 
(Figure  4.1.13b).  A  number  of  cells  showed  batches  of  staining 
distributed  either  evenly  in  coarse  speckled-like  staining  (Figure 
4.1.13d  &  e,  top)  or  unevenly  in  granular  pattern  (Figure  4.1.13a,  centre 
&  top  right).  The  FITC  staining  indicates  the  presence  of  the  HeLa 
antigen(s)  during  the  interphase  as  well  as  mitosis.  When  mitotic  cells 
were  cytocentrifuged  then  fixed  and  allowed  to  react  with  R3.1  (1/100) 
antiserum,  no  defined  FITC-stained  chromosomal  structures  were  identified 
(Figure  4.1.14). -  121  - 
ITable  5:  The  ratio  of  DNA:  protein  of  chromatin  preparations  from  human 
cell  lines.  The  protein  content  was  measured  by  Bradford's 
method  and  the  DNA  estimated  by  Burton's  procedure. 
K562  1:  1.9 
HeLa  1:  1.8 
H.  Ep-2  1;  1.8 
Chang  liver  1:  1.5 
FL  1;  1.4. 
KB  lsl.  4 
HT1080  1  j,  l.  4 
2M  salt  extracted  chromatir  1:  0.214 
214  salt/5M  urea  extracted  chromatic  1:  0.097 -  122  - 
Figure  4.1.13  FITC-staining  of  HeLa  Mitotic  Cells  Reacted  with  R3.1 
Antiserum 
Indirect  immunofluorescent  staining  of  HeLa  cells  on 
cover  slips  treated  with  colcimid  for  18  hours,  fixed 
and  allowed  to  react  with  R3.1  antiserum  (1/200). 
a,  b,  d  fluorescent  staining  (X2000) 
c&e  phase  contrast  of  b&d  respectively 
(X2000) 0 I -  123  - 
Figure  4.1.14  FITC-staining  of  Mitotic  HeLa  Cells  Cytocentrifuged  and 
Reacted  with  R3.1  Antiserum 
Indirect  immunofluorescent  staining  of  HeLa  cells  grown 
in  culture  and  treated  with  colcemid  for  5h  before 
harvesting.  The  mitotic  cells  were  cytocentrifuged  on 
slides,  fixed  then  allowed  to  react  with  R3.1  (1/100) 
antiserum. 
(a,  c)  fluorescent  staining  (X500  &  X2000 
respectively) 
(b)  phase  contrast  of  a  (X500) b 
wiv -  124  - 
Discussion 
Immunological  methods  have  long  been  used  for  the 
characterisation  and  detection  of  nuclear  components.  The  antisera 
against  these  components  were  generally  raised  in  rabbits.  Different 
rabbits  respond  variably  to  any  given  antigen  complex.  Antisera  to  HeLa 
dehistonised  nuclear  preparations  were  found  by  immunocytochemical 
methods  to  localise  the  antigen  (or  antigen  complex)  specifically  in  the 
nuclei  (Campbell  et  al.,  1979;  Briggs  et  al.,  1979)  or  nuclear  matrix 
(Wojtkowiak  et  al.,  1982).  Although  in  these  preparations  the  antigen 
complex  was  prepared  in  a  similar  way  using  2M  salt-5M  urea  extraction,  a 
different  pattern  of  reactivity  was  observed.  The  reported  antisera 
obtained  against  the  above  2M  salt-5M  urea  extracted  chromatin  were 
raised  in  white  New  Zealand  rabbits.  It  is  possible  that  different 
rabbits  may  give  a  different  response  to  this  kind  of  antigen  complex. 
The  antiserum  R3.1  was  raised  in  a  Half  Lop  rabbit. 
The  specificity  of  antisera  raised  against  2M  salt-5M  urea 
extracted  fraction  has  been  tested  with  a  number  of  cell  lines  (Campbell 
et  al.,  1979;  Wojtkowiak  et  al.,  1982),  but  there  has  been  no  previous 
attempt  to  examine  a  wider  range  of  tissue-culture  established  human  and 
non-human  cells.  In  this  attempt  R3.1  antiserum  was  allowed  to  react  by 
C'F  and  ELISA  with  human  cell  lines  derived  from  different  tissues 
(blood,  liver,  amnion,  mouth,  skin  and  larynx).  These  cells  are  of 
epithelial  and  non-epithelial  origin  (Table  2a). 
In  the  previous  attempts,  microcomplement  fixation  was  the  only 
sensitive  technique  used  to  examine  the  specificity  of  antisera. 
Examining  the  specificity  pattern  of  R3.1  antiserum  obtained  by  C'F  assay 
(Figure  4.1.11)  implies  that  R3.1  is  cell  specific.  However,  the  ELISA 
technique  shows  a  considerably  different  reactivity  (Figure  4.1.12). 
Although  in  the  latter  technique  (ELISA),  R3.1  antiserum  showed  a  high 
reactivity  with  HeLa  chromatin,  other  human  epithelial  (Chang  liver  &  FL) -  125  - 
cell  lines  also  exhibited  a  great  deal  of  immunoreactivity.  Therefore, 
the  use  of  two  sensitive  techniques  which  work  by  two  different 
mechanisms  (the  microcomplement  fixation  &  ELISA),  simultaneously,  gives 
wider  scope  for  looking  at  the  specificity  of  a  given  antiserum. 
This  difference  between  C'F  assay  and  ELISA  has  several  possible 
explanations: 
1.  The  plate  binding  capability  of  the  antigens  may  vary.  ELISA 
is  a  very  sensitive  technique  which  depends  on  the  binding  of  the 
antigens  to  a  solid  phase  (the  ELISA  plate).  Since  there  may  be  a 
differential  capacity  of  certain  proteins  to  bind  to  the  plate  and 
because  ELISA  involves  several  washings  which  might  affect  the  low 
affinity  binding  proteins,  an  enrichment  and  increase  in  the  binding  of  a 
given  component  is  probable.  Moreover,  out  of  the  10jg  of  chromatin 
layered  per  well,  an  unknown  amount  of  antigen  actually  binds  to  the 
plate  (see  Figure  4.1.1). 
2.  Because  of  the  high  sensitivity  of  ELISA,  minor  antigens,  which 
are  common  to  certain  types  of  tissue  culture  cells  (HeLa,  Chang  liver  & 
FL  epithelial  cell  lines  grown  in  culture  for  many  years),  may  be 
detected,  while  these  antigens  are  possibly  missed  by  the  C'F  assay. 
Added  to  this  is  the  polyclonality  of  the  antiserum  (R3.1)  in  which 
antibodies  of  different  abundance  and  affinity  may  alter  the  apparent 
specificity  at  various  dilutions  of  antibody  and  antigen  in  the  two 
assays. 
3.  A  third  possible  difference  is  that  the  ELISA  involves  detecting 
the  first  antibody  by  an  anti-IgG  second  antibody,  thus  the  ELISA 
preferentially  selects  IgG  class  of  antibodies. 
Earlier  reports  have  indicated  that  the  immunogenic  components 
of  HeLa  dehistonised  chromatin  reside  in  the  high  salt-resistant  residual 
fraction  (Campbell  et  al.,  1979).  Although  only  a  small  amount  of 
protein  is  tightly  bound  to  the  DNA,  the  immunoreactivity  tested  by  C'F -  126  - 
assay  was  found  to  be  associated  with  the  residual  protein  fraction  in 
complex  formation  with  human  (homologous)  DNA  (Dunn  et  al.,  1980).  This 
immunoreactivity  was  reported  to  be  sensitive  to  micrococcal  nuclease 
digestion  (Campbell  et  al.,  1979;  Briggs  et  al.,  1979;  Dunn  et  al., 
1980). 
Using  R3.1  antiserum,  it  is  again  possible  to  demonstrate  that  a 
great  deal  of  HeLa  chromatin  antigenicity  is  susceptible  to  micrococcal 
nuclease  digestion  (Figures  4.1.2-4.1.4).  Such  antigenicity  that  can 
only  be  assayed  in  the  presence  of  two  discrete  components  (DNA  & 
protein)  is  difficult  to  analyse  for  the  role  played  by  each  separate 
component.  Massive  amounts  of  micrococcal  nuclease  (7500U/0.3mg  DNA/ml) 
were  used  for  the  digestion  which  drastically  reduced  the 
immunoreactivity  of  chromatin  with  R3.1  antiserum.  About  65-85%  of  the 
activity,  as  monitored  by  ELISA  and  C'F  assays  respectively,  was  lost 
(Figures  4.1.2  &  4.1.3).  This  high  loss  of  immunoreactivity  was 
restored  by  the  addition  of  HeLa  DNA  to  the  digested  chromatin. 
The  earlier  reports  using  antiserum  raised  in  white  New  Zealand 
rabbit  suggested  that  only  when  a  large  amount  of  micrococcal  nuclease 
(above  150U/3pg  DNA/0.5m1)  was  used,  a  considerable  degree  of 
immunoreactivity  of  HeLa  chromatin  was  lost.  This  was  monitored  by  C'F 
assay  (Campbell  et  al.,  1979).  It  is  possible  that  the  antigen  complex 
which  reacts  with  R3.1  antiserum  is  different  in  being  highly  susceptible 
to  nuclease  digestion.  Figure  4.1.10  shows  that  HeLa  nuclear  lamina- 
matrix-enriched  preparation  exhibited  only  half  the  activity  of  the  same 
amount  of  chromatin  preparation.  This  is  believed  to  be  largely  due  to 
the  use  of  micrococcal  nuclease  digestion  during  the  course  of  the  matrix 
preparation  (Section  3.8.7),  even  though  that  very  small  amount  of 
nuclease  was  involved  (for  a  limited  period  of  time).  The  amount  of 
micrococcal  nuclease  used  for  the  lamina  preparation  was  estimated  to  be 
approximately  10U/0.3mg  DNA/ml. -  127  - 
It  is  possible  that  other  reasons  have  contributed  collectively 
to  this  reduction  in  immunoreactivity  shown  in  Figure  4.1.10.  Among 
these  possibilities  are  the  following: 
1.  The  use  of  a  high  concentration  of  2-mercaptoethanol  to  prevent 
disulfide  bridge  formation  might  have  reduced  the  possibility  of  complex 
formation  (between  DNA  &  protein)  and/or  may  have  caused  the  loss  of 
important  proteins  essential  for  the  complex  component  which  is  in  turn 
necessary  for  the  antigen  immunoreactivity.  Supporting  this  idea  is  the 
recent  finding  of  Lebkowski  and  Laemmli  (1982)  that  in  the  dehistonised 
chromatin  preparation,  the  addition  of  2-mercaptoethanol  to  the  lysis 
mixture  leads  to  a  partial  unfolding  of  the  DNA  and  a  selective  loss  of 
proteins. 
2.  Additionally,  that  the  preparation  was  subjected  to  a  very  high 
salt  (3M  NaCl)  extraction  procedure  which  possibly  solubilised  some 
important  component(s)  of  the  complex  antigen. 
Lebkowski  and  Laemmli  (1982)  described  two  forms  of 
histone-depleted  HeLa  nuclear  proteins.  Type  I  protein  structure  which 
was  obtained  by  2M  NaCl  extraction,  is  represented  by  the  three  nuclear 
laminar  proteins  of  Mr  60,000-70,000  and  high  molecular  weight  residual 
species.  Histone  extraction  in  the  presence  of  2-mercaptoethanol 
produced  type  II  structure  which  comprises  almost  exclusively  the  major 
laminar  proteins  (Mr  60,000;  68,000  &  70,000)  and  two  minor  proteins  of 
Mr  64,000  &  200,000.  A  laminar  protein  enriched  preparation  was  also 
obtained  by  McKeon  et  al.  (1983),  using  a  slightly  different  approach. 
Wojtkowiak  et  al.  (1982)  have  raised  antisera  against  2M  salt-5M 
urea-extracted  chromatin  fraction  from  HeLa  cells.  These  sera  showed  a 
wide  range  of  cross  reactivity  not  only  with  other  human  malignant  cell 
preparations  in  the  immunoblot,  but  with  a  number  of  protein  bands  in  the 
HeLa  chromatin  fraction.  The  antisera  also  reacted  with  many  bands  in 
the  nuclear  matrix  preparation  and  many  of  these  proteins  were  found  to -  128  - 
be  common  to  other  HeLa  subcellular  fractions  including  nucleoli  and  RNP 
particles.  Detke  &  Keller  (1982)  have  presented  data  which  suggest  that 
the  major  chromosome  scaffold  proteins  are  also  the  major  proteins  of  the 
nucleoskeleton.  However,  no  similarity  between  the  reactive  protein 
bands  shown  by  Wojtkowiak  et  al.  (1982)  and  the  major  nucleoskeletal 
proteins  has  been  noted.  Moreover,  although  these  antisera  were  raised 
against  HeLa  antigen  preparation  similar  to  that  reported  by  Campbell  et 
al.  (1979)  and  Briggs  et  al.  (1979),  no  DNA-dependent  immunoreactivity 
was  reported. 
On  the  other  hand,  R3.1  antiserum  was  elicited  against  the  same 
dehistonised  chromatin  fraction  (extracted  by  2M  salt-5M  urea)  and  again 
its  immunoreactivity  showed  great  dependence  on  the  presence  of 
homologous  DNA  complex  formation  (Figures  4.1.2  &  4.1.3).  Unlike  the 
antisera  reported  by  Wojtkowiak  et  al.  (1982),  R3.1  antiserum  showed  very 
slight  reactivity  with  proteins  on  the  immunoblot  (Figure  4.1.5).  Using 
the  sensitive  immunoblot  technique  reported  by  Towbin  et  al.  (1979),  R3.1 
antiserum  reacted  with  only  two  protein  bands  (Mr  43,000  &  45,000)  in  the 
chromatin  and  dehistonised  chromatin  fractions  (Figure  4.1.5).  Since  it 
had  been  shown  that  the  chromatin  antigen  which  reacted  with  R3.1 
requires  complex  formation  between  the  DNA  and  protein(s)  (Figures  4.1.2 
&  4.1.3),  HeLa  DNA  was  added  to  the  blot  following  the  method  of  Bowen  et 
al.  (1980)  which  was  reported  to  allow  considerable  DNA  binding  to  the 
proteins  on  the  blot.  The  DNA-treated  electroblot  was  then  prepared  to 
react  with  R3.1  antiserum.  No  major  immunoreactivity  change  was 
observed  except  that  a  protein  group  of  Mr  68,000-70,000  showed  marginal 
reactivity  with  the  antiserum.  The  failure  of  additional  DNA  to  produce 
a  major  change  in  the  immunoreaction  pattern  may  be  because  the  ability 
of  the  DNA  to  bind  to  the  blot  is  limited,  and  not  enough  is  bound  to 
make  the  necessary  conformational  alterations  on  the  antigen  to  make  it 
accessible  to  antibody  reaction.  Since  it  has  been  observed  (see -  129  - 
results  section)  that  SDS  treatment  of  chromatin  greatly  reduces  its 
immunoreactivity  with  R3.1  antiserum,  another  reason  why  the  addition  of 
DNA  did  not  produce  a  significant  change  on  the  protein  activity  may  be 
due  to  an  irreversible  denaturation  of  the  target  antigen  in  the 
SDS-polyacrylamide  gel,  so  that  even  after  the  limited  reconstitution 
with  DNA  on  the  blot  no  extensive  renaturation  occurred.  The  third 
possibility  is  that  the  proteins  on  the  blot  are  restricted  by  the  nature 
of  their  binding  to  the  nitrocellulose  paper  which  may  not  permit  an 
adequate  reconstitution  with  DNA. 
There  are  other  points  which  could  also  be  considered  before 
drawing  any  conclusion  regarding  the  immunoreactivity  of  R3.1  on  the 
electroblot. 
1.  The  use  of  3%  stacking  gel  and  the  addition  of  urea  to  the  gel 
mixture  enhances  the  protein  resolution.  This  additional  modification 
may  possibly  trap  large  molecules  of  DNA  on  the  top  of  the  gel.  It  is 
also  possible  that  some  protein  molecules,  tightly  bound  to  DNA  are 
trapped  with  it.  This  is  unlikely  since  the  stained  gel  and  the 
amido-black-stained  electroblot  showed  no  protein  staining,  at  the  top  of 
both  the  gel  and  the  blot. 
2.  It  is  obvious  that  large  molecules  of  DNA  are  unable  to  enter 
the  high  percentage  gel.  DNA  in  the  concentration  of  100pg/ml  was  added 
to  the  blot  before  its  reactivation  with  R3.1  in  an  attempt  to  enhance 
the  antigen  immunoreaction.  This  amount  of  DNA  is  not  the  limiting  step 
for  its  binding  ability,  since  a  lower  amount  of  DNA  (10ig/ml)  gave  a 
comparatively  similar  pattern  of  immunoreactivity.  The  amount  of  DNA 
added  to  the  blot  is  far  more  (approximately  10-15  times)  than  the 
original  DNA  content  in  the  chromatin  or  dehistonised  chromatin  loaded  on 
the  polyacrylamide  gel. 
Consequently,  it  is  possible  to  conclude  that  proteins  68,000 
and  70,000  are  part  of  the  HeLa  immunogen  complex  which  requires  DNA -  130  - 
binding  for  its  immunoreactivity  with  R3.1  antiserum.  Based  on  the 
immunofluorescent  staining  (Figure  4.1.6)  and  the  results  in  Figure 
4.1.10,  which  show  a  considerable  amount  of  reactivity  lying  within  the 
nuclear  lamina-enriched  HeLa  preparation  (predominantly  comprises  the 
60,000;  68,000  &  70,000  proteins  as  reported  by  McKeon  et  al.,  1983),  it 
may  be  suggested  that  part  of  the  antigen  complex  is  associated  with 
nuclear  lamina  proteins  or  proteins  which  constitute  a  component  of  the 
nuclear  membrane.  The  former  possibility  (i.  e.  association  with  lamina 
proteins)  is  more  likely.  Supporting  evidence  for  this  is  the  different 
distribution  of  fluorescent  reactivity,  after  treatment  with  colcemid, 
which  indicates  the  presence  of  the  antigen  at  various  stages  of  the  cell 
cycle  (Figures  4.1.6,  &  4.1.13  &  4.1.14).  This  could  be  correlated  with 
Detke  &  Keller's  (1982)  report  that  the  lamina  proteins  are  dispersed 
throughout  the  cell  cycle. 
The  high  titre  of  immunoreactivity  of  R3.1  antiserum  towards 
HeLa  chromatin  (Figures  4.1.1,4.1.11  &  4.1.12)  contrasts  strongly  with 
the  poor  reaction  seen  on  the  immunoblot  (although  the  technique  is  very 
sensitive)  and  it  is  important  to  clarify  this  discrepancy.  It  is 
likely  that  the  major  antigenic  reactivity  can  not  be  visualised  on  the 
immunoblot.  This  speculation  can  lead  to  a  more  feasible  conclusion. 
The  major  antigen  complex  which  is  reactive  with  R3.1  antiserum  may  be  a 
large  complex  of  delicately  (and  maybe  specifically)  associated  DNA  with 
protein.  It  is  also  possible  that  more  than  one  protein  is 
participating  in  this  complex  immunoreactivity,  and  that  upon  separating 
the  protein  components  by  electrophoresis,  no  significant  restoration  of 
activity  on  the  immunoblot,  even  after  the  addition  of  DNA,  could  be 
achieved.  It  is  likely  that  the  major  immunoreactivity  of  this  complex 
is  highly  dependent  on  this  delicate  and  balanced  association  between  the 
two  discrete  components  (DNA  &  protein).  The  immunogen  complex  is 
susceptible  to  disorganisation  by  the  effect  of  SDS  treatment, 
electrophoresis  and  DNA  digestion. -  131  - 
4.2  Results  Obtained  Using  R2.1  Antiserum 
R2.1  antiserum  was  raised  in  a  white  English  rabbit  immunised 
with  2M  salt-extracted  HeLa  chromatin  given  as  two  (150pg  DNA) 
subcutaneous  injections  ten  days  apart  and  one  intravenous  booster  six 
days  before  bleeding  the  animal. 
The  antiserum  showed  a  high  titre  on  reaction  with  HeLa 
chromatin.  The  immunoreaction  was  demonstrated  by  C'F  assay  (Figure 
4.2.1)  and  ELISA  (Figure  4.2.2).  A  dilution  as  high  as  1/1200-1/1600 
was  still  enough  to  show  a  considerable  amount  of  immunoreactivity  with 
the  HeLa  antigen. 
When  R2.1  antiserum  was  allowed  to  react  with  other  chromatins 
of  human  and  non-human  origin,  different  patterns  of  reactivity  were 
observed.  In  C'F  assay,  two  human  epithelial  cell  lines,  KB  and  Chang 
liver  chromatins  showed  little  C'F  activity  (20%)  when  reacted  with  R2.1 
antiserum  at  a  dilution  of  1/300  (Figure  4.2.1a).  Similar  results  were 
found  by  ELISA,  where  KB  and  Chang  liver  chromatins  showed  just  below  20% 
of  the  activity  of  HeLa  chromatin  at  an  antiserum  dilution  of  1/200-1/400 
(Figure  4.2.2a).  However,  a  non-epithelial  human  cell  line  (K562) 
showed  high  reactivity  with  R2.1  at  serum  concentration  of  1/200-1/300  in. 
both  the  C'F  and  ELISA  techniques. 
Other  human  chromatins  from  cell  lines  such  as  the  laryngeal 
carcinoma  (H.  Ep-2)  and  the  fibrosacroma  (HT1080)  also  exhibited  little 
(30%)  immunoreactivity  in  comparison  with  HeLa  chromatin,  when  tested  by 
ELISA  (Figure  4.2.2a). 
In  contrast  to  the  human  chromatins,  chromatins  from  non-human 
cell  lines  (BSC-1,  L929  &  NS1)  showed  no  significant  immunoreactivity 
(less  than  10%)  in  comparison  to  HeLa  activity  in  both  the  C'F  and  ELISA 
techniques  (Figures  4.2.1b  &  4.2.2b).  These  cell  lines  were  green 
African  monkey  kidney,  mouse  fibroblast  and  mouse  myeloma  respectively. -  132  - 
Figure  4.2.1a  C'F  Assay  of  R2.1  with  Human  Chromatins 
Complement  fixation  assay  of  various  human  chromatins 
(20Ng  of  protein)  fixed  with  different  concentrations  of 
R2.1  antiserum.  Antibody  and  antigen  controls  were 
subtracted. 
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A  K562 
p  Chang  liver 
KB 
Antibody  control  at  1/300  dilution  showed  a  5%  C'F  while  it  was  only  1%  at  1/1200  dilution.  Antigen  controls  were  as  follows: 
0%  C'F  :  HeLa,  I562 
1%  C'F  :  Chang  liver 
4ý  C'F  :  K3 Figure  4.2.1a 
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Figure  4.2.1b  C'F  Assay  of  R2.1  with  Non-human  Chromatins 
Complement  fixation  assay  of  HeLa  chromatin  compared  with 
various  non-human  chromatins  (20pg  of  protein)  fixed  with 
different  concentrations  of  R2.1  antiserum.  Antibody  and 
antigen  controls  were  subtracted. 
O  HeLa 
A  L929 
0  BSC-1 
V  NS1 
Antibody  control  at  1/300  dilution  showed  a  57,  C'F  while  it  was  only  1%  at 
1/1200  dilution.  Antigen  controls  were  as  follows: 
0%  :  HeLa,  NS1 
1%ý  :  BSC-1,  L929 Figure  4.2.1b 
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Figure  4.2.2a  ELISA  of  R2.1  with  Human  Chromatin 
Enzyme  linked  immunoassay  of  different  concentrations  of 
R2.1  antiserum  reacted  with  human  chromatins  (10pg  of 
protein  layered  in  each  well)  immobilised  on  an  ELISA 
plate.  Antigen  and  antibody  controls  were  subtracted. 
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Antibody  control  was  highest  at  1/200  dilution  (0.08  A492  unit)  while 
antigens  controls  were  as  follows: 
HeLa  0.126  A429  unit 
BT1080  .  0.102  A492  unit 
KB  .  0.101  A492  unit 
K562  0.105  A429  unit 
Chang  liver  :  0.107  A492  unit 
H.  Ep-2  0.129  A492  unit Figure  4.2.2a 
1.0 
0.75- 
A492 
0.5 
0.25 
0.0 
antiserum  dilution  (  x10 
2) 
1  11  /16  8  /4  /  2 -  135  - 
Figure  4.2.2b  ELISA  of  R2.1  with  Non-human  Chromatins 
Enzyme  linked  immunosorbent  assay  of  different 
concentrations  of  R2.1  antiserum  reacted  with  HeLa  and 
non-human  chromatins  (10jig  of  protein  layered  in  each 
well)  immobilised  on  an  ELISA  plate.  Antibody  and 
antigen  controls  were  subtracted. 
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Antigen  controls  were  found  to  be: 
HeLa  1  0.126  A492  unit 
L929  :  0.111  A492  unit 
BSC-1  :  0.130  A492  unit 
NS1  r  1.120  A492  unit Figure  4.2.2b 
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To  demonstrate  whether  R2.1  reactivity  with  HeLa  chromatin  is  . 
dependent  on  DNA:  protein  complex  formation  or  not,  the  chromatin  was 
digested  with  large  amount  of  micrococcal  nuclease  (2500U/O.  lmg/ml). 
The  nuclease  digested  chromatin  was  then  allowed  to  react  with  R2.1 
antiserum  using  the  ELISA.  About  70%  of  the  chromatin  immunoreactivity 
with  R2.1  was  retained  after  nuclease  digestion  (Figure  4.2.3).  The 
lost  immunoreactivity  was  almost  restored  on  reconstituting  the  digested 
chromatin  with  HeLa  DNA  alone  (Section  3.8.2).  The  HeLa  DNA  alone 
exhibited  very  low  reaction  (10%)  compared  with  the  chromatin  reactivity 
(Figure  4.2.3).  This  suggests  that  approximately  a  third  of  HeLa 
chromatin  reactivity  with  R2.1  antiserum  requires  the  presence  of  HeLa 
DNA.  This  part  of  the  immunoreactivity  does  not  lie  within  the  DNA 
alone. 
In  order  to  determine  the  protein  antigen(s)  of  HeLa  chromatin 
and  dehistonised  chromatin,  these  fractions  were  run  on  an  SDS-gel  and 
then  transferred  onto  nitrocellulose  paper  and  allowed  to  react  with  R2.1 
antiserum  (1/250)  using  the  immunoperoxidase  method  described  in  Section 
3.5.4.1.  Figure  4.2.4  shows  a  typical  result.  Both  the  chromatin 
fraction  and  the  2M  salt-extracted  chromatin  (lanes  6&  7)  showed  an 
intense  reaction  corresponding  to  a  range  of  approximate  molecular 
weights  of  42,000-52,000. 
In  an  attempt  to  find  out  whether  preincubating  the  protein  blot 
with  HeLa  DNA  has  any  effect  on  the  pattern  of  the  immunologically 
reactive  proteins  or  not,  one  strip  of  protein-containing  nitrocellulose 
paper  was  incubated  with  DNA  as  described  in  Section  3.6.3.5  then  allowed 
to  react  with  R2.1  antiserum.  Chromatin  proteins  (lanes  8&  10)  show 
the  same  high  colour  intensity  indicating  that  the  reactive  proteins  are 
of  molecular  weights  42,000-52,000.  Moreover,  the  intense  and  thick 
band  of  the  2M  salt-extracted  fraction  (lane  9)  extends  further  to -  13  7- 
Figure  4.2.3  ELISA  of  R2.1  with  Nuclease-digested  and  -undigested 
HeLa  Chromatins 
Enzyme  linked  immunoassay  of  R2.1  antiserum  (1/250) 
allowed  to  react  with  different  concentrations  of  HeLa 
antigen  immobilised  on  an  ELISA  plate.  Antibody  and 
antigen  controls  were  subtracted.  (Chromatin  measured  as 
total  protein  content  and  HeLa  DNA  estimated  as  total  DNA 
content). 
O  Undigested  HeLa  chromatin 
p  Micrococcal  nuclease-digested  HeLa  chromatin 
reconstituted  with  HeLa  DNA 
D  Micrococcal  nuclease-digested  HeLa  chromatin 
D  HeLa  DNA  alone 
The  average  antibody  control  was  0.1  while  antigen  controls  varied  slightly 
witl'the  amount  of  antigen  plated  and  the  highest  was  found  at  about 
Q'17  A492  unit  for  the  undigested  chromatin  at  2.25pg  concentration. Figure  4.2.3 
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Figure  4.2.4  Protein  Blot  of  HeLa  Chromatin  Reacted  with  R2.1  and 
Normal  Rabbit  Sera 
Protein  immunoblot  of  R2.1  antiserum  (strips  C  and  D)  and 
normal  rabbit  serum  (strip  A)  reacted,  at  a  dilution  of 
1/250,  with  chromatin  (lanes  1,6,8  and  10)  and  2M 
salt-extracted  chromatin  (lanes  2,7  and  9)  preparations 
from  HeLa  cells  visualised  by  using  the  immunoperoxidase 
method.  Lanes  3  and  5  are  the  amido-black  stained 
proteins  corresponding  to  chromatin  and  dehistonised 
chromatin  respectively.  Lane  4  is  the  molecular  weight 
marker  (from  top:  phosphorylase  b  94,000;  bovine  serum 
albumin  67,000;  ovalbumin  43,000;  carbonic  anhydrase 
30,000;  soybean  trypsin  inhibitor  20,100;  OC-lactalbumin 
14,400).  The  proteins  were  analysed  in  a  10%  Laemmli 
polyacrylamide  gel  containing  0.5M  urea.  Strip  D  has 
been  incubated  with  HeLa  DNA  prior  to  its  reaction  with 
R2.1. 
Although  the  core  histone  'proteins  were  well  separated  (lane  3),  Hl  histone 
was  not  found  as  intense  (in  our  chromatin  preparation)  as  any  individual  core  histones. 
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encompass  a  range  of  40,000-52,000  of  molecular  weight.  In  addition,  a 
faint  and  again  unresolved  thick  band  corresponding  to  a  molecular  weight 
range  of  52,000-64,000  was  visible  in  both  chromatin  and  dehistonised 
chromatin  fractions  only  on  pretreating  the  blot  with  DNA  prior  to  the 
antibody  reaction.  Another,  very  faint  but  single,  protein  bandscan  be 
seen  at  approximate  molecular  weights  of  80,000  and  above  100,000  in  the 
DNA  treated  blot  (arrows). 
Normal  rabbit  serum  (1/250)  again  failed  to  show  any  reactivity 
with  HeLa  chromatin  and  dehistonised  chromatin. 
Examination  of  the  amido-black  stained  blot  shows  that  both 
chromatin  (lane  3)  and  dehistonised  chromatin  (lane  5)  have  one 
detectable  band  at  the  range  of  Mr  43,000-45,000.  No  other  band  at  the 
range  of  Mr  40,000-52,000  could  be  seen.  This  may  indicate  the  presence 
of  amido-black-undetected  proteins  above  and  below  the  43,000-45,000 
protein  band(s).  While  these  proteins  are  not  detectable  by  amido-black 
staining,  they  are  readily  observed  by  immunoblotting.  This  exemplifies 
the  usefulness  and  efficiency  of  the  sensitive  immunoblotting  technique. 
Indirect  immunofluorescence  was  employed  to  determine  the 
subcellular  localisation  of  the  HeLa  antigen.  HeLa  cells  were  grown  on 
coverslips,  washed,  lysed,  fixed  and  allowed  to  react  with  R2.1  antiserum 
(1/100)  then  FITC-conjugated  second  antibody.  The  immunofluorescent 
stained-cells  were  inspected  under  the  fluorescent  microscope.  Figure 
4.2.5  demonstrates  that  the  immunoreactivity  is  distributed  in  both 
nuclei  and  cytoplasm.  The  fluorescent  staining  is  more  intense  in 
nuclei  with  negatively  stained  nucleoli  (Figure  4.2.5a-e).  Filamentous 
structures  extending  from  the  cytoplasmic  periphery  (Figure  4.2.5f  &  g) 
could  also  be  seen  using  high  magnification. 
In  order  to  examine  whether  the  cytoplasmic  staining  was  of  the 
cytokeratin  type  or  not,  the  FITC  technique  was  employed  with  the  aim  of 
preserving  the  structure  of  the  keratin  filaments.  The  method  is 
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Figure  4.2.5  FITC-staining  of  HeLa  Cells  Reacted  with  R2.1 
_  ý:,;  ý. 
Indirect  immunofluorescent  staining  of  HeLa  cells  reacted 
with  R2.1  (1/100)  antiserum.  The  cells  were  grown  on 
coverslips  and  treated  as  described  in  section  3.7.4. 
(a)  X310 
(b  &  C)  X500 
(d  &  e)  X2000 
(f  &  g)  X2000  with  reference  to  filamentous  structures 
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described  in  section  3.7.3  and  the  fluorescent  staining  is  shown  in 
Figure  4.2.6.  No  distinct  filamentous  structures  were  identified 
although  predominant  cytoplasmic  staining  was  noted.  The  intermediate 
filaments  of  HeLa  cells  are  largely  of  the  prekeratin  and  vimentin  type 
and  these  are  both  of  molecular  weights  higher  than  52,000.  Since  no 
strong  immunoreactivity  of  R2.1  antiserum  with  proteins  higher  than  Mr 
52,000  in  the  chromatin  and  dehistonised  chromatin  fractions  was  detected 
(Figure  4.2.4),  it  is  likely  that  the  antiserum  is  either  not  directed 
primarily  against  this  type  of  protein,  or  that  the  prekerat'in  and 
vimentin  groups  of  cytoplasmic  location  are  probably  not  contaminating 
the  chromatin  preparations. 
To  clarify  this  finding,  a  cytokeratin  preparation  from  whole 
HeLa  cells  was  run  on  a  gel,  blotted  onto  nitrocellulose  paper,  and 
allowed  to  react  with  R2.1  antiserum,  by  the  immunoperoxidase  method 
(Figure  4.2.7).  In  addition  to  the  thick  band  of  Mr  42,000-52,000  (lane 
2),  another  strongly  reactive  broad  band  at  approximate  range  of 
molecular  weight  of  54,000-61,000  was  observed.  Another  group  of 
proteins  in  the  cytokeratin  preparation  (lane  2)  showed  a  strong 
immunoreactivity  with  R2.1  antiserum  at  Mr  20,500-24,000.  These  two 
groups  of  proteins  were  not  present  in  the  nuclei  and  2M  salt-extracted 
chromatin  preparations  (lane  3&  4).  The  cytokeratin  as  well  as  the 
nuclei  preparation  (lane  2&  3)  both  exhibited  another  immunoreactivity 
at  approximate  Mr  of  15,000-16,000,  which  was  absent  in  the  2M 
salt-extracted  chromatin  (lane  4). 
Lane  (3)  in  Figure  4.2.7  represents  nuclei  prepared  by  the 
Chauveau  method  and  allowed  to  react  with  R2.1  (1/250)  antiserum  in  the 
immunoblot.  A  reaction  similar  to  that  of  the  dehistonised  chromatin 
(lane  4)  was  observed  while  there  was  no  immunoreactivity  with  proteins 
corresponding  to  molecular  weight  ranges  of  54,000-61,000  and 
20,500-24,000.  This  suggests  that  there  were  no  reactive  proteins  in -  142  - 
Figure  4.2.6  FITC-staining  of  HeLa  Keratin  Structures  Reacted 
with  R2.1 
(a)  An  indirect  immunofluorescent  staining  of  HeLa  cells 
prepared  on  coverslips  as  described  in  section  3.7.3 
preserving  the  cytokeratins  then  allowed  to  react  with 
R2.1  antiserum  (1/150).  (X2000) 
(b)  Phase  contrast  of  cells  in  a  (X2000) 
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Figure  4.2.7  Immunoblot  of  R2.1  Reacted  with  HeLa  Subfractions 
Compared  with  Human  and  Non-human  Dehistonised 
Chromatins 
A  protein  immunoblot  (section  3.5.4.1)  of  R2.1  antiserum 
reacted  with  2M  salt-extracted  chromatin  preparations 
(lanes  4-12)  from  different  human  and  non-human  cell 
lines,  as  well  as  with  HeLa  keratin  preparations  (lane  2) 
(section  3.8.6)  and  HeLa  nuclei  (lane  3)  (section 
3.1.1.1).  Lane  (1)  is  a  blot  of  protein  marker  stained 
with  amido-black.  The  protein  preparations  were  run  on  a 
10%  Laemmli  gel  plus  0.5M  urea. 
Lanes  1:  protein  marker  (from  top:  phosphorylase  b  94,000; 
bovine  serum  albumin  67,000;  ovalbumin  43,000; 
carbonic  anhydrase  30,000;  soybean  trypsin 
inhibitor  20,100;  oC-lactalbumin  14,400). 
2:  HeLa  keratin  preparation 
3:  HeLa  nuclei  preparation 
4  HeLa  5  K562 
6  FL  7  KB 
8:  Chang  liver  9  HT1080 
10  :  BSC-1  11  CHO 
12  :  BHK-21 10  11  12 
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these  two  ranges  of  molecular  weights,  present  in  the  preparation  of 
nuclei. 
Whether  the  cytoplasmic  immunofluorescent  staining  seen  in 
Figures  4.2.5  and  4.2.6  is  due  to  naturally  occurring  anti-intermediate 
filament  antibodies  in  the  rabbit  antiserum  or  to  contaminants  in 
immunising  nuclear  proteins,  remains  to  be  established.  However,  it  is 
possible  that  some  of  these  protein  antigens  are  nuclear  but  because  they 
are  synthesised  in  the  cytoplasm,  and  therefore  have  been  localised  there 
by  immunofluorescence.  Furthermore,  it  is  also  possible  that  one  (or 
more)  of  the  proteins  in  the  range  of  Mr  42,000-52,000  is  genuinely 
nuclear  but  masked  by  the  overlapping  of  other  reactive  proteins  (of 
cytoplasmic  localisation)  which  are  of  similar  or  approximately  similar 
molecular  weights. 
An  efficient  method  of  resolving  the  immunoreactive  bands  at 
42,000-52,000  is  by  the  use  of  highly  purified  radiolabelled  antibody  as 
shown  in  Figure  4.2.8.  Three  highly  resolved  and  sharp  bands  of 
molecular  weights  corresponding  to  approximately  54,000,51,000  and 
45,000  were  clearly  observed  on  the  autoradiogram,  in  the  lane  which 
represents  the  keratin  preparation  (lane  1).  Interestingly,  only  one 
single  and  sharp  band  at  Mr  51,000  could  be  seen  in  the  nuclear 
preparation  obtained  by  the  method  of  Chauveau  method  (lane  2),  while  in 
the  lane  representing  the  2M  salt-extracted  chromatin  (lane  3),  three 
bands  of  approximate  molecular  weights  of  52,000,49,000  and  43,000  were 
observed.  This  may  suggest  that  one  protein  (51,000)  at  least  could  be 
assigned  to  the  nuclear  fraction.  The  other  two  proteins  in  the 
dehistonised  fraction  (Mr  49,000  &  43,000)  may  be  present  in  too  small 
quantities  in  nuclear  preparations,  to  be  detected  on  the  immunoblot. 
The  relative  amount  of  these  two  proteins  may  be  enriched  in  the 
dehistonised  chromatin  preparation.  The  molecular  weights  of  these -  145  - 
Figure  4.2.8  Autoradiography  of  R2.1  Reacted  with  HeLa 
Subfractions 
An  autoradiogram  of  a  protein  immunoblot  of  R2.1  antiserum 
(1/300)  described  in  section  3.5.4.2  reacted  with  HeLa 
keratin  preparation  (lane  1),  HeLa  nuclei  prepared  by 
Chauveau  method  (lane  2)  and  2M  salt-extracted  chromatin 
(lane  3).  The  second  antibody  (affinity  purified 
anti-rabbit  IgG)  was  labelled  by 
125 
I  as  described  in 
methods  section. Mrx10 
3 
Mrx10 
3 
54- 51 
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bands  were  estimated  by  running  a  marker  protein  standard,  simultaneously 
on  the  same  gel.  The  blot  corresponding  to  the  protein  marker  was 
stained  with  amido-black,  then  aligned  with  the  negative  of  the 
autoradiogram  to  indicate  the  approximate  molecular  weight  of  the 
reactive  proteins. 
It  is  suggested  by  Lewis  and  Laemmli  (1982)  that  isolation  of 
the  nuclei  in  a  buffer  containing  polyamines  (spermine  and  spermidine) 
and  digitonin  with  subsequent  sedimentation  of  nuclear  pellet  through 
sucrose  gradients  results  in  elimination  or  reduction  of  contamination  by 
intermediate  filaments.  The  total  chromatin  obtained  from  this  method 
and  the  Chauveau  method  of  preparation  was  electrophoresed  on  a  long 
polyacrylamide  gel  and  transferred  onto  a  nitrocellulose  paper.  The 
blot  was  then  allowed  to  react  with  R2.1  antiserum  diluted  400  times  with 
TN-GS-BSA  buffer.  The  use  of  a  more  dilute  antiserum  should  minimise 
the  reaction  of  non-specific  or  less  abundant  antibodies  thus  reducing 
interference.  Figure  4.2.9  shows  little  difference  between  the  two 
preparative  methods  (lanes  5&  6).  Moreover,  it  can  be  seen  that  only 
one  band  is  visible  at  a  molecular  weight  of  51,000  in  lane  (6)  which 
contains  the  chromatin  obtained  by  the  Chauveau  method,  while  lane  (5) 
showed  a  broader  reaction  at  approximately  the  same  molecular  weight. 
Chromatin  prepared  by  the  routine  procedure  (section  3.1.2)  demonstrated 
an  immunoreactivity  at  approximate  molecular  weight  of  50,000-51,000 
(lane  3).  Again,  the  2M  salt-extracted  chromatin  (lane  2)  showed  a 
strong,  broad  and  unresolved  band  at  a  range  of  Mr  42,000-52,000  which 
may  be  due  to  the  enrichment  of  the  other  reactive  proteins  in  this  kind 
of  preparation.  It  is  worth  noting  that  the  cytoplasmic  fraction 
exhibited  no  detectable  immunoreactivity  with  R2.1  (1/400)  antiserum 
(lane  4). 
The  results  shown  in  Figure  4.2.8  (lane  2)  in  conjunction  with 
those  presented  in  Figure  4.2.9  (lanes  3&  6)  confirm  that  one  major 
nuclear  protein  is  immunoreactive  in  these  subcellular  fractions.  It  is -  147  - 
Figure  4.2.9  Immunoblot  of  R2.1  Reacted  with  HeLa  Subfractions 
Protein  immunoblot  of  R2.1  antiserum  reacted  with 
different  subcellular  preparations  from  HeLa  cells. 
Lane  1:  Amido-black-stained  protein  marker 
2:  2M  salt-extracted  chromatin 
3:  Chromatin  preparation 
4:  Cytoplasmic  fraction 
5.  Nuclei  prepared  by  the  polyamine  method  (section 
3.1.1.2) 
6  Nuclei  prepared  by  the  Chauveau  method m 
-00 -  148  - 
also  possible  to  suggest  that  proteins  of  approximate  molecular  weights 
of  42,000-43,000  and  49,000  usually  present  in  the  dehistonised  chromatin 
preparation  may  be  minor  components  in  the  total  chromatin  fraction  and 
become  enriched  and  detectable  in  the  2M  salt-extracted  chromatin. 
However,  the  possibility  that  the  43,000  and  49,000  bands  are  genuinely 
cytoplasmic  proteins,  perhaps  of  the  cytokeratin  type  contaminating  the 
chromatin  preparations,  can  not  be  ruled  out. 
Mitotic  HeLa  cells  fixed  on  coverslips  reacted  with  R2.1 
antiserum.  Although  the  intensity  of  FITC  staining  in  these  cells  is 
not  as  bright  as  in  interphase  (Figure  4.2.5),  it  is  clear  that  all  the 
cells  have  shown  fluorescent  immunoreaction  (Figure  4.2.10a,  c&  e). 
Examination  of  the  swollen  mitotic  cells  revealed  unidentified 
speckled-structures  scattered  throughout  the  cell  (Figure  4.2.10g). 
Although  the  mitotic  cells  were  cytocentrifuged  according  to  the  method 
of  Stenman  et  al.  (1975),  before  reaction  with  the  antibody,  in  an 
attempt  to  spread  and  detect  the  chromosomes,  the  fluorescent  staining 
has  not  revealed  clear  metaphase  chromosomal  structures  (Figure 
4.2.10g).  However,  this  does  not  rule  out  the  presence  of  chromosomal 
decoration  because  the  antiserum  (R2.1)  is  polyclonal  and  may  have 
reacted  with  other  components  which  hinder  the  clear  identification  of 
chromosomal  staining. 
Figure  4.2.7  shows  that  other  human  dehistonised  chromatins  give 
different  pattern  of  immunoreactivity  with  R2.1  antiserum,  though  there 
are  some  similarities.  It  is  interesting  to  note  that  the  K562  cell 
line  which  is  a  myelogenous  leukemia  line,  despite  exhibiting  a  high 
reactivity  with  R2.1  in  both  C'F  and  ELISA  techniques,  shows  only  one 
major  band  at  Mr  49,000  (lane  5).  The  FL  cell  line  which  is  of  an 
epithelial  origin  exhibited  a  broad  and  unresolved  reactive  band  at  Mr 
41,000-49,000  (lane  6).  KB  chromatin  (lane  7)  reacted  less  vigorously 
showing  two  faint  bands  corresponding  to  molecular  weights  of  45,000  and -  149  - 
Figure  4.2.10  FITC-stained  Mitotic  HeLa  Cells  Reacted  with  R2.1 
An  indirect  immunofluorescent  staining  of  HeLa  cells 
swollen  in  hypotonic  solution  and  spread  and  fixed  on 
slides  by  cytocentrifugation  then  allowed  to  react  with 
R2.1  (1/100)  antiserum. 
(a,  c  &  e)  :  FITC  staining  (X500) 
(b,  d  &  f)  Phase  contrast  of  cells  in  a,  c  and  e 
(g)  :  FITC  staining  (X2000) 'i 
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48,000.  On  the  other  hand,  Chang  liver,  which  showed  very  little 
activity  in  C'F  and  ELISA,  its  dehistonised  chromatin  demonstrated  a 
strong  immunoreaction  with  R2.1  antiserum  at  Mr  42,000,45,000  and  49,000 
although  some  overlapping  was  also  noted  at  the  same  range  of  molecular 
weight.  Weak  immunoreaction  at  Mr  51,000  and  59,000  was  also  observed 
in  the  immunoblot  (lane  8).  The  fibrosarcoma  cell  line,  HT1080,  showed 
clear  reactive  protein  bands  at  Mr  42,000,44,000  and  49,000  (lane  9). 
Of  the  non-human  chromatins,  only  the  green  African  monkey 
kidney  cell  line  (BSC-1)  showed  a  clear  immunoreaction  at  49,000  (lane 
10),  while  both  hamster  cell  lines  (CHO  &  BHK-21)  exhibited  a  weaker 
reaction  corresponding  to  proteins  at  molecular  weights  of  59,000  and 
64,000  (lanes  11  &  12). -  151  - 
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When  the  isolated  nuclei  of  HeLa  cells  were  extracted  with  2M 
salt-buffer,  a  group  of  proteins  believed  to  have  high  affinity  to  DNA 
could  be  sedimented  through  1M  sucrose  bed.  This  2M  salt-extracted 
chromatin  was  strongly  antigenic.  and  the  resulting  polyclonal  antiserum 
(R2.1)  was  used  to  determine  and  characterise  the  immunologically 
reactive  groups  in  HeLa  chromatin  as  well  as  in  other  human  and  non-human 
cell  lines,  using  different  techniques  (C'F,  ELISA,  immunoblotting  and 
immunofluorescence).  The  amount  of  protein  remaining  after  2M 
salt-extraction  is  greater  than  the  residual  protein  left  behind  in  2M 
salt-5M  urea-extraction.  Adding  to  this  is  the  irreversible 
denaturation  of  some  nuclear  components  (such  as  some  enzymes)  which 
could  be  avoided  or  considered  less  likely  by  excluding  the  urea  from  the 
extraction  buffer. 
Both  C'F  assay  and  ELISA  (Figures  4.2.1  &  4.2.2)  demonstrated 
very  small  immunoreactivity  between  R2.1  and  non-human  chromatins.  On 
the  other  hand,  different  reactivity  patterns  with  respect  to  human 
chromatins  was  observed.  Human  epithelial  cells  (Chang  liver,  KB  and 
H.  Ep-2)  showed  between  20-30%  of  the  reactivity  of  HeLa  chromatin  at  an 
antiserum  dilution  of  over  1/200.  Exceptionally  higher  reactivity  was 
exhibited  by  human  blood  cell  line  (K562)  in  C'F  assay  (more  than  80% 
C'F)  as  well  as  ELISA  (approximately  40%  of  HeLa  chromatin  reactivity). 
Unlike  the  immunoreactivity  of  the  antigen-complex  seen  with 
R3.1  antiserum  and  those  reported  by  Campbell  et  al.  (1979)  which  were 
raised  against  2M  salt-5M  urea-extracted  chromatin,  only  a  third  of  the 
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immunoreaction  of  R2.1  with  HeLa  chromatin  was  lost  extensive  micrococcal 
nuclease  digestion  (Figure  4.2.3).  The  lost  immunoreactivity  was  again 
almost  restored  on  reconstituting  the  digested  chromatin  with  HeLa  DNA, 
while  the  DNA  alone  failed  to  exhibit  any  significant  reaction  with  R2.1 
antiserum. -  152  - 
The  need  for  DNA  association  (for  part  of  the  antigen)  was  once 
again  demonstrated  when  a  group  of  immunologically  reactive  proteins 
showed  a  faint  reaction  after  treating  the  immunoblot  with  HeLa  DNA  prior 
to  its  reactivity  with  R2.1  antiserum.  These  reactive  groups  were  seen 
in  both  chromatin  and  dehistonised  chromatin  fractions  (Figure  4.2.4). 
The  first  group  which  was  not  clearly  resolved  on  the  blot  occupy  a  range 
of  molecular  weights  of  52,000-64,000.  The  other  DNA-dependent  reactive 
groups  could  be  seen  (arrows)  at  higher  molecular  weights  (approximately 
Mr  80,000  &  100,000).  A  third  and  again  unresolved  group  which  showed 
clearly  strong  reaction  with  R2.1  antiserum  after  treating  the  blot  with 
HeLa  DNA  was  also  observed  at  a  range  of  Mr  40,000-42,000,  overlapping 
the  other  group  (42,000-52,000)  which  did  not  require  DNA-association  for 
its  immunoreaction. 
There  is  a  great  difference  in  the  intensity  of  reaction  between 
the  HeLa  interphase  and  metaphase  cells  as  viewed  by  FITC  staining 
(Figure  4.2.5  &  4.2.10).  This  difference  could  be  attributed  to  the 
absence  (or  decrease)  of  some  components  of  the  reactive  antigen(s) 
during  mitosis.  The  pattern  seen  in  mitotic  cells  did  not  show  any 
distinct  FITC-stained  chromosomal  structures.  This  may  be  due  to  the 
overlapping  of  chromosomal  and  non-chromosomal  reactions. 
It  is  obviously  relevant  to  determine  whether  all  the  reactive 
groups  seen  on  the  immunoblot  are  nuclear,  or  cytoplasmic.  The  risk  of 
cytoplasmic  contamination  stems  mainly  from  a  group  of  proteins 
(collectively  called  cytokeratins  and  specifically  termed  intermediate 
filaments  -  I.  F.  )  which  resist  solubilisation  by  non-ionic  detergents 
(such  as  triton  X-100)  and  by  low  or  high  salt-extraction  (reviewed 
recently  by  Moll  et  al.  1982  &  Lazarides  1982). 
Although  Franke  et  al.  (1979)  have  reported  the  presence  of  only 
four  major  intermediate  filament  protein  bands  in  HeLa  cells  of  Mr 
54,000,52,000,48,000  and  46,000,  recent  reports  have  demonstrated -  153  - 
another  two  immunologically  reactive  protein  groups  at  Mr  43,000  and 
50,000  (Bravo  et  al,  1983)  and  at  58,000  and  65,000-67,000  (Tseng  et  al. 
1982). 
Figure  4.2.7  (lane  2)  shows  a  cytokeratin  preparation  from  HeLa 
cells  reacting  with  four  groups  of  proteins  on  the  immunoblot. 
Comparing  these  immunologically  reactive  groups  with  that  of  the 
dehistonised  chromatin  (lane  4),  it  is  possible  to  detect  that  only  one 
group  (42,000-52,000)  is  common  to  both  preparations,  while  the  other 
three  groups,  (54,000-61,000,20,500-24,000  &  15,000-16,000)  are  confined 
to  the  keratin  preparation.  The  chromatin  preparation  (Figure  4.2.4) 
exhibited  a  reaction  pattern  exactly  similar  to  the  dehistonised  fraction 
(lanes  6&  7).  Unlike  the  keratin  preparation  (Figure  4.2.7,  lane  2), 
no  other  reactive  group  (other  than  the  42,000-52,000  group)  could  be 
seen  in  either  of  these  two  preparations  (chromatin  and  dehistonised 
chromatin;  Figure  4.2.4,  lanes  6&  7)  nor  in  the  nuclear  fraction 
(except  the  Mr  15,000-16,000  group)  seen  in  Figure  4.2.7,  lane  (3). 
It  is  important  to  emphasise  that  HeLa  intermediate  filaments 
have  been  shown  to  be  distinct  (Franke  et  al.  1979;  Moll  et  al.  1982). 
It  is  also  noteworthy  that  antisera  and  monoclonal  antibodies  produced  by 
immunising  the  animals  with  dehistonised  chromatin  fraction  have  also 
exhibited  specific  reactivity  with  intermediate  filament  class  of 
proteins  (Schmidt  et  al.  1981;  Turner,  1981). 
The  major  cytokeratin  proteins  in  HeLa  cells  (vimentin  and 
phosphovimentin)  are  of  Mr  54,000-55,000,  and  another  two  cytokeratins  of 
Mr  52,000  and  58,000  have  been  identified  (Bravo  &  Celis,  1982). 
Consequently,  some  of  the  reactive  proteins  (which  reacted  with  R2.1)  in 
this  region  of  the  keratin  preparation  (Figures  4.2.7,  lane  2&4.2.8 
lane  1)  may  be  assigned  to  cytoplasmic-reactive  groups  including 
intermediate  filaments.  This  could  also  be  correlated  with  some  of  the 
cytoplasmic  reaction  seen  by  immunofluorescent  staining  (Figure  4,2,5  & -  15  4- 
4.2.6).  Since  there  are  no  distinctly  defined  filaments  or  meshwork 
arrays  or  fibrils,  it  is  difficult  to  speculate  whether  these  fibrous 
structures  are  of  the  intermediate  filament  type  or  of  actin  (Mr 
43,000).  Hindering  this  identification  is  the  possibility  of  a  mixture 
of  a  number  of  cytoplasmically  reactive  groups,  present  together,  which 
mask  the  presence  of  a  defined  filamentous  organisation. 
The  relative  intensity  of  the  reactive  group  in  the  dehistonised 
chromatin  fractions,  shown  in  Figure  4.2.7,  implies  that  the  HeLa 
fraction  (lane  4)  has  approximately  the  same  immunoreactivity  as  that  of 
Chang  liver  chromatin  (lane  8).  This  is  in  contrast  to  the  results 
shown  in  Figure  4.2.2a  where  HeLa  chromatin  demonstrated  very  high 
immunoreaction  with  R2.1  antiserum,  in  comparison  with  Chang  liver 
chromatin.  The  latter  demonstrated  only  20%  of  HeLa  chromatin 
immunoreactivity.  This  could  be  explained  as  follows: 
1)  Some  of  these  reactive  groups  are  of  intermediate  filament 
(I.  F.  )  contaminants  which  are  common  to  both  cell  lines.  Their 
contribution  (I.  F.  )  to  the  immunoreactivity  of  HeLa  chromatin  is  probably 
equivalent  to  the  observed  20%  exhibited  by  Chang  liver  chromatin. 
2)  Much  of  the  specific  HeLa  antigen  immunoreaction  is  associated 
with  a)  DNA-complex  formation.  Evidence  supporting  this  possibility  is 
that  part  (at  least  30%)  of  the  HeLa  antigen  requires  DNA-association  to 
exert  its  immunoreaction  with  R2.1  antiserum  (Figure  4.2.3),  and  b) 
chromatin  components  of  a  complex  of  components  which  are  more  abundant 
in  HeLa  chromatin  than  in  Chang  liver.  Upon  2M  salt  extraction  of  both 
chromatins,  enrichment  of  the  nonspecific  components  has  taken  place  in 
both  dehistonised  fractions  (HeLa  &  Chang  liver).  These  components  may 
be  common  to  many  epithelial  and  related  cell  lines  (HeLa,  Chang  liver, 
FL  and  HT1080).  This  would  result  in  overlapping  between  the 
chromatin-associated  reactive  proteins  and  the  cytoplasmic  contaminants 
in  a  broad  reactive  band,  and  indicate  that  the  dehistonised  fraction  of -  155  - 
HeLa  chromatin  exercises  a  similar  reactivity  pattern  with  those  of  other 
epithelial  cell  lines  on  the  blot. 
Amongst  the  reactive  group  of  Mr  42,000-52,000  in  HeLa  chromatin 
preparations,  at  least  one  band  (Mr  51,000)  is  genuinely  a  nuclear 
protein  (Figures  4.2.8  lane  2&4.2.9  lane  3&  6).  The  rest  of  the 
reactive  proteins  in  this  region  are  either  cytoplasmic  contaminants  or  a 
result  of  overlapping  between  nuclear  and  non-nuclear  bands.  The 
FITC-staining  of  whole  HeLa  cells  (Figure  4.2.5)  indicates  that  the 
predominant  immunofluoresence  is  concentrated  in  the  nuclei.  This 
implies  that  the  majority  of  the  reactive  antigens  are  of  nuclear 
localisation.  Further  support  to  this  idea  is  the  DNA-requirement  for 
part  (30%)  of  the  HeLa  chromatin  reactivity  demonstrated  in  Figures  4.2.3 
and  4.2.4,  and  also  by  the  observation  in  Figures  4.2.8  and  4.2.9  which 
shows  that  the  Mr  51,000  protein  is  nuclear  associated.  Thus  the 
nuclear  antigen  visualised  by  FITC-staining  is  very  probably  from  two  or 
more  sources:  - 
1)  Nuclear  protein(s)  represented  mainly  by  Mr  51,000  which  do  not 
require  complex  formation  with  DNA  for  immunoreactivity.  The  presence 
of  other  reactive  nuclear  protein(s)  of  this  class  in  the  region  of 
42,000-52,000  is  highly  possible  (Figure  4.2.8  lane  3). 
2)  Nuclear  antigens  which  require  the  presence  of  DNA-complex 
formation  for  immunoreactivity.  These  antigens  are  represented  by 
(a)  strongly  reactive  proteins,  Mr  40,000-42,000  (Figure  4.2.4  lane  9). 
(b)  very  weakly  reactive  bands  at  Mr  80,000  and  above  100,000. 
(c)  intermediately  reactive  protein  bands  at  Mr  52,000-64,000. 
The  last  finding  is  in  agreement  with  the  report  of  Lebkowski 
and  Laemmli  (1982)  in  which  it  is  emphasised  that  major  DNA-binding 
proteins,  in  2M  salt-extracted  HeLa  chromatin,  are  of  molecular  weights 
of  60,000-70,000  and  include  bands  at  Mr  60,000,68,000  and  70,000  and  a 
minor  protein  at  Mr  64,000. -  156  - 
In  summary  it  can  be  suggested  that  R2.1  antiserum,  which  has 
been  raised  in  a  rabbit  against  2M  salt-extracted  chromatin,  reacts  with 
two  different  groups  of  proteins  in  HeLa  cells. 
1.  Nuclear  proteins:  This  group  is  of  two  types: 
(a)  Nuclear  proteins  whose  immunoreactivity  necessitates 
DNA-binding  in  order  to  dictate  the  required  antigenic  determinants 
presentation  for  R2.1  reaction.  Some  of  these  proteins,  are  possibly 
the  type  of  nuclear  laminar  proteins  (Mr  60,000-70,000)  described  by 
Lebkowski  and  Laemmli  (1982). 
(b)  Nuclear  proteins  which  react  with  R2.1  antiserum 
regardless  of  the  presence  of  DNA-binding. 
2.  The  second  group  is  that  of  cytoplasmic  localisation.  This 
group  again  could  be  divided  into  two  subgroups. 
(a)  Those  of  cytoplasmic  contaminants  represented  mainly  by 
the  cytokeratins  or  other  filamentous-forming  proteins. 
(b)  Those  of  nuclear  origin  but  reacted  in  the  cytoplasm 
because  they  are  synthesised  there. 
It  is  also  interesting  to  note  that  Adolph  (1980a)  has  reported 
that  a  cluster  of  the  scaffold  proteins  in  HeLa  cells  is  of  the 
approximate  molecular  weight  range  of  50,000-55,000.  Although  this 
report  has  been  contradicted  recently  by  Lebkowski  and  Laemmli  (1982)  who 
suggested  that  these  proteins  represent  intermediate  filaments 
contamination,  Figures  4.2.4,4.2.8  and  4.2.9  indicated  that  a  protein  of 
Mr  51,000  is  amongst  the  residual  nuclear  scaffold  components.  In 
addition,  DNA-binding  proteins  (Figure  4.2.4)  are  also  among  the  residual 
proteins  and  could  be  immunologically  localised  at  a  molecular  weight 
range  of  52,000-64,000.  This  is  also  in  agreement  with  Adolph's 
previous  report  (Adolph,  1980a)  as  well  as  with  the  suggestion  of -  15  7- 
Lebkowski  and  Laemmli  (1982),  since  the  DNA-binding  proteins  recognised 
by  R2.1  reaction  accommodate  parts  of  the  two  groups  of  proteins 
(50,000-55,000  and  60,000-70,000)  reported  by  Adolph  (1980a)and  Lebkowski 
&  Laemmli  (1982)  respectively. -158- 
4.3  Results  and  Discussion  of  Monoclonal  HNo-G7 
HNo-G7  is  a  monoclonal  antibody  resulting  from  the  fusion  of 
spleen  cells  from  a  BALB/c  mouse  immunised  with  dehistonised  HeLa 
chromatin  and  X63-Ag8-653  (653)  plasmacytoma  cells.  The  fusion  schedule 
is  outlined  in  Figure  4.3.1a.  The  murine  hybridoma  cell  line  was  cloned 
four  times  by  limited  dilution  at  0.5-1  cell/well  and  has  been 
established  in  culture  for  more  than  18  months  without  loss  of 
secretion.  The  established  clone  can  be  frozen  and  recovered  from 
liquid  nitrogen  and  when  grown  to  exhaustion  secretes  30pg  IgM/106 
cells/day  as  estimated  by  ELISA  with  reference  to  controls  of  standard 
mouse  IgM.  Recloning  shows  no  revertant  colonies  and  the  line  is  now 
assumed  to  be  stable. 
The  hybridoma  line  which  produces  the  cells  is  shown  in  Figure 
4.3.1b  forming  a  colony. 
HNo-G7  was  shown  to  be  from  an  IgM-secreting  hybridoma  both  by 
ELISA  assays  utilising  class-specific  antisera  and  internal 
radio-labelling  (Fig.  4.3.2). 
The  reaction  of  the  monoclonal  antibody  and  its  unknown  antigen 
was  initially  investigated  with  respect  to  the  pH  of  the  ELISA  assay 
since  other  monoclonal  antibodies  have  been  shown  to  have  very  precise 
assay  requirements  in  this  respect  and  these  would  clearly  affect 
subsequent  characterisation  (Fraser  et  al.,  1982;  Mossman  et  al., 
1980).  Figure  4.3.3  shows  that  the  pH  does  not  have  a  substantial 
effect  on  the  assay  of  the  monoclonal  antibody  with  immobilised  HeLa 
chromatin  at  pH7-11.  Figure  4.3.4  demonstrates  that,  although  the 
binding  to  the  plate  differs  at  various  pH  values,  it  is  at  saturation  at 
the  usual  concentrations  of  antigen  employed  (l0pg/well).  The 
difference  at  low  antigen  concentration  could  also  be  attributed  to  the 
buffer  system  used  for  immobilising  the  antigen,  but  this  again  has  no 
significant  effect  on  the  course  of  this  study  since  carbonate  is  the 
routinely  used  buffer.  ' -  159  - 
Figure  4.3.1a  Fusion  Schedule 
Step  Day  Operation 
1  -28  Injection  with  100  P9  DNA  of  dehistonised 
chromatin  prepared  by  2M  salt  -  5M  urea 
extraction  (see  section  3.2.2)  in  complete 
Freund's  adjuvant,  intraperitoneally. 
2  -18  Injection  with  100rg  DNA  of  dehistonised 
chromatin  as  above. 
3  -5  Injection  of  100pg  dehistonised  chromatin 
in  saline,  intraperitoneally. 
40  Fusion  (see  section  3.3.5). 
5  14-18  Assay.  Positive  clones  selected  subcloned 
at  0.5-1  cell/well. 
6  30-34  Clones  assayed.  Positives  selected  and 
subcloned  at  0.5-1  cell/well. 
7  Steps  5&6  repeated  twice. -  160  - 
Figure  4.3.1b  Hybridoma  Colony  of  HNo-G7 
HNo-G7  Hybridoma  colony  visualised  under  Light  Microscope 
(X125) Oil: 
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Fiqure  4.3.2  Immunoglobulin  Secretion  of  HNo-G7 
Immunoprecipitate  of  secreted  immunoglobulin  (internally 
labelled  with  [35S]-methionine)  from  the  P3-X63-Ag8(IgG 
secreting)  myeloma  cell  line  (lane  1)  and  HNo-G7 
Hybridoma  (lane  2)  analysed  on  a  10%  SDS-PAGE.  The 
proceduresof  radiolabelling  and  immu  noprecipitation  are 
described  in  section  3.5.2.  The  gel  mixture  is  of  a 
ratio  of  0.8:  30  (bisacrylamide:  acrylamide) 3 
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Figure  4.3.3  pH  Effect  on  HNo-G7  Immunoreactivity 
The  effect  of  pH  on  the  immunoreactivity  of  HNo-G7  with 
HeLa  chromatin  as  tested  by  ELISA  (Procedure  is  described 
in  section  3.4.4). 0.7 
0.6 
o"5 
0.4 
A492 
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Figure  4.3.4  Effect  of  Ag-  Coating  Buffer 
ELISA  of  HNo-G7  antibody  reacted  with  various  amounts  of 
HeLa  chromatin,  suspended  and  immobilised  in  the  ELISA 
plate  using  different  coating  buffers. 
O  In  carbonate  buffer  pH9.5 
A  In  PBS  pH7.3 
0  In  TN  buffer  pH7.4 A  492 
0.6 
0.4 
0.2 
0.0 
r9  of  HeLa  chromatin 
1.25  2.5  5  10 -  164  - 
The  "Chequerboard"  ELISA  of  the  monoclonal  antibody  with  the 
antigen  (Fig.  4.3.5.  a)  is  performed  to  give  an  indication  of  the 
dilutions  of  culture  supernatant  which  may  be  used  for  assay  of  both 
antibody  and  antigen.  While  visual  inspection  of  the  plate  gives  a 
clear  indication  of  the  results,  the  data  are  also  read  by  "Titretek 
Multiskan  Spectrophotometer"  to  give  a  more  detailed  analysis  and 
laboratory  record.  Figure  4.3.5b  shows  selective  reading  from  the  above 
"Chequerboard".  It  is  clear  that  at  excess  antibody  (diluted  up  to 
1/64)  there  is  only  small  difference  (less  than  0.2  A492  units)  between 
the  reactivity  of  HNo-G7  with  various  concentrations  of  HeLa  chromatin 
above  2.5pg/well.  This  again  indicates  that  a  near  saturation  of 
antigen  binding  is  reached  when  more  than  2.5pg/well  of  chromatin  is 
layered  on  the  ELISA  plate. 
The  specificity  of  HNo-G7  was  then  tested  by  its  reaction  with 
other  human  chromatins  in  comparison  to  HeLa  chromatin.  Figure  4.3.6 
shows  the  reaction  in  comparison  to  two  other  established  human 
epithelial  cell  lines  (H.  Ep-2  &  Chang  liver)  and  a  fibrosarcoma  line, 
HT1080.  It  is  clear  that  either  the  same  antigen  or  the  same 
determinant  is  present  in  the  other  epithelial  cell  lines  but  that  there 
is  no  detectable  antigenic  activity  in  the  fibrosarcoma  cell  line.  It 
is  also  clear  that  the  antigenic  determinant  is  not  present  on  purified 
human  DNA. 
The  quantitative  difference  between  the  various  types  of  chromatin 
could  reflect  differential  binding  of  the  antigen  to  the  ELISA  plate. 
Consequently,  a  competition  assay  as  described  in  section  3.4.5  was  also 
employed  to  examine  this  phenomenon.  HeLa  and  other  human  chromatins  at 
different  concentrations  were  incubated  at  4°C  for  18-24  hours  with  a 
fixed  amount  of  HNo-G7  culture  supernatant  diluted  1/20  to  absorb  the 
antibody.  The  mixture  was  centrifuged  briefly  and  50pl  of  a  supernatant -  165  - 
Figure  4.3.5a  A  Chequerboard  ELISA  of  HNo-G7  with  HeLa  Chromatin 
ELISA  of  different  dilutions  (1-1/64)  of  HNo-G7  antibody 
(lanes  B-"H)  with  various  concentrations  (40pg-0.08pg)  of 
HeLa  chromatin  (lanes  3-.  12)  on  an  ELISA  plate.  Wells 
numbered  A3-A12  represent  the  antigen  control  of  various 
amounts  of  HeLa  chromatin,  while  antibody  controls  of 
different  dilutions  are  represented  by  wells  numbered 
2B-2H.  Well  number  A2  was  not  treated  intially  with 
either  antigen  or  HNo-G7  but  at  the  final  stage  of  the 
procedure  was  incubated  with  anti-mouse-IgG-peroxidase- 
conjugated  antiserum. ug  of  Ag 
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Figure  4.3.5.  b  ELISA  of  HNo-G7  with  HeLa  Chromatin 
ELISA  of  different  dilutions  of  HNo-G7  antibody  with 
various  concentrations  of  HeLa  chromatin  selected  from 
the  "chequerboard"  test  in  Figure  4.3.5a.  Antibody  and 
antigen  controls  were  subtracted. 
O  HNo-G7  antibody  diluted  1/16 
HNo-G7  diluted  1/32 
A  HNo-G7  diluted  1/64 A  492 
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Figure  4.3.6  ELISA  of  HNo-G7  with  Human  Chromatins 
Enzyme  linked  immunosorbent  assay  of  HNo-G7  (1/20) 
antibody  reacted  with  different  concentrations  of  various 
human  chromatins.  Antibody  and  antigen  controls  were 
subtracted.  All  chromatins  measured  as  total  protein 
content  and  DNA  estimated  as  total  DNA  content. 
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Anttbody.  "co  trol  was  0.07  A492  unit  while  the  antigen  controls  were  as 
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from  each  sample  was  then  added  to  a  fixed  amount  of  HeLa  chromatin 
immobilised  on  an  ELISA  plate.  The  results  are  shown  in  Figure 
4.3.7a.  Much  of  the  reactive  antibody  was  absorbed  by  the  HeLa 
chromatin  while  H.  Ep-2  and  Chang  liver  chromatins  exhibited  lower 
absorption  profiles.  The  data  are  shown  with  greater  clarification, 
replotted  as  a  percentage  in  Figure  4.3.7b.  It  can  be  seen  that  HeLa 
chromatin  at  a  concentration  of  20pg/50pl  of  antibody  (1/20)  was  able  to 
bind  almost  80%  of  the  reactive  antibody  while  H.  Ep-2  and  Chang  liver 
chromatins  were  only  able  to  bind  35%  and  25%  at  the  same 
concentrations.  The  data  thus  appear  to  indicate  that  the  antigenic 
determinant  is  either  present  at  lower  concentrations  or  less  accessible 
in  the  chromatins  of  the  two  other  epithelial  cell  lines. 
The  HNo-G7  monoclonal  antibody  reacted  variably  with  subcelluar 
preparations  from  HeLa  cells  (Fig.  4.3.8).  Chromatin,  cytoplasmic, 
nucleolar  and  2M  salt  soluble  extracts  of  chromatin  were  allowed  to  react 
with  the  monoclonal  antibody  on  ELISA,  using  fixed  amounts  of  each 
preparation  (10ig  protein/well)  bound  to  the  plate.  The  chromatin 
preparation  again  demonstrated  high  reactivity  with  HNo-G7  and 
considerable  but  lesser  activity  was  also  present  in  cytoplasmic  and  " 
nucleolar  preparations.  The  2M  salt-soluble  chromatin,  which  had  been 
extensively  dialysed  against  PBS  buffer,  failed  to  show  any  activity. 
As  this  preparation  contains  large  amounts  of  histones  these  results 
indicate  that  the  antigen  is  unlikely  to  be  a  histone. 
In  order  to  confirm  that  the  qualitative  difference  between  the 
different  subcellular  fractions  does  not  reflect  differential  binding  of 
the  proteins  to  the  ELISA  plate,  a  competition  assay  was  performed  in  a 
manner  similar  to  the  assay  used  for  Figure  4.3.7a  and  b.  The  results 
are  shown  in  Figures  4.3.9a  and  b.  It  can  be  seen  that  HeLa  chromatin 
competed  very  effectively  against  itself  as  would  be  expected  with  80%  of -  169  - 
Figure  4.3.7a  Competition  ELISA  of  HNo-G7  with  Human  Chromatins 
Enzyme  linked  immunoassay  of  HNo-G7  (1/20)  absorbed  with 
various  concentration  of  human  chromatins.  The 
supernatants  (50pl)  after  this  incubation  were  allowed  to 
react  with  constant  amount  of  HeLa  chromatin  immobilised 
on  an  ELISA  plate  (section  3.4.5). 
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Figure  4.3.7b  Percentage  of  Absorbed  HNo-G7  Used  in  Competition  ELISA 
of-Human  Chromatins 
The  amount  of  the  remaining  reactive  antibody  (HNo-G7), 
after  absorption  with  the  chromatins  described  in  4.3.7a, 
expressed  in  percentage  of  total  free  HNo-G7  reacted  with 
the  immobilised  HeLa  chromatin. 
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Figure  4.3.8  ELISA  of  HNo-G7  with  HeLa  Subfractions 
Enzyme  linked  immunoassay  of  different  concentrations  of 
the  HNo-G7  antibody  reacted  with  fixed  amount  of  HeLa 
P,  Ote1ý, 
cell  subcellular  fractions  (10)tg/well)  immobilised  on  an 
ELISA  plate.  Antibody  and  antigen  controls  were 
subtracted. 
O  HeLa  chromatin 
13  Cytoplasmic  preparation 
Nucleolar  preparation 
0  2M  salt-soluble  chromatin  (Histones) 
(the  soluble  protein  was  dialysed  against  PBS  and 
the  precipitate  resuspended  in  the  coating  buffer 
as  for  the  other  preparations). 
Antibody  control  waß  0.05  A492  unit  and  the  antigens  controls  were  as 
follows: 
HeLa  chromatin  :  0.14  A492  unit 
Cytoplasmic  preparation  :  0.16  A492  unit 
nucleolar  preparation  :  0.16  A492  unit  t  Histone-rich  fraction  0.103  A492  unit A492 
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Figure  4.3.9a  Competition  ELISA  of  HNo-G7  with  HeLa  Subfractions 
Enzyme  linked  immunoassay  of  HNo-G7  (1/20)  absorbed  by 
various  concentrations  of  HeLa  subcellular  fractions. 
The  supernatant  of  the  mixture  was  allowed  to  react  with 
HeLa  chromatin  immobilised  (10Ng/well)  on  an  ELISA 
plate.  Antibody  and  antigen  controls  were  subtracted. 
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Figure  4.3.9b  Percentage  of  Absorbed  HNo-G7  Used  in  Competition  ELISA 
of  HeLa  Subfractions 
The  amount  of  HNo-G7  antibody  absorbed  by  different 
concentrations  of  HeLa  cell  subcellular  fractions 
expressed  as  a  percentage  of  free  HNo-G7  reacted  with 
immobilised  HeLa  chromatin  on  an  ELISA  plate. 
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the  antibody  being  absorbed  at  a  concentration  of  20pg  of  protein  per 
501i1  of  HNo-G7  (1/20).  Both  cytoplasmic  and  nucleolar  preparations  were 
able  to  absorb  33%  of  the  HNo-G7  immunoactivity  at  the  same  protein 
concentration. 
The  antigen  was  further  characterised  by  treatment  with  a  variety 
of  enzymes  before  reaction  with  the  monoclonal  antibody.  Figure  4.3.10 
shows  that  antigenic  activity  was  unimpaired  by  treatment  with  excess  of 
either  DNAase  I  or  RNAase  A,  indicating  that  the  antigen  itself  is 
unlikely  to  be  DNA  or  RNA  and  that  it  has  no  apparent  conformational 
dependence  on  DNA  or  RNA  for  activity.  Trypsin  treatment,  on  the  other 
hand,  totally  abolished  the  immunoreactivity  indicating  that  the  antigen 
is  likely  to  be  a  protein  or  an  epitope  dependent  on  intact  protein  for 
its  reaction  with  antigen. 
The  subcellular  localisation  of  the  antigen  was  further 
investigated  by  immunofluorescent  staining  of  HeLa  cells  grown  and  fixed 
on  coverslips.  The  cells  were  allowed  to  react  with  the  monoclonal 
antibody  followed  by  FITC  conjugated  rabbit  anti-mouse  IgG.  The 
immunofluorescence  is  clearly  concentrated  in  the  nucleoli  (Fig.  4.3.11) 
and  some  less  intense  staining  is  also  evident  in  the  cytoplasm  and  at 
the  nuclear  boundary  (4.3.11).  The  cytoplasmic  staining  was  less 
intense  than  the  nucleolar  one,  and  this  is  shown  more  clearly  at  high 
magnification  (Fig.  4.3.11b  &  c).  A  control  sample  (in  which  tissue 
culture  medium  replaced  the  monoclonal  antibody)  showed  very  little 
staining  (Fig.  4.3.12). 
In  order  to  investigate  whether  the  antigen  was  present  in 
metaphase  chromosomes,  and  in  particular  on  those  with  nucleolar 
organiser  regions,  a  metaphase  chromosome  spread  was  prepared  as 
described  in  sections  3.7.7  and  3.7.8  and  reacted  with  the  monoclonal 
antibody  in  the  same  manner  as  the  interphase  cells.  The  chromosomes -  175  - 
Figure  4.3.10  ELISA  of  HNo-G7  with  Enzymes-Treated  HeLa  Chromatin 
Enzyme  immunoassay  of  monoclonal  antibody  (HNo-G7) 
reacted  with  different  concentrations  of  HeLa  chromatin 
and  enzyme-treated  chromatin.  The  enzyme  concentrations 
were  in  excess  as  described  in  section  3.4.6.  Antibody 
and  antigen  controls  were  subtracted. 
O  HeLa  chromatin  untreated 
Q  DNAase  I-treated  (5001ig/ml)  chromatin 
1  RNAase  A-treated  (200rg/ml)  chromatin 
0  Trypsin-treated  HeLa  (200jg/ml)  chromatin 
No  attempt  was  made  to  estimate  the  extent  of  digestion  of  DNA  or 
RNA.  However  the  nucleases  were  used  in  amounts  which  were  in 
substantial  excess  (as  judged  by  specific  activity)  to  these  required 
to  digest  all  the  nucleic  acid  present. Ä  492 
0.8 
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0.4 
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Figure  4.3.11  FITC-staining  of  HeLa  Cells  Reacted  with  HNo-G7  and  653 
Culture  Supernatants 
Indirect  immunofluorescent  staining  of  HeLa  cells  reacted 
with  HNo-G7  antibody  (1/10). 
a)  Low  magnification  (X500) 
b&  c)  High  magnification  (X2000) 
d)  Black  and  white  photograph 
1.  FITC  stained  cells  (X375) 
2.  Phase  contrast  of  1  (X375) 
3.  FITC  stained  cells  (X500) 
4.  FITC  stained  cells  (X2000) 
5.  FITC-control  of  HeLa  cells  reacted  with 
Culture-Supernatant  from  653  myeloma  cells. C d 
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Figure  4.3.12  FITC-control  of  HeLa  Cells  Reacted  with  RPMI-FCS 
Indirect  immunofluorescent  staining  of  HeLa  cells  treated 
with  RPMI-FCS  instead  of  the  first  antibody  (HNo-G7) 
followed  by  anti-mouse  IgG-  FITC-conjugated  second 
antibody  (X500). -  178  - 
were  also  separately  stained  with  Giemsa  to  ensure  that  the  quality  of 
the  spread  was  adequate  (Fig.  4.3.13).  No  fluorescence  was  detected  in 
these  preparations  with  the  monoclonal  antibody  indicating  that  either 
the  antigen  is  not  present  in  detectable  quantity  or  it  is  not  accessible 
in  metaphase  chromosomes. 
In  view  of  the  fact  that  neither  DNA  nor  RNA  were  required  for 
antigenic  activity,  experiments  designed  to  further  characterise  the 
protein  component  of  the  antigen  by  immunoblotting  were  then 
undertaken.  Immunoblotting  of  a  monoclonal  antibody  presents  particular 
technical  problems  as  it  is  likely  that  only  a  single  epitope  will  be 
present  on  each  molecule  of  the  antigenic  protein  and  the  signal  is 
therefore  likely  to  be  extremely  weak  in  comparison  to  that  from  a 
polyclonal  antiserum.  It  is  therefore  important  to  have  as  high  a 
concentration  of  specific  protein  antigen  as  possible  on  the 
nitrocellulose  paper.  Dehistonised  chromatin  was  consequently  chosen 
for  this  procedure  as  more  of  the  relevant  material  may  be  loaded  on  the 
gel  in  the  absence  of  the  histones.  Two  different  preparations  of 
dehistonised  chromatins  were  employed.  The  first  was  extracted  with  2M 
salt  and  the  second  with  sulfuric  acid  by  the  method  of  Bhorjee  and 
Pederson  (1973)  (section  3.1.4).  The  result  is  shown  in  Figure  4.3.14a 
using  the  immunoperoxidase  (section  3.5.4.1)  detecting  procedure.  the 
monoclonal  antibody  used  was  collected  from  culture  supernatant  after 
growing  the  cells  to  exhaustion.  Figure  4.3.14b  also  illustrates  the 
reaction  of  monoclonal  HNo-G7  with  2M  salt-dehistonised  chromatin 
resolved  on  an  SDS-gel  electrophoresis  and  blotted  onto  a  nitrocellulose 
paper.  The  reaction  was  monitored  and  detected  by  a  second  antibody 
(rabbit  anti-mouse  IgM,  H+L)  followed  by  labelled 
125 
I-protein  A.  In 
both  Figures  4.3.14a  and  4.3.14b,  a  reactive  antigen  of  approximate 
molecular  weight  44,500-45,000  was  observed.  This  reactive  antigen 
could  be  seen  in  both  the  acid-extracted  and  the  2M  salt-extracted -  179  - 
Figure  4.3.13  Giemsa  Staining  of  HeLa  Metaphase  Chromosomes 
HeLa  chromosome  spread  stained  with  Giemsa  staining  as 
described  in  sections  3.7.7  and  3.7.8  (X2000). -s 
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Figure  4.3.14a  Immunoblot  of  HNo-G7  Reacted  with  HeLa  Dehistonised 
PAL.  ----i:  -- 
Protein  immunoblot  of  the  HNo-G7  antibody  reacted  with 
nonhistone  chromosomal  fraction  prepared  by  sulfuric  acid 
extraction  (lane  c)  or  2M  salt-extraction  of  the  HeLa 
chromatin  (lane  d),  resolved  on  a  10%  Laemmli  gel. 
Detection  of  antibody  reaction  was  by  the 
immunoperoxidase  method  (section  3.5.4.1).  Lane  (a) 
represents  the  amido  black-stained  acid  extracted  - 
nonhistone  proteins  and  lane  (b)  is  the  molecular  weight 
protein  marker  (from  top:  phosphorylase-b,  94,000; 
bovine  serum  albumin,  67,000;  ovalbumin,  43,000; 
carbonic  anhydrase,  30,000;  soybean  trypsin  inhibitor, 
20,100). abCd 
rX103 
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67- 
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20.1_ Figure  4.3.14b  Autoradiograph  of  HNo-G7  Reacted  with  HeLa  Dehistonised 
Chromatins 
Protein  immunoblot  of  HNo-G7  antibody  (concentrated  X3  by 
PEG  6,000)  reacted  with  2M  salt-extracted  nonhistone 
chromosomal  protein  fraction  (from  HeLa  cells),  resolved 
on  8.5%  Laemmli  gel  and  blotted  onto  nitrocellulose 
paper.  The  reaction  was  detected  by  the  protein  A 
method  as  described  in  section  3.5.4.3. 
Lane  (1)  An  autoradiogram  of  the  antibody  reaction  detected  by 
125I-protein  A.  (Eight  hours  exposure) 
Lane  (2)  Amido  black  stained  2M  salt  extracted  chromatin  blotted 
on  nitrocellulose  paper. 
Lane  (3)  Protein  marker  (from  top:  phosphorylase  b,  94,000; 
bovine  serum  albumin,  67,000;  ovalbumin,  43,000; 
carbonic  anhydrase,  30,000;  trypsin  inhibitor,  20,100; 
d-lactalbumin,  14,400). 
Note:  Staining  of  the  blot  was  by  0.1%  amido  black  in  2%  acetic  acid  and 
destaining  by  2%  hot  (900C)  acetic  acid.  This  modification  is 
to  prevent  any  shrinkage  of  the  blot  (Du  Bois  &  Rosen,  1983). ls-.,:.  i.  M-.:..  i -  182  - 
Figure  4.3.14c  Autoradiograph  of  Control-Immunoblot 
An  autoradiograph  of  protein  immunoblot  of  supernatant 
(concentrated  X5)  from  an  irrelevant  IgM-Secreting 
hybridoma  (anti-human  thyroglobulin)  reacted  with  the 
HeLa  2M  salt-extracted  nonhistone  chromosomal  protein 
fraction  resolved  on  8.5%  Laemmli  gel  and  blotted  onto 
nitrocellulose  paper.  The  reaction  was  detected  by  the 
protein  A  method.  (Exposure  was  for  14  hours). -  183  - 
nonhistone  chromosomal  protein  fractions.  Normal  mouse  serum  (from  an 
unimmunised  animal  diluted  1/200)  showed  no  reactivity  with  HeLa 
dehistonised  chromatin  nor  did  the  supernatant  from  other  IgM-secreting 
mouse  hybridomas  (irrelevant  IgM)  (Figure  4.3.14C). -  164  - 
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The  HNo-G7  monoclonal  antibody  was  clearly  shown  to  be  of  the  IgM 
class  both  by  ELISA  and  internal  radio-labelling.  IgM  producing 
hybridomas  may  be  expected  to  be  less  predominant  in  a  fusion  from  a 
hyperimmune  animal  since  they  are  generally  produced  early  in  the  immune 
response.  The  labelled  antibody  used  in  the  selection  assay  was 
directed  against  IgG  heavy  and  light  chains  so  it  may  be  expected  to 
detect  all  isotypes  because  of  its  reaction  with  the  light  immunoglobulin 
chain.  IgM  antibodies  have  in  general  lower  intrinsic  affinity  for  the 
antigen  than  IgG  antibodies  directed  to  the  same  epitope  (Rodwell  et  al., 
1983).  However,  their  multivalence  can  lead  to  an  experimentally  high 
affinity  in  selection  procedures.  Additionally,  some  antigens  such  as 
the  ABO  blood  grouping  antigens,  appear  to  elicit  an  isotype  specific  IgM 
response  (Taussig,  1979).  With  a  single  sample,  it  is  not  possible  to 
say  whether  the  fact  that  HNo-G7  is  an  IgM  reflects  an  isotype  preference 
of  the  antigen,  a  phenomenon  related  to  the  immunisation  and  selection 
procedure,  or  chance. 
The  internal  radio-labelling  of  the  monoclonal  antibody  provides 
information  relating  not  only  to  its  class  but  also  to  its  monoclonal 
nature,  since  the  hybridoma  cell  line  clearly  does  not  synthesise  any 
other  isotype.  The  possibility  that  the  antibody  is  not  monoclonal  but 
is  the  product  of  two  different  co-existing  hybridomas  both  secreting  IgM 
cannot  be  totally  discounted  but  it  is  highly  unlikely  since  the 
hybridoma  cell  line  has  been  subcloned  repeatedly  at  0.5  cell/well  and 
antibody  secretion  and  titre  have  remained  constant  over  a  period  over  18 
months.  In  mixed  cultures  this  is  almost  never  true.  Attempts  to 
obtain  final  proof  of  the  true  monoclonal  nature  of  the  antibody  by 
isoelectric  focussing  were  abandoned  because  of  the  extreme  difficulty  of 
introducing  such  a  large  molecule  into  the  gel  medium. -  185  - 
The  preliminary  characterisation  of  the  binding  of  the  antigen  to 
the  ELISA  plate  and  the  chequerboard  assay  are  extremely  important  in  the 
design  of  any  screening  system  for  a  monoclonal  antibody.  It  is 
important  to  be  able  to  bind  as  much  chromatin  as  possible  to  the  plate 
in  order  to  detect  positive  fusion  clones  as  early  as  possible  so  that 
they  may  be  cloned  before  overgrowth  by  non-secreting  cells  can  occur. 
However,  it  is  also  vital  that  the  antigen  is  bound  stably  to  the  plate 
and  is  not  able  td  leach  off  during  washing  procedures  (Lehtonen  & 
Viljanen,  1980)  since  leached  antigen  could  react  with  the  monoclonal 
antibody  with  both  being  removed  during  a  subsequent  wash. 
Early  ELISA  assays  utilised  high  pH  buffers  for  antigen  binding 
(Engvall  &  Perlman,  1971).  While  more  antigen  may  bind  under  these 
conditions,  incubation  with  antibody  is  carried  out  at  lower  pH  values 
and  it  is  again  vital,  for  the  reasons  described  above,  that  antigen 
bound  at  high  pH  does  not  desorb  during  subsequent  incubations  at  lower 
pH  values.  In  addition,  the  pH  dependence  of  the  antibody  -  antigen 
reaction  itself  can  affect  the  screening  procedure  strongly  since  some 
monoclonal  antibodies  exhibit  very  sharp  pH  profiles  (Fraser  et  al., 
1982).  The  experiments  described  in  Figures  4.3.3  and  4.3.4  indicate 
that  pH  effects  are  unlikely  to  affect  either  antigen  binding  or  reaction 
with  antibody  under  the  routine  assay  conditions  employed. 
The  actual  amount  of  antigen  bound  to  the  plate  can  be  readily 
determined  with  a  pure  protein  antigen  since  it  is  possible  to  radiolabel 
such  an  antigen  and  determine  the  percentage  of  radioactivity  bound  at 
various  protein  concentrations.  However,  with  chromatin  as  an  antigen 
this  is  almost  impossible  since  the  multiple  components  may  incorporate 
label  differentially  and  also  bind  differentially.  However,  some 
indication  may  be  obtained  from  the  chequerboard  assay  since  the 
absorbance  at  492nm  was  comparable  over  the  range  of  2.5-20pg/well  at 
fixed  antibody  concentration  (Fig.  4.3.5).  Accordingly,  it  is  possible -  186  - 
to  suggest  that  the  antigen  binding  onto  the  ELISA  plate  is  restricted 
above  a  concentration  of  2.5pg/well. 
Very  small  amounts  of  antigen  (155ng/well)  could  be  detected  by 
the  monoclonal  antibody  as  shown  by  the  chequerboard.  This  suggests 
either  that  the  affinity  of  the  antibody  is  extremely  high,  or  that  the 
protein  is  present  in  substantial  amounts  in  chromatin.  Variation  of 
the  antibody  concentration  over  the  dilution  range  of  1  to  1/32  at  fixed 
antigen  concentration  also  has  minimal  effect,  indicating  that  at  a 
concentration  of  1/32  there  is  still  sufficient  antibody  in  the 
supernatants  to  saturate  all  the  antigen  molecules  bound  to  the  plate. 
In  principle,  some  indication  of  the  antigen  bound  to  the  plate 
can  be  obtained  from  the  competition  ELISA  assay  where  HeLa  chromatin  is 
effectively  competed  against  itself.  Thus  again  with  a  simple  protein 
antigen  and  at  limiting  concentrations  of  antibody,  the  amount  of  protein 
competitor  required  to  abolish  all  antibody  reactivity  may  be  regarded  as 
a  rough  indication  of  the  amount  of  protein  actually  bound  to  the 
plate.  Even  in  this  situation  such  a  conclusion  is  suspect  since  the 
binding  of  proteins  to  ELISA  plates  causes  some  degree  of  denaturation 
(Berkowitz  &  Webert,  1981).  With  chromatin  as  antigen,  any  such 
conclusions  become  even  less  valid.  Firstly,  some  components  of 
chromatin  may  bind  more  readily  to  the  plate  than  others  and  consequently 
the  comparison  of  competing  antigen  in  solution  with  plate  bound  test 
antigen  is  not  possible.  The  antibody  is  an  IgM  with  ten  potential 
binding  sites  in  solution  and  it  is  highly  unlikely  that  all  these  could 
bind  to  antigen  on  the  plate  for  obvious  steric  considerations. 
Additionally,  the  pieces  of  free  competing  chromatin  may  have  multiple 
copies  of  antigen  on  them  further  confusing  the  results.  The 
comparatively  large  amounts  of  antigen  required  for  self  competition  with 
HeLa  chromatin  probably  reflect  the  fact  that  the  antibody  is  being  used 
in  excess  as  indicated  by  the  chequerboard  experiment  and  it  is  not -  187  - 
possible  to  use  the  data  to  give  a  meaningful  estimate  of  the  amount  of 
antigen  actually  bound  to  the  plate. 
Many  of  the  above  considerations  also  apply  to  the  use  of 
conventional  or  competition  ELISA,  to  compare  different  preparations  of 
chromatin  or  subcellular  fractions.  However,  on  a  comparative  base  of 
protein  (or  DNA)  concentration  the  data  from  Figures  4.3.6  and  4.3.7 
appear  to  indicate  that  the  antigen  is  present  in  substantially  greater 
amounts  in  HeLa  chromatin  than  in  the  chromatin  of  other  epithelial  cell 
lines  and  that  it  is  not  detectable  in  a  fibrosarcoma  cell  line.  there 
are  several  possible  interpretations  of  this  result.  The  most  likely  is 
that  the  antigen  is  related  to  the  metabolic  activity  of  the  nucleoli  in 
some  way  and  as  this  differs  with  different  cell  lines,  so  the  amount  of 
antigen  also  varies  on  a  protein  or  DNA  basis.  Another  possible 
interpretation  is  that  the  antigen  is  more  accessible  in  HeLa  chromatin 
than  the  other  cell  lines.  There  may  also  be  an  effect  relating  to  the 
number  of  nucleoli  (at  least  five  pairs  of  chromosomes  carry  nucleolar 
organisers  (Flavell  &  Martini,  1982))  which  may  be  greater  in  HeLa  cells 
which  carry  a  large  aneuploid  chromosome  complement  (Adams  et  al., 
1981).  The  lack  of  any  apparent  antigen  in  a  fibrosarcoma  cell  line  may 
indicate  that  the  antigen  has  some  preference  for  epithelial  cells  but 
this  cannot  be  definitely  ascertained  until  a  wider  panel  of  human  cell 
lines  has  been  tested. 
With  a  monoclonal  antibody  the  possibility  that  the  antigen  is  an 
epitope  which  is  present  on  different  proteins  in  each  case  (for  example 
a  carbohydrate  residue)  can  not  be  ruled  out. 
The  use  of  conventional  and  competition  ELISA  assays  to  determine 
the  subcellular  localisation  of  the  antigen  carries  even  greater  hazards 
of  interpretation  since,  while  competing  chromatins  all  have  similar 
physical  characteristics  (this  is  especially  true  comparing  Chang  liver 
and  HeLa  chromatins  which  are  slightly  different  from  H.  Ep-2  chromatin  as -  188  - 
illustrated  in  Figure  4.3.15),  the  competing  antigens  in  subcellular 
localisation  have  very  dissimilar  physical  properties.  In  addition,  the 
preparation  of  the  various  components  may  result  in  substantial  cross 
contamination.  Within  these  limits,  it  is  however  possible  to  conclude 
from  Figures  4.3.8  and  4.3.9  that  the  antigen  is  present  in  chromatin, 
nucleolus  and  cytoplasm  and  not  detectable  in  the  2M  NaCl-extracted 
fraction  which  contains  the  bulk  of  the  histones.  The  comparatively 
large  amount  present  in  the  cytoplasm  on  the  protein  basis  is 
surprising.  As  the  immunofluorescent  staining  (Fig.  4.3.11)  is 
predominantly  nucleolar,  the  comparatively  small  amount  in  the  nucleoli 
is  also  unexpected.  However,  the  nucleolar  preparation  consists  mainly 
of  condensed  histones  which  compete  with  other  proteins,  including  the 
antigen,  on  the  basis  of  total  protein  estimation  and  it  should  be  noted 
from  Figure  4.3.9  that  at  high  concentrations  the  nucleolar  preparation 
competed  almost  as  well  as  cytoplasm  in  the  competition  assay. 
A  general  correlation  with  immunofluorescence  may  be  made  but  it 
is  quantitatively  different.  This  difference  may  again  be  attributed  to 
several  factors.  The  physical  nature  of  the  antigen  in  the  various 
preparations  may  affect  its  ability  to  bind  to  the  plate  or 
differentially  affect  the  reaction  of  plate  bound  chromatin  antigen  with 
competitor  in  solution.  It  is  also  very  possible  that  the  antigen  may 
move  from  one  cell  compartment  to  another  during  the  preparative 
procedure  as  in  the  case  described  by  Davis  et  al.  (1978)  who  reported  a 
nucleolar  antigen  which  was  preferentially  localised  in  the  nucleoli  in 
immunocytochemistry  but  which  appeared  to  be  able  to  equilibrate  between 
the  nucleoplasm  and  the  cytoplasm  during  isolation.  Additionally, 
preparation  of  the  nucleoli  by  the  method  of  Bhorjee  and  Pederson  (1973) 
which  involves  sonication  may  result  in  the  loss  of  substantial  amounts 
of  antigen.  It  is  also  possible  that  the  antigen  may  genuinely  be 
present  in  substantial  amounts  in  the  cytoplasm  as  well  as  the  nucleoli -  189  - 
Figure  4.3.15a  Protein  Blot  of  Human  Chromatins 
An  amido  black  stained  blot  comparing  three  chromatin 
preparations  from  epithelial  human  cell  lines.  The  blot 
stained  by  0.1%  amino  black  as  described  in  Fig.  4.3.14b. 
Lane  (1)  Molecular  weight  marker:  from  top:  bovine 
serum  albumin,  67,000;  ovalbumin,  43,000; 
carbonic  anhydrase,  30,000;  soybean  trypsin 
inhibitor  20,100. 
Lane  (2)  HeLa 
Lane  (3)  H.  EP-2 
Lane  (4)  Chang  liver 
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Figure  4.3.15b  Protein  Blot  of  HeLa  Subfractions 
An  amido  black  stained  blot  comparing  three  subcellular 
HeLa  fractions  with  2M  salt-extracted  Chang  liver 
chromatin.  Staining  and  destaining  was  as  described  in 
Fig.  4.3.14b. 
Lane  (1)  HeLa  cytoplasmic  fraction 
Lane  (2)  HeLa  chromatin 
Lane  (3)  HeLa  2M  salt-extracted  chromatin 
Lane  (4)  Molecular  weight  marker:  from  top:  bovine 
serum  albumin,  67,000;  ovalbumin,  43,000; 
carbonic  anhydrase,  30,000;  soybean  trypsin 
inhibitor,  20,100 
Lane  (5)  Chang  liver  2M  salt-extracted  chromatin 
Figure  4.3.15c  Coomassie  blue-stained  Laemmli  gel  of  HeLa  chromatin 
fractions 
Coomassie  blue-stained  SDS-gel  electrophoresis  (10%)  comparing  2M 
salt-5M  urea  extracted-chromatin 
(lane  1),  chromatin  preparation  (lane  2),  2M 
salt  extracted-chromatin 
(lane  3)  and  protein  markers  (lane  4)  [from  top: 
phosphorylase  b  94,000,  bovine  serum  albumin  67,000,  ovalbumin  43,000, 
carbonic  anhydrase  30,000,  soybean  trypsin  inhibitor  20,100  and 
a-lactalbumin  14,400) 
Note:  In  lane  2,  although  the  core  histones  are  well  resolved,  the  H1  histone 
showed  less  intensitrthanthe  core  histones. ýýuý  ýr-,  3,15  h 
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either  because  it  is  synthesised  there  or  because  it  performs  some 
cytoplasmic  function.  Finally,  with  a  monoclonal  antibody,  the 
possibility  of  reaction  with  the'same  epitope  on  two  different  proteins 
must  always  be  considered  as  discussed  above. 
The  data  shown  in  Figure  4.3.10  indicate  that  the  antigen  is 
neither  DNA  nor  RNA.  Since  antibodies  to  nucleic  acid  antigens  are  not 
readily  raised  in  BALB/c  mice  this  is  not  surprising.  However,  a  low 
level  of  anti-DNA  antibodies  is  present  in  the  sera  of  many  animals  and 
indeed  humans  (Winger  et  al.,  1983)  and  such  a  possibility  must  obviously 
be  investigated.  The  relatively  high  concentration  of  DNA  (in 
comparison  to  any  individual  protein,  see  Table  5  for  DNA  :  total  protein 
ratio)  in  the  chromatin  used  for  screening  also  makes  it  possible  that  a 
low  affinity  antibody  to  DNA  could  have  been  selected.  An  antibody  to 
RNA  was  probably  less  likely  but  such  monoclonal  antibodies  have  been 
produced  (Eilat  et  al.,  1980,1982).  Antibodies  to  DNA  are  readily 
generated  from  other  strains  of  mice  (Lee  et  al.,  1981;  Jacobs  &  Tron, 
1982;  Lerner  et  al.,  1981;  Kioke  et  al.,  1982)  but  have  not  been 
reported  with  BALB/C  strain. 
The  fact  that  DNA  and  RNA  are  not  required  for  antigenic  activity 
also  indicates  that  the  antigen  does  not  require  nucleic  acids  to 
maintain  its  antigenic  configuration  and  in  this  respect  it  differs  from 
the  HeLa  antiserum  described  by  Dunn  et  al.  (1980)  which  requires  human 
DNA  for  activity. 
Figure  4.3.10  also  shows  that  proteolysis  destroys  antigenic 
activity.  While  the  most  likely  interpretation  of  this  information  is 
that  the  antigen  is  a  protein,  it  is  also  possible  that  the  epitope 
itself  is  a  carbohydrate  residue  bound  to  a  protein  and  removed  with  the 
protein  fragments  on  proteolysis. 
The  immunofluorescence  pictures  (Fig.  4.3.11)  indicate  strong 
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nucleolar  localisation  but  also  some  cytoplasmic  presence.  While  the -  192  - 
most  obvious  explanation  of  these  data  is  that  the  antigen  has  a  presence 
in  both  parts  of  the  cell  as  discussed  above,  it  is  also  possible  that  it 
has  changed  its  location  during  preparation  of  the  cells  for 
immunohistochemistry.  Redistribution  of  cytoplasmic  components  to  the 
nucleus  has  been  reported  in  one  case  (Briggs  et  al.,  1981)  but  the 
nuclear  staining  showed  no  specific  nucleolar  localisation  and  it  seems 
unlikely  that  the  antigen  is  a  purely  cytoplasmic  protein. 
Since  DNA  and  RNA  are  not  necessary  components  for  the 
immunoreactivity  of  HNo-G7  antibody,  it  is  anticipated  that  the  detection 
of  the  corresponding  antigen  on  the  immunoblot  is  more  feasible.  Two 
nonhistone  chromosomal  protein  preparations  were  analysed  on  SDS-PAGE, 
blotted  onto  a  nitrocellulose  paper  then  allowed  to  react  with  the 
antibody  using  the  immunoperoxidase  method  (Fig.  4.3.14a  lanes  c&  d). 
An  antigen  of  approximate  molecular  weight  of  44,500-45,000  was 
detected.  However,  the  intensity  of  the  reactive  band  was  not  strong. 
This  could  be  explained  either  by  the  possibility  that  a  limited  amount 
of  antibody  was  available  in  the  tissue  culture  supernatant  or  by  the 
likelihood  that  the  amount  of  antigen  on  the  blot  was  not  sufficient. 
There  are  many  reports  in  the  literature  of  monoclonal  antibodies 
(particularly  to  chromatin)  which  do  not  immunoblot  or  which  blot  poorely 
(e.  g.  Turner,  1983).  The  general  interpretation  is  that  such  antigens 
have  epitopes  which  are  irreversibly  denatured  by  the  preliminary 
electrophoresis.  However,  others  like  Yurchenko  et  al.  (1982)  have 
blotted  a  variety  of  protein  epitopes  successfully.  Work  in  our  own 
laboratory  has  clearly  shown  that  many  sera  blot  non-specifically  with 
proteins  such  as  molecular  weight  marker  proteins  (Campbell  et  al., 
personal  communication),  and  the  general  area  of  immunoblotting  is  very 
much  less  well  defined  than  indicated  in  elementary  laboratory 
textbooks.  Accordingly,  a  sandwich  blot  utilising  Protein  A  was  used  to 
identify  the  antigen  more  clearly.  This  blot  is  based  on  the  known 
.  ý.  Jýý -  193  - 
ability  of  Protein  A  to  bind  strongly  to  rabbit  IgG  but  not  to  many  mouse 
monoclonal  antibodies  and  certainly  not  to  mouse  IgM  monoclonal 
antibodies.  The  limited  reaction  of  the  mouse  specific  IgM  is  amplified 
with  unlabelled  rabbit  anti-mouse  IgM  (H+L)  antibodies  and  the  final 
complex  is  decorated  with  high  specific  activity 
125 
1  labelled  Protein 
A.  Background  staining  is  reduced  by  the  use  of  0.5%  Tween  20,  which 
cannot  be  used  successfully  with  enzyme  immunoblots  because  of  the 
substantial  reduction  in  enzyme  activity  induced  by  the  bound 
detergent.  This  blotting  system,  which  is  a  modification  of  the 
process  of  Batteiger  et  al.  (1982)  has  a  high  signal  to  noise  ratio  in 
comparison  to  other  available  techniques.  In  practice,  this  technique 
also  indicated  that  the  antigen  was  a  protein  in  the  molecular  weight 
range  45,000  (Fig.  4.3.14b). 
The  antigenic  determinant  recognised  by  HNo-G7  is  therefore  a 
protein  (possibly  with  carbohydrate  epitopes)  which  has  a  molecular 
weight  in  the  region  of  45,000,  localised  by  immunohistochemical 
techniques  primarily  in  the  nucleoli  but  also  present  in  the  cytoplasm, 
and  not  dependent  on  nucleic  acids  for  its  immunoreactivity.  It  is 
present  in  smaller  amounts  or  with  lower  availability  in  other  human 
epithelial  cells  but  is  not  apparently  available/present  in  fibrosarcoma 
cells.  A  comparison  with  other  published  nucleolar  antigens  is 
obviously  necessary  and  this  is  given  in  Table  6. 
The  antigens  described  in  Table  6  fall  into  four  separate 
categories  as  indicated.  The  first  group  of  reported  "nucleolar 
specific"  antisera  are  polyclonal  (Busch  et  al.,  1979).  In  view  of  the 
potential  heterogeneity  of  such  antigens  (Section  4.1  and  Section  4.2)  it 
is  difficult  to  make  a  detailed  comparison  of  HNo-G7  with  these  antisera 
as  they  may  vary  with  rabbit,  titre  and  bleed.  However,  the  claims  of 
Busch  et  al.  (1979)  that  their  antiserum  specifically  detects  the 
nucleoli  of  all  human  malignant  tumour  cells  tested  indicate  that  such -  194  - 
Table  6  Nucleolar  Antigens 
Molecular  Specificity  of 
Reference  weight  Antigen  Source 
1)  Busch  et  al.  (1979)  54,000  (Human  Tumour  (Rabbit 
Chan  et  al.  (  1980)  (  Nucleoli  (Polyclonal 
2)  Davis  et  al.  (1978)  Various  (Tissue  specific  (Rabbit 
Marachi  et  al.  (1979)  (Related  to  (Polyclonal 
Satoh  &  Busch  (1983)  (Metabolic  (& 
Ler-º\.  w  oJ:  L.  (  19gß)  (Activity  (Autoimmune 
mouse 
monoclonal 
3)  Reddy  et  al.  (1983)  Various  (Limited  Tissue  (Human 
Bernstein  et  al.  (1982)  (or  Species  (Polyclonal 
(Specificity 
4)  This  work  45,000  (Human  Epithelial  (Mouse 
(Tissue  Culture  (Monoclonal 
(Cells  with  Apparent 
(Preference  for  HeLa 
..  ý.  J  h' -  195  - 
antibodies  may  have  possible  diagnostic  applications.  Monoclonal 
antibody  HNo-G7  clearly  recognises  a  different  antigenic  determinant  from 
such  sera  since  molecular  weight  determination  indicates  that  their  major 
antigen  is  substantially  larger  than  that  of  HNo-G7  (Chan  et  al., 
1980).  In  addition,  the  antigen  is  extracted  by  low  salt  (Busch  et  al., 
1979)  and  this  makes  it  less  likely  to  co-purify  with  the  high  salt 
associated  HNo-G7  antigen. 
The  second  group  of  nucleolar  antigens  are  not  necessarily  tumour 
specific  but  are  reported  to  exhibit  some  degree  of  tissue  specificity  or 
correlation  with  growth  and  metabolic  activity  (Davis  et  al.,  1978; 
Marashi  et  al.,  1979;  Satoh  &  Busch,  1983).  These  have  all  been 
detected  with  polyclonal  sera  and  are  subject  to  the  reservations 
outlined  above.  The  limited  characterisation  of  the  antigens  in  this 
group  makes  them  difficult  to  compare  with  the  HNo-G7  antigen  but  there 
appears  to  be  little  similarity. 
The  third  group  of  antigens  which  may  be  considered  as  "nucleolar" 
come  from  polyclonal  human  sources,  usually  from  patients  with  systemic 
rheumatic  diseases  involving  autoantigens  such  as  progressive  systemic 
sclerosis  (Bernstein  et  al.,  1982)  and  scleroderma  (Reddy  et  al., 
1983).  Other  examples  from  this  group  include  "cyclin"  which  may  be 
identical  to  "proliferating  cell  nuclear  antigen"  (Mathews  et  al.,  1984), 
and  others  reviewed  by  Tan  (1982).  Where  molecular  weights  have  been 
determined,  none  correlate  with  the  HNo-G7  antigen.  Additional 
complications  arise  not  only  from  the  polyclonality  of  the  serum  but  also 
from  the  autoimmune  nature  of  the  response.  Such  antisera  may  detect 
antigens  not  amenable  to  conventional  immunisation  techniques  as  the  host 
has  a  specific  defect  which  permits  the  synthesis  of  antibodies  which  are 
normally  suppressed.  HNo-G7  was  raised  in  a  BALB/c  mouse  with  no 
autoimmunity  in  its  genetic  background. -  196  - 
The  final  group  in  Table  6  are  genuine  monoclonal  antibodies  which 
show  nucleolar  staining.  HNo-G7  falls  into  this  category.  No  other 
monoclonal  antibodies  which  react  with  nucleoli  have  been  reported  to 
date.  However,  a  preliminary  report  of  three  monoclonal  antibodies  to 
purified  La  antigen  is  also  of  interest  (Smith  et  al.,  1984).  Anti-La 
antibodies  precipitate  distinct  sets  of  snRNPs.  The  group  of  mouse  RNAs 
associated  with  these  RNPs  are  of  90-100  nucleotides  long  (Reviewed  by 
Busch  et  al.,  1982).  The  structure  of  human  La  RNAs  is  not  yet  known. 
Other  monoclonal  antibodies  to  chromosomal  proteins  have  been 
reported.  In  particular,  two  groups  have  used  HeLa  cells  for 
immunisation.  Bhorjee  et  al.  (1983)  reported  several  monoclonals  raised 
in  BALB/c  mice  with  a  very  similar  immunising  antigen  to  the  one  used  to 
make  HNo-G7  (2M  salt-5M  urea  extracted  chromatin).  However,  none  of 
these  antibodies  showed  nucleolar  staining.  Davis  et  al.  (1983) 
produced  monoclonal  antibodies  which  react  strongly  with  mitotic  cells 
and  weakly  with  interphase  cells.  Monoclonal  antibodies  directed  to 
chromatin  or  chromosomal  proteins  have  also  been  described  utilising 
Drosophila  (Saumweber  et  al.,  1980;  Howard  et  al.,  1981),  avian  red 
blood  cells  (Vanderbilt  &  Anderson,  1982;  Kane  et  al.,  1982)  and  rat  and 
human  tissues  and  cell  lines  (Turner,  1981)  as  primary  antigen.  Many  of 
these  antibodies  react  with  antigens  that  have  interesting  cell  cycle 
dependence  (Howard  et  al.,  1981;  Dippold  et  al.,  1981;  Risau  et  al., 
1982;  Davis  et  al.,  1983)  but  none  show  the  dramatic  nucleolar  staining 
of  HNo-G7  which  would  appear  therefore  to  be  a  monoclonal  antibody 
recognising  a  different  epitope  from  others  hitherto  reported  in  the 
literature. 
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5.  General  Discussion 
The  class  of  nonhistone  chromosomal  proteins  remain  bound  to  DNA 
after  extraction  with  either  2M  NaCl  alone  or  with  5M  urea  has  proved 
exceedingly  intractable  to  biochemical  analysis.  This  is  due  partly  to 
their  complexity  and  partly  to  their  relative  insolubility  in  the  absence 
of  DNA.  Their  functional  role  remains  therefore  obscure  but  is  clearly 
of  general  interest.  Immunological  approaches  have  considerable 
potential  both  in  the  characterisation  of  these  proteins  and  the 
assessment  of  their  distribution  within  the  cell  and  among  different 
types  of  cell. 
R3.1  antiserum  was  raised  in  a  rabbit  immunised  with  HeLa 
dehistonised  chromatin  extracted  with  both  salt  and  urea.  The  major 
antigens  in  this  serum  are  in  some  way  structurally  dependent  on  the 
presence  of  both  protein  and  DNA  (section  4.1).  This  requirement  may 
reflect  simple  or  complex  organisation.  For  example,  protein-protein 
interaction  may  be  a  pre-requisite  for  DNA  binding.  Two  recent  reports 
of  this  type  of  complex  reaction  support  the  possibility  of  this 
concept.  Staufenbiel  and  Deppert  (1984)  have  shown  that  a  group  of 
chromosonal  proteins  from  HeLa  and  3T3  cells  interact  both  among 
themselves  and  also  with  DNA  and/or  other  nuclear  structural 
components.  Werner  et  al.  (1984)  have  also  suggested  that  a  form  of 
protein-protein-DNA  complex  is  required  for  the  salt  stable  anchorage  of 
the  residual  DNA.  In  addition,  they  have  reported  covalent  linkage  of 
some  nuclear  proteins  to  DNA.  These  proteins  are  highly  insoluble  when 
the  covalent  linkage  is  broken.  It  is  unlikely  that  the  antigen 
recognised  by  R3.1  or  reported  earlier  in  HeLa  cells  (Dunn  et  al.,  1980) 
is  covalently  linked  since  most  of  the  activity  can  be  recovered  by 
reconstitution  which  would  not  be  expected  to  result  in  covalent 
linkage.  However,  such  a  possibility  cannot  be  entirely  discounted. 
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R.  3.1  antiserum  could  obviously  be  directed  against  nuclear 
lamina  proteins,  nuclear  matrix  proteins  or  both.  Some  of  the  abundant 
nuclear  matrix  and  the  major  lamina  proteins  lie  within  the  same  range  of 
molecular  weight  but  can  be  differentiated  by  their  structural  and 
functional  roles  (Agutter  &  Birchall,  1979;  Franke  et  al.,  1981). 
Staufenbiel  and  Deppert  (1984)  have  shown  that  the  nuclear  lamina  is  not 
solubilised  during  mild  DNase  digestion  or  sequential  salt  extraction  of 
mammalian  nuclei  in  situ.  In  addition,  Lebkowski  and  Laemmli  (1982) 
have  demonstrated  that  lamina  proteins  exhibit  considerable  affinity  to 
bind  DNA.  On  these  bases  lamina  proteins  are  clear  potential  candidates 
for  R3.1  major  antigens. 
The  analysis  of  nuclear  matrix  proteins  by  Werner  et  al.  (1984) 
showed  two  forms.  The  minor  fraction  was  that  with  covalent  linkage  to 
DNA  referred  to  above.  The  major  fraction  was  serologically  related  to 
the  minor  one  but  not  covalently  attached  to  DNA  or  dependent  on  DNA  for 
its  immunological  activity.  This  pattern  does  not  reflect  the  behaviour 
of  the  major  antigens  to  R3.1. 
It  is  interesting  to  note  that  Werner  et  al.  (1984)  found 
nuclear  matrix  proteins  remaining  in  association  with  purified  eukaryotic 
DNA.  As  R3.1  antiserum  did  not  react  with  purified  HeLa  DNA,  either  the 
preparation  of  DNA  was  protein-free  or  the  R3.1  antigens  do  not  represent 
matrix  proteins. 
There  is,  therefore,  little  evidence  to  suggest  that  the  major 
R3.1  antigens  are  matrix  proteins.  It  is,  on  the  other  hand,  possible 
that  they  represent  at  least  some  lamina  proteins. 
The  use  of  only  2M  NaCl  and  no  urea  to  extract  HeLa  chromatin 
results  in  a  different  spectrum  of  major  antigens.  The  nuclear 
preparation,  however  highly  purified,  is  generally  accompanied  by 
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co-sedimenting  collapsed  intermediate  filaments  of  cytoplasmic  origin -  199  - 
(Staufenbiel  &  Deppert,  1982).  This  class  of  protein  is  resistant  to 
extraction  with  salt  and  non-ionic  detergents  and  is  likely  to 
contaminate  the  2M  NaCl-extracted  chromatin.  The  intermediate  filaments 
are  highly  antigenic  (reviewed  by  Lazarides,  1982).  Therefore  they  may 
dominate  the  antiserum  produced  while  forming  only  a  small  component  of 
the  immunising  antigen.  As  intermediate  filament  proteins  can  show 
considerable  cell  specificity  (Osborn  &  Weber,  1982),  it  is  very  possible 
that  much  of  the  early  work  which  appeared  to  detect  cell  specific 
nuclear  proteins  was  reflecting  this  type  of  antigen.  The  importance  of 
the  proof  on  nuclear  localisation  of  the  antigen  and  establishment  of 
other  criteria  such  as  DNA  binding  is  therefore  considerable  (Briggs  et 
al.,  1979;  Bowen  et  al.,  1980;  Lebkowski  &  Laemmli,  1982).  Since  R2.1 
antiserum  shows  a  strong  filamentous  cytoplasmic  reaction,  it  is  very 
likely  that  this  is  a  result  of  the  presence  of  antibodies  against 
keratins  in  the  antiserum.  This  is  emphasised  by  the  strong  reaction  of 
R2.1  with  keratin  preparation  on  the  immunoblot  at  the  range  of  molecular 
weight  covering  the  intermediate  filaments  (54,000-61,000  & 
42,000-52,000). 
The  relationship  of  the  major  antigens  in  R2.1  to  nuclear  lamina 
or  matrix  proteins  is  not  clear.  The  immunoblotting  of  R2.1  antiserum 
shows  no  indication  of  the  major  lamina  proteins  of  molecular  weight 
68,000-70,000  although  the  nuclear  staining  shows  a  similar  pattern  to 
that  of  an  anti-lamina  monoclonal  antibody  recently  reported  by  Krohne  et 
al.  (1984).  The  nuclear  matrix  is  relatively  stable  under  the 
conditions  of  antigen  extraction,  however,  and  could  have  been  present  in 
the  immunising  antigen  (Capco  et  al.,  1982).  The  matrix  network  in  HeLa 
cells  appear  to  remain  connnected  to  the  cytoskeleton  after  extraction 
with  high  salt  buffer  and  can  be  shown  by  electron  microscopy  to  be  more 
dense  than  the  cytoskeleton  (Capco  et  al.,  1982).  In  addition,  lamina -  200  - 
proteins  have  also  been  reported  to  be  stable  under  similar  conditions 
(Lebkowski  &  Laemmli,  1982).  The  relatively  high  density  of 
FITC-staining  surrounding  the  nuclei  may  therefore  possibly  represent 
antigens  present  on  the  nuclear  envelope  or  matrix. 
Capco  et  al.  (1982)  also  showed  that  extraction  of  nuclei  at 
high  ionic  strength  buffer  yielded  a  filamentous  nuclear  network  well 
organised  in  a  three-dimensional  anastomosing  structure  where  the  nucleoli 
are  enmeshed.  The  intranucleolar  filaments  are  situated  deep  within  the 
nucleus.  In  situ  fractionation  has  shown  the  persistance  of  preserved 
nucleolar  structures  during  high  salt  extraction  (Staufenbiel  &  Deppert, 
1984).  Consequently,  the  presence  of  nucleolar  components  in  chromatin 
which  has  been  extracted  with  2M  NaCl  5M  urea  is  not  surprising  and  the 
HNo-G7  antibody  presumably  detects  such  a  component.  It  is  interesting 
to  note  that  the  R3.1  antiserum  shows  no  comparable  antigen.  The 
difference  could  be  due  to  the  variation  in  immunological  response 
between  rabbit  and  mouse  but  is  more  likely  to  reflect  the  ability  of 
monoclonal  antibody  technology  to  select  antibodies  directed  to  a 
specific  protein  which  may  be  a  minor  serum  antigen. 
The  main  structural  components  of  the  nucleolus  are  though  to  be 
condensed  ribosomal  DNA,  histones,  RNA  species  and  ribosomal  protein 
precursors.  The  HNo-G7  antigen  is  a  protein  which  has  no  obvious 
association  with  RNA  or  DNA  (section  4.3).  The  data  suggest  that  it  is 
not  a  histone.  It  remains  possible  that  it  is  a  ribosomal  protein  or  a 
precursor  of  such  a  protein.  Alternatively,  it  may  be  a  protein  which 
plays  a  role  in  nucleolar  structure  or  function  but  bears  no  serological 
relationship  to  ribosomal  proteins. 
The  molecular  weight  of  the  IiNo-G7  antigen  is  close  to  that  of 
actin.  In  this  context  it  is  interesting  to  note  the  prevalence  of 
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actin  in  preparations  of  chromatin  and  nuclear  matrix  proteins  (Capco  et -  201  - 
al.,  1982;  Bravo  et  al.,  1982;  LeStourgeon  et  al.,  1975).  It  seems 
unlikely,  however,  that  HNo-G7  is  reacting  with  actin  since  the 
immunofluorescence  is  not  characteristic  of  anti-actin  antibodies 
described  by  Weber  et  al.  (1976).  Another  major  protein  which  has 
recently  been  shown  to  co-focus  with  actin  (using  two-dimensional  gel 
electrophoresis)  in  HeLa  cytoskeletal,  chromatin  and  matrix  preparations 
(Capco  et  al.,  1982)  is  of  interest.  The  protein  is  resistant  to  the 
extraction  conditions  used  in  these  preparations  and  its  molecular  weight 
is  similar  to  actin.  However,  it  is  not  clear,  from  this  report  (Capco 
et  al.,  1982),  whether  this  protein  is  of  nucleolar  localisation  or  not. 
The  work  described  in  this  thesis  has  emphasised  the  complexity 
not  only  of  nuclear  proteins  but  also  of  the  contaminants  which  can 
co-purify  with  them.  Immunological  analysis  is  of  particular  value  in 
such  a  situation,  since  nuclear  localisation  or  the  lack  of  it  can  be 
clearly  established  by  immunocytochemical  techniques.  Such  antigens  can 
then  be  further  investigated  and  purified  by  immunological  means.  The 
comparative  simplicity  of  the  use  of  a  monoclonal  antibody  as  opposed  to 
conventional  sera  to  identify  nuclear  antigens  is  also  evident. 
A  striking  feature  of  current  advances  in  recombinant  DNA 
technology  is  that  even  when  the  entire  sequence  of  a  eukaryote  gene  has 
been  established,  in  the  majority  of  cases  little  can  be  deduced  about 
the  control  of  its  differential  expression  in  the  cell.  It  is  to  be 
hoped  that  immunological  analysis  of  the  chromosome  may  help  in  the 
identification  of  some  of  the  molecules  involved  in  this  task. 
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